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Abstract 
Estrogen receptor-α (ERα) is expressed in two-thirds of BCs and is a well-known 
prognostic and predictive marker. For this reason it is one of the most studied 
proteins in BC. To understand how ERα positive BC develops, it is crucial to 
investigate both how this protein is regulated and which genes are modulated by 
it. MicroRNAs (miRNAs) control gene expression post-transcriptionally by 
interacting through sequence complementarity to their target transcripts. 
Through a microarray approach, we identified the subset of miRNAs modulated 
by ERα, that include up-regulation of miRNAs derived from the processing of two 
paralogous primary (pri-) transcripts, pri-miR-17-92 and pri-miR-106a-363. 
Characterisation of the miR-17-92 locus confirmed that the ERα target protein c-
MYC binds its promoter in an estrogen-dependent manner. These findings 
indicated that miRNAs derived from these pri-miRNAs (miR-18a, miR-19b and 
miR-20b) target and down-regulate ERα, whilst a subset of pri-miRNA-derived 
mature miRNAs inhibit protein translation of the ERα transcriptional p160 co-
activator, AIB1. Therefore, different subsets of the miRNAs identified act as part 
of a negative autoregulatory feedback loop.  We observed that levels of pri-miR-
17-92 increase earlier than the mature miRNAs derived from it, implicating 
precursor cleavage modulation after transcription. Pri-mir-17-92 is immediately 
cleaved by Drosha to pre-miR-18a, indicating that its regulation occurs during 
the formation of the mature molecule from the precursors.  
Furthermore, we wanted to explore the new kinases that regulate the ERα 
activity. Thereby, we performed kinome screening (by RNAi technologies) to 
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determine kinases that regulate ERα in MCF-7 BC cells and identified a novel 
kinase, LMTK3, which acts as positive regulator of ERα's transcriptional activity. 
This could be a new therapeutic target and/or a novel biomarker for BC, 
although further studies are required to validate this. Together, these studies 
identify new transcriptional and translational factors that regulate ERα expression 
in BC. 
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HCC - Hepatocellular carcinoma 
HER2 - Human Epidermal growth factor Receptor 2 
hnRNP A1 - heterogeneous nuclear ribonucleoprotein A1 
hnRNP E2 - heterogeneous nuclear ribonucleoprotein E2 
KH - hnRNP K homology domains 
KSRP - KH-type splicing regulatory protein 
LBD - Ligand binding domain 
M9 - nucleocytoplasmic shuttling signal sequence 
MAPK - Mitogen-activated protein kinase 
MCF-7 - Michigan Cancer Foundation -7 
miRNA –  microRNA 
mRNA – messenger RNA 
PARP – Poly (ADP-ribose) polymerase Inhibitors 
21 
 
 
 
 
 
PBS - Phosphate Buffered Saline 
PCR - Polymerase chain reaction 
PKC - Protein kinase C 
Pol II - RNA polymerase II 
PR - Progesterone 
PTEN - Phosphatase and tensin homologue 
RanBP - ran-binding protein 
RBPs - RNA binding proteins  
RGG - Arg-Gly-Gly box 
RNAi ‐ RNA interference 
RISC – RNA induced silencing complex  
RRM - RNA Recognition Motifs 
SDS - Sodium dodecyl sulphate 
SERM - Selective ER modulator 
siRNA - small interfering RNA 
SRC1 - Steroid receptor coactivator 1 
TBS - Tris buffered saline 
TGFβ - Transforming Growth Factor beta 
TIF2 - transcriptional mediators/intermediary factor 2 
TRIM-NHL - Tripartite motif (consisting zinc fingers of both RING type and B 
Box type and a coiled-coil domain) NHL repeats. 
TUT4 - Terminal Uridylyl Transferase 4 
UCG - Ultraconserved gene 
UTR – Untranslated region 
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Chapter 1: Introduction 
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1.1 Introduction 
Cancer is caused by the uncontrolled proliferation and inappropriate survival of 
damaged cells. Healthy cells have developed safeguards to ensure that cell 
division, differentiation and death occur in a timely and coordinated fashion, both 
during foetal development and throughout life. Loss of control at cell cycle 
checkpoints can ultimately result in uncontrolled and abnormal growth of cells, 
often resulting in their migration to other tissues. When abnormal cells migrate 
to other tissues in the body, this process is known as metastasis [3, 4]. Most 
cancer-associated mortality is due to metastasis and yet it remains the most 
poorly understood element of cancer pathogenesis [5]. Loss of function of a 
tumour suppressor gene, or activation of an oncogene, is often responsible for 
the loss of cell cycle control and subsequent control of cellular proliferation 
leading to cancer progression [6-9]. 
1.1.1 Global Cancer Incidence 
Cancer is the leading cause of death in economically developed countries and the 
second leading cause of death in developing countries [10]. In 2008 there were 
more than 156,000 cancer-related deaths in the UK, accounting for 1 in 4 (27%) 
of deaths from all causes. Primary malignancies of the lung, bowel, breast and 
prostate account for almost half of all cancer related deaths in the UK [11]. (An 
aging population and the “modern lifestyle” of alcohol, cigarettes and processed 
foods are likely responsible for the increasing incidence and  increase in the 
global burden of cancer [12].  
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It is estimated that 12.7 million cancer cases and 7.6 million cancer deaths have 
occurred worldwide in 2008, with 64% of deaths being in the economically 
developing world [13]. The incidence of all new cancer cases in economically 
developing countries is nearly double that of developed countries [12, 13]. Worse 
survival is likely to be related to a combination of a late stage at diagnosis and 
limited access to optimal treatment. Public education on diet and alcohol 
moderation, vaccinations (eg. human papilloma virus vaccines) and smoking 
cessation campaigns could all reduce the burden of cancer globally [12]. 
However, the treatment of aggressive and metastatic cancer requires the on-
going endeavours of scientists and clinicians to fully understand the cancer cell 
biology and identify novel targets for treatment. 
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Figure 1: The most common diagnosed cancer cases in UK (excluding 
non-melanomatous skin cancers), 2010. The figure shows the number of 
males and females affected by different types of cancer per year in the UK. 
(www.cancerresearchuk.org) 
            
   
The 20 Most Common Cancers in UK 
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1.1.2 Breast Cancer Incidence 
Globally, breast cancer is the most commonly diagnosed cancer and the leading 
cause of cancer death among females, accounting for 23% of all new cancer 
cases and 14% of cancer deaths. In economically developing countries, it has 
now overtaken cervical cancer as the most common cause of cancer-related 
death in women [12-14]. In the UK it is also the most commonly diagnosed 
cancer in women (Fig. 1), and is the third most common cause of cancer-related 
death (after Bowel and Lung cancer) [15]. Approximately 45,000 new diagnoses 
of breast cancer are made in the UK every year and approximately 12,000 
patients will die annually of their disease [16]. National screening programmes 
resulting in earlier detection, more streamlined clinical services and better 
therapies have resulted in a marked reduction in the annual death rate since the 
1980s [17]. 
1.2 Breast Cancer 
Risk factors for developing breast cancer include obesity, alcohol consumption, 
radiation, Lifelong Estrogenic Exposure and exposure to different carcinogens 
[17, 18], as well as genetic susceptibility. 10% of all breast cancers are thought 
to be hereditary [19], in which a the inheritance of a mutated gene predisposes 
the individual to the development of breast cancer. The most common genetic 
aberrations seen in breast cancer are in BRCA1 (breast cancer type 1 
susceptibility protein) and BRCA2 (breast cancer type 2 susceptibility protein) 
[20-23]. BRCA1 is located on chromosome 17q21 and BRCA2 is located on 
chromosome 13q12.3. BRCA1 and BRCA2, which are both tumour suppressor 
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genes, are involved in multiple cellular functions like DNA damage repair, 
maintaining genomic integrity and transcriptional regulation. Mutations within 
BRCA1 and/or 2 leads to translation of truncated proteins that lack normal 
function and are unable to perform their usual function of homologous 
recombination and DNA repair properly, hence increasing the risk of 
accumulating other genetic mutations due to DNA damage and hence promoting 
breast cancer genesis [22, 24].  
1.2.1 Biomarkers in Breast cancer 
Biomarkers are often useful in clinical practice. A prognostic biomarker may 
suggest how a cancer is going to behave, whilst a predictive biomarker can 
inform clinicians about the likelihood of a cancer responding to a particular 
treatment. The Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2 
receptors are three important biomarkers routinely used in clinics [25], and are 
often important in treatment decision. [25]. ER is the most commonly 
overexpressed receptor and is known to be a strong predictor of response to 
endocrine therapy such as tamoxifen and the aromatase inhibitors [26]. Breast 
cancer cells that lack of all three receptors often called Triple negative breast 
cancer (TNBC) account for 15-20% of breast cancers, but are often much more 
aggressive in their phenotype [27]. 
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1.2.2 Endocrine therapy in Breast cancer 
Approximately 70% of all breast cancer overexpress the estrogen receptor and 
are known as “ER positive” [28]. In such tumours hormonal treatment is directed 
at ER signalling pathways, inhibiting the hormonal stimulation of malignant cells 
by estrogen. Current options for reducing estrogen stimulation of the ER include 
surgical or chemical ovarian ablation, selective oestrogen receptor modulators 
(SERMs) and aromatase inhibitors (AIs)  [29]. AIs chemically inhibit the 
production of estrogen by inhibiting the function of the enzyme responsible for 
the conversion of androgens to estrogen [30, 31] and SERMS such as tamoxifen, 
fulvestrant and raloxifene inhibit estrogen and ER interactions [32-34].  
1.2.3 SERMs and Aromatase inhibitors 
Tamoxifen has been responsible for a significant improvement in the life 
expectancy of many breast cancer patients. It is an anti-estrogen that 
competitively inhibits the binding of estrogen to ERα, hence downregulating 
estrogenic signalling within the cell.  It is used routinely in clinical practice in the 
management of patients with both advanced ER positive breast cancer and in the 
adjuvant (post-operative) treatment of early ER positive cancers [35, 36]. Since 
its discovery in the 1950s, tamoxifen has become one in a class of drugs called 
selective ER modulators (SERMs) (Fig. 2A), which now also includes raloxifene, 
fulvestrant, arzoxifene and lasofoxifene [37, 38]. 
SERMs act either by targeting ERα for proteasomal degradation or preventing 
receptor-ligand interaction thereby inhibiting ERα-dependent proliferation [39, 
40]. 
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Aromatase Inhibitors (AIs) are a newer class of drug, often used in post-
menopausal breast cancer patients, who produce most of their estrogen in the 
adrenal glands and fat cells and not the ovaries. The mechanism of action of AIs 
differs from SERMS in that they inhibit the enzyme aromatase, which is 
responsible for catalysing androgen to estrogen. In doing so, they reduce the 
amount of circulating estrogen and hence limit estrogen-ER interactions and 
consequent downstream signalling [41-43]. Some AIs, such as letrozole (Fig 2B) 
and anastrozol, compete with estrogen precursors for the enzymatic active site of 
aromatase [44, 45] whereas the AI exemestane (Fig. 2B) covalently binds to 
aromatase and suppresses its activity [46]. Although hormonal therapies have 
significantly changed the prognosis of some early breast cancers, many of these 
tumours will eventually relapse and patients will die from their disease. Cancer 
cells become resistant to therapies, and patients develop side effects of the 
medications, hence the need for new treatment options continues.  
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                   Tamoxifen                                               Raloxifene 
   
                                        
                      Letrozole                                                 Exemestane     
 
 
 
 
Figure 2: Chemical structure of SERMs and Aromatase Inhibitors.  
Structures of two common (A) SERMs and (B) Aromatase Inhibitors which are 
often used in clinical practice.  Adapted from [47, 48] 
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1.3 Estrogens 
Estrogen exhibits a broad spectrum of biological functions ranging from brain 
development, bone health, development of reproductive organs, effects on 
vascular systems, female sexual behaviour, breast cancer genesis and 
progression [47, 49, 50]. The most potent intracellular estrogen produced in the 
body is 17β-estradiol (E2) (Fig 3).  Estrone (E1) and estriol (E3) (Fig 3) are also 
high-affinity estrogen ligands but they are much weaker agonists for the 
estrogen receptor (ERs) than E2 [51, 52].  
 
 
 
 
           Estradiol                              Estriol                                       Estrone 
 
 
 
 
Figure 3: Chemical structure of Estrogens. The predominant intracellular 
estrogen produced in the body is 17β-estradiol (E2) and weaker agonists on 
estrogen receptors; estrone (E1) and estriol (E3). Adapted from [47] 
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1.3.1 Estrogen receptor 
The effects of estrogen are mediated by two estrogen receptors (ERs), ERα and 
ERβ, members of the nuclear receptor (NR) gene superfamily. In late 1950s, the 
pioneering finding in the field was the discovery of estrogen binding protein, 
today recognised as ERα [53]. Estrogen receptor alpha (ERα) is an important 
nuclear receptor linked to progression of the majority of human breast cancers 
[29, 54, 55]. 
1.3.2 Structure of Estrogen Receptor-α 
The human Estrogen Receptor-α (ERα) gene is located on chromosome 6q25.1 
and encodes a protein of 595 amino acids. It contains a central DNA binding 
domain (DBD) consisting of two zinc finger motifs which is involved in DNA 
recognition and binding, whereas ligand binding occurs in the COOH-terminal 
multifunctional ligand binding domain (LBD) (Fig 4). The NH2-terminal domain is 
not conserved and represents the most variable domain both in sequence and 
length [51]. In the region D, a “hinge” region is involved in nuclear localisation 
and interaction with heat shock protein complexes [56]. Transcriptional 
activation occurs through at least two distinct transactivation domains located in 
the NH2-terminal A/B region (AF-1) and the COOH-terminal E region of the 
receptor (AF-2) (Fig 4). The AF-1 domain is hormone-independent, whereas the 
AF-2 domain is estrogen-dependent; both AF domains are required for maximal 
ERα transcriptional activity [57-60]. The two ERs (ERα and ERβ) share a high 
degree of sequence homology except in their amino-terminal domains, and they 
have similar affinities for E2 and bind the same DNA response elements [51]. 
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                         AF1                   DBD                                   LBD/AF2 
 
ERα/ ERβ homology: 18%         97%    30%                      59%               18% 
ERβ 
                                          
                    
 
 
 
 
 
Figure 4: Structure of human Estrogen receptor with different domains.  
The NH2 terminal consists of the A/B domain which encodes ligand independent 
transcription activation function AF1; the C domain contains the DNA binding 
domain (DBD) while D domain encodes the “hinge” region and finally domain E 
constitutes the ligand-binding domain (LBD).  Adapted from  [61] 
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1.3.3 Estrogen Receptor Signalling 
ER mediates expression of its target gene signalling through two different 
mechanisms; genomic and non-genomic signalling. In genomic signalling, ERs 
control the expression of genes either directly interacting with DNA via ERE 
sequences or indirectly through interaction with other transcription factors like c-
fos/ c-jun without directly binding to DNA [62]. In the non-genomic signalling 
pathway, effects of the ER are facilitated by membrane bound ERs without 
affecting transcription [63]. 
1.3.4 Genomic signalling of Estrogen Receptor 
Genomic functions of ERα are mediated by either classical or non-classical 
signalling. Ligand-receptor binding of estradiol and ERα mediates gene 
expression by causing ERα binding to a 13bp palindromic sequence called the 
‘Estrogen Response Element’ (ERE). Classical signalling of ERα involves direct 
interaction with DNA via ERE sequences in promoter regions of estrogen-
regulated genes with the help of co-activators (Fig 5). EREs were first identified 
in the Xenopus vitellogenin A2 gene and found to have the consensus sequence 
AGGTCAnnnTGACCT, where ‘n’ represents any nucleotide [64].  
ERα regulated genes, including pS2/TFF1 (trefoil factor 1), were first identified  
by cloning of cDNAs induced by estrogen treatment of breast cancer cells [65]. 
Upon 17-β-estradiol (E2) binding, ERs mediate transcription with the help of co-
activators like SRC-1, TIF2 and AIB1 by interacting directly with specific response 
elements (EREs) located in the promoter region of its target genes (Fig 5) [66-
68]. AIB1 (also known as SRC-3), is a p160 co-activating oncogene 
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overexpressed in different types of cancer, specifically breast tumours [69] and is 
associated with regulating ERα transcriptional activity [70].  AIB1 has been 
shown to increase ERα transcriptional activity through chromatin remodelling by 
recruiting co-factors that possess histone acetyl-transferase activity [71]. 
Remarkably, it has also been shown that AIB1 regulates ERα degradation by the 
recruitment of components involved in the ubiquitin-proteasome pathway. 
However, suppressing AIB1 leads to ERα stabilisation in the presence of estradiol 
(E2) and subsequent reduction of ERα transcriptional activity [1, 72]. The activity 
of AIB1 is regulated by phosphorylation which leads to high level of AIB1 
degradation [73, 74]. After estrogenic induction, ERα mRNA stability is 
substantially reduced within 1 hour of stimulation [58, 75]. Furthermore, the 
interactions between E2 and ERα speed-up receptor degradation through the 
ubiquitin-proteasome pathway, an effect associated with its major co-activator 
AIB1 [58, 76].  
Through the non-classical pathway, ERα can also regulate gene transcription 
indirectly by binding to nuclear proteins, such as AP1 and SP1 transcription 
factors [77].  Estrogen bound ER can initiate expression of collaginase and IGF-
1 through an interaction with c-fos and c-jun at AP1 binding sites, and stimulation 
of CyclinD1 is through the interaction with SP1  [63]. The cellular response to 
estrogen is highly regulated at multiple levels including transcription, RNA 
stability and post-translational modifications [75, 76, 78, 79].  
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Figure 5: Model of classical and non-classical actions of the estrogen 
receptor (ER). In Classical pathway, Estrogen binds to ER and translocates to 
the nucleus where activated the receptor binds to ERE and recruits co-activators 
to activate gene transcription. In non-classical pathway, the activated receptor 
binds to transcription factors like c-jun/c-fos and cyclinD1 via AP1 and SP1 sites 
respectively and thereby enhance transcription of the target genes. Modified 
from [80]. 
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After ER ligand activation, both genomic and non-genomic ER pathways regulate 
different growth factor signalling pathways that are crucial for breast cancer 
biology. The selective modulation of ER pathways, in combination with inhibition 
of upstream and downstream activated growth factor signalling pathways, will 
lead to more effective treatments [81-83]. There are several ongoing randomized 
clinical trials currently hoping to improve response rates in patients who might 
benefit from such combined treatments. The significant treatment of breast 
cancer will also require a combination of basic experimental models with genomic 
and proteomic tumour characterization [39, 84, 85].  
Over the last decade RNAi biology has completely changed the understanding of 
gene regulation. Small non-coding RNAs like microRNAs (mRNAs) have already 
proven their role in cancer biology and other diseases and shown their 
importance at different levels of gene regulation. The role of mRNAs in the 
regulation of the estrogen receptor pathway is likely to further advance our 
understanding of this important and clinically relevant cell signalling pathway, 
and could result in the identification of novel drug targets, and a new approach 
to the prevention and treatment of human breast cancer. 
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1.4 MicroRNAs 
MicroRNAs (miRNAs) are endogenous non-coding RNAs of approximately 22 
nucleotides length which were first discovered in Caenorhabditis elegans in 1993 
[99, 100], and are now known to be important regulators of gene expression, 
involved in the control of many biological processes including cell differentiation, 
growth and metabolism [95-98]. They are one of the largest gene families 
comprising of ~1% of the genome. Through their base pair interactions with 
messenger RNA (mRNA) they act as post-transcriptional modulators of gene 
expression, preventing translation of mRNA and resulting in post-transcriptional 
gene repression [88-90].  Base pairing at the 3′ UTR end, 5’ UTR end, promoter 
or coding regions of the mRNA does not need to be fully complementary to 
induce repression [91, 92]. 
In other circumstances, when the miRNAs interact partially with the sequences of 
their target mRNAs called seed region, they induce their translational repression  
Most human miRNAs are predicted to interact with at least several hundred 
target mRNAs in a sequence specific manner involving Watson & Crick base-
pairing within 2-8 nucleotides of the miRNA [88, 93, 94]. A single miRNA can 
bind to and regulate many different mRNA targets and, conversely, several 
different miRNAs can bind to and cooperatively control a single mRNA target 
[101, 102]. Analogous to transcription factors, miRNAs regulate mRNAs in a 
combinatorial fashion and single miRNAs can repress the translation of many 
mRNAs [103]. 
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1.4.1 Functions of MicroRNAs 
Over the past decade, miRNAs have proved to have an important role in most 
biological pathways and also to play a critical role in many human diseases [86]. 
Hence an understanding of their function is imperative if we are to better 
understand disease.  
 
Initially it was thought that microRNAs targeted the 3’ UTR of mRNA genes and 
down regulated them either by degrading the mRNA or by inhibiting their 
translation in the cytoplasm [87-89]. However, in more recent years, it has been 
shown that miRNAs can localize in the nucleus of cells [90] and that they can 
also target other regions of the genes including the 5’ UTR, promoter regions 
and coding regions [91-94]. As described below, miRNAs have also been shown 
to up-regulate translation [92, 95].  
1.4.2 Distinct role of MicroRNAs 
Eiring et al. [96] showed for the first time that miRNAs are also able to act as 
decoys (dual role of miRNAs) and in doing so prevent translational repression.  
The study showed that miR-328 acts as a decoy by binding to hnRNPE2 
(Heterogeneous nuclear ribonucleoprotein E2) which subsequently prevents it 
from repressing CEBPA mRNA which is involved in myeloid cell differentiation. It 
has also been recently shown that miR-29 prevents HuR from binding to the 
3'UTR of the A20 transcript, therefore acting as a decoy for HuR and shielding 
the A20 trancripts [97]. Pseudogenes such as PTENP1 behave in a similar 
manner, but instead act as decoys for the miRNAs themselves. For example, 
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PTEN1P binds to oncogenic miRNAS (onco-miRs), which prevents them from 
binding to the PTEN transcript, an important tumour suppressor gene [98].  
Another important role recently identified is that of competing endogenous RNAs 
(ceRNAs). It has been shown that ceRNAs can regulate miRNA through their 
ability to compete for miRNA binding on the target gene, acting as endogenous 
decoys for miRNAs [99]. Such active regulation of miRNAs may be important in 
cancer biology as well as playing a pivotal role in drug resistance, and is worthy 
of further exploration [100]. It has been shown that mir-369-3 targets the AU-
rich elements of the TNF gene, where most of RNA-binding proteins bind [95]. 
miR-373 has been shown to bind to the promoter of E-cadherin (CDH1) and 
regulate transcription, which shows the role of miRNAs at transcriptional level 
[92].  
miRNAs are also important in epigenetics. These “epi-miRNAs”, such as the 
recently identified miR-29 family, directly control epigenetic machinery through a 
regulatory loop in this case of the miR-29s by targeting the regulating enzymes 
DNMT3A and DNMT3B in lung cancer [101]. Other epi-miRNAs have been shown 
to control the expression of regulatory enzymes of the epigenetic machinery 
[102-106]. There are more distinct roles of miRNAs discovered over the recent 
years which have been summarized in the figure below (Fig. 6). The field of 
miRNA research therefore requires further focus on the interplay that connects 
the regulatory mechanisms and their functions.   
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Figure 6: Cross talk between miRNAs and their targets. Interactions 
between miRNA and their targets through various mechanisms. These are the new 
functions/role of microRNAs discovered over the recent years. Modified from [87]. 
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1.4.3 miRNA genes 
miRNA genes were initially thought to be transcribed from the intergenic regions 
(between protein-coding genes) of the genome but later it was also shown most 
of them are located within the intron or exon regions of the protein-coding genes 
[107-110]. Most of the miRNAs are transcribed from a single polycistronic 
transcription units (TU) and are structured into clusters; more than half of the 
miRNA loci are in close proximity (<50kb) to the next miRNA [111-113]. Clusters 
often contain two or more miRNAs with similar sequences and this combination 
allows synergistic biological effects [111]. 
 
1.5 MicroRNA Biogenesis 
miRNA biogenesis was initially thought to be universal for the processing of all 
mature miRNAs, but since their discovery many alternative processing pathways 
have been discovered [114]. 
1.5.1 Trancription of the primary miRNA transcript and DROSHA 
processing 
In a typical ‘canonical pathway’ most of the miRNAs are transcribed from 
endogenous genes by RNA polymerase II [115, 116] or in some cases by RNA 
polymerase III [117], then the transcripts are capped and polyadenylated [118]. 
The resulting primary, or pri-miRNA, transcript extends both 5′ and 3′ from the 
miRNA sequence, and two sequential processing reactions trim the transcript into 
the mature miRNA.  
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In the first processing step, which occurs in the nucleus, the pri-miRNA is 
cleaved (also called cropping) into pre-miRNA, an approximately 70-nucleotide 
hairpin stem loop intermediate, by a microprocessor complex which consists of 
Drosha, an RNase III enzyme and DGCR8 which functions as a molecular ruler to 
govern the accurate cleavage site [109, 119, 120]. Over the years it is been 
discovered that the microprocessor complex contains a diversity of cofactors 
including the hnRNPs, RNA helicases p68 (DDX5) and p72 (DDX17), DEAD box 
and many other RNA-binding proteins [121, 122]. Further discussion of the RNA 
binding proteins involved in Drosha processing is found below. These assisting 
factors may function to promote the fidelity, specificity or activity of Drosha 
cleavage [118]. Surprisingly, Drosha-mediated processing of pri-miRNAs into pre-
miRNAs is not always compulsory. A few intron-derived miRNAs called “mirtrons” 
are directly released from their host transcripts after splicing as pre-miRNA, 
thereby skipping the Drosha cleavage [123-125].  
1.5.2 Nuclear transport of the pre-miRNAs by Exportin-5 (xpo-5) 
After its formation, the pre-miRNA is actively transported from the nucleus to the 
cytoplasm by the Ran-GTP-dependent transporter Exportin 5 (Exp 5) [126, 127]. 
Drosha cleavage occurs co-transcriptionally, before splicing of the host RNA 
[109] and produces a product with a two-nucleotide 3′ overhang, which is a 
distinguishing characteristic of RNase III-mediated cleavage. The overhang is 
recognised by XPO-5, which transports the pre-miRNA into the cytoplasm via a 
Ran-GTP-dependent mechanism [113, 128]. When there is depletion of XPO-5, 
there is accumulation of the pre-miRNAs, and mature miRNAs are significantly 
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reduced [127].  XPO-5 together with complex  [guanosine triphosphate (GTP) 
bound of the cofactor Ran GTPase in the nucleus], binds to the precursors and 
then releases the precursors in the cytoplasm following the hydrolysis of Ran-
GTP to Ran-GDP [127, 129]. 
1.5.3 Cytoplasmic processing of pre-miRNAs by Dicer  
In the cytoplasm, the pre-miRNA is further ‘diced’ into an approximately 22-
nucleotide miRNA duplex by Dicer, another RNase III enzyme, in collaboration 
with the dsRBD proteins TRBP/PACT [130, 131]. Dicer was originally found to 
have a role in generating siRNAs for RNA interference (RNAi) but later it was 
shown that removal of Dicer eliminates the production of mature miRNAs and 
therefore has a crucial role for miRNA processing [132]. Dicer cleaves the 
precursors into 22nt miRNA duplexes by recognising the two-nulceotide 
overhangs at the 3’ end. In some cases, like the processing of let-7 family (which 
is negatively regulated by Lin-28), this is done by recruiting terminal uridylyl 
transferases (TUTs) to the pre-miRNA and producing a long single-stranded tail 
of Uracils (known as oligo-uridylation) at the 3′ end of the precursor, therefore 
blocking further processing by Dicer [133]. However, recently it was reported 
that pre-let-7 can be uridylated by TUTs (TUT2, TUT4 and TUT7) even in the 
absence of LIN28, but in this case only one Uracil (mono-uridylation) is added, 
producing a two-nucleotide 3′ overhang which is recognised by Dicer for further 
processing [134]. Dicer interacts with its partners TRBP and PACT, neither of 
which is required for the cleavage reaction itself but contribute to the formation 
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of the RNA-induced silencing complex (RISC) by recruiting to Ago2, the final core 
component [130, 135, 136].  
 1.5.4 Loading of miRNAs to the RISC complex for mRNA tageting  
The major components of RISC are the proteins of the Argonaute (AGO) family 
which function in both miRNA and siRNA pathways. Ago2 is the most crucial 
component of the RNA-induced silencing complex (RISC) [137]. The 
miRNA/miRNA* duplex is unwound by universal helicase and separated into a 
functional guide strand which is complementary to the mRNA target, and a 
passenger strand which is subsequently degraded [107]. However the universal 
helicase responsible for miRNA/miRNA* unwinding has not yet been identified 
[114]. The functional guide strand selected for incorporation into the miRISC and 
guiding depends on the thermodynamic stability of the base pairs at the two 
ends of the duplex; the miRNA strand with the relatively unstable base pair at its 
5' end (e.g. GU pair compared with a GC pair) is loaded into miRISC [113, 114, 
138, 139]. The miRISC then binds by imperfect base pairing to the 3'UTR of the 
target mRNA in a sequence-specific manner which is called the ‘seed region’, and 
induces mRNA cleavage or translational repression [140]. 
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Figure 7: The ‘linear’ canonical pathway of microRNA processing. The 
miRNA processing pathway has long been viewed as linear and universal to most 
of the mammalian miRNAs. Modified from [141] 
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1.6 microRNA and cancer 
MicroRNAs are involved in a wide range of developmental and physiological 
processes; their dysregulation is linked to many human cancers [86]. 
Interestingly, it was found that more than 50% of miRNA genes are located in 
cancer-associated genomic regions or in fragile sites (deletions or amplifications) 
[142]. Over the years, many studies have shown that miRNAs can act as 
oncogenes or tumour suppressor genes, creating molecular signatures for a 
variety of cancers [143-145]. miRNAs have shown to be diagnostic and 
prognostic markers for human cancers, as well as targets for molecular therapy 
[146]. Table 1 shows a timeline of the most important discoveries linking 
miRNA’s role in cancer, since their discovery in 1993. 
 
Year Discovery Species Reference 
1993 first miRNA (lin-4) discovered C. elegans [147, 148] 
2002 First miRNAs alterations 
(miR15 and miR16 deleted 
or downregulated) found in 
in most chronic lymphocytic 
leukemias 
Human [149] 
2004 miRNA genes (>50%) are 
located in cancer-associated 
genomic regions or fragile 
sites 
Human [142] 
2004 First miRNA (let-7) described 
as diagnostic/prognostic 
biomarker 
Human [150] 
2005 miRNA-target interaction 
relevant to cancer (by 
dowregulating RAS) 
C. elegans, 
Human 
[151] 
2005 First microRNA cluster (mir-
17–92) to describe as a 
potential human oncogene 
Human [152] 
2005 First time to link between 
miRNAs and the MYC 
oncogene 
Human, rat [153] 
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2006 MicroRNAs (hsa-mir-155 and 
hsa-let-7a-2) as molecular 
signatures that differ in 
tumor histology 
Human [154] 
2006 Epigenetic regulation (DNA 
methylation and histone 
deacetylase inhibition) of 
miRNAs that may act as 
tumor suppressors. 
Human [155] 
2007 First miRNA (mir-10b) in 
deregulation of cancer 
metastasis 
Human [156] 
2007 miRNAs can affect epigenetic 
changes and cause the 
reactivation of silenced 
tumor suppressor genes 
Human [101] 
2007 Some miRNAs can target 5’-
UTR of the genes. 
C. elegans, 
Human 
[91] 
2007 miRNAs can regulate ncRNAs 
from the category of long 
ultraconserved genes (UCGs) 
Human [157] 
2008 functional single nucleotide 
polymorphism (SNP) in the 
miRNA seed region 
Human [158] 
2009 proof of concept of miRNA 
delivery (mir-26a) as cancer 
therapy in HCC. 
Human, Mouse [159] 
2010 miRNA (mir-328) as 
molecular decoys 
Human, Mouse [160] 
2010 overexpression of a single 
miRNA (mir-21) is sufficient 
to cause cancer 
Mouse [161] 
 
 
2011 
Use of Engineered biological 
systems (HeLa cancer cell 
classifier selectively identifies 
HeLa cells and triggers 
apotosis without affecting 
non-HeLa cell types based 
on expression levels of a 
customizable set of 
 
 
 
Human  
 
 
 
 
[162] 
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endogenous microRNAs) 
 
2013 
miRNAs act as modulators of 
mRNA–mRNA interactions  
 
Human 
[163] 
 
2013 
A Phase I study of MRX34, a 
miR-34-based therapy and 
the first ever microRNA 
mimic to advance into a 
human clinical trial 
 
Human 
 
[164] 
 
 
 
1.6.1  miR-17-92 Cluster in Cancer 
The miR-17-92 cluster, a polycistronic gene, was investigated following a series 
of observations linking the miRNAs arising from this cluster to cancer 
pathogenesis [165]. The human mir-17-92 cluster is located within 800 base 
pairs in the noncoding gene C13orf25 with a chromosomal location at 13q31.3. It 
encodes for six miRNAs: miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 and 
miR-92-1 [86]. Based on these observations, it was shown for the first time by 
direct experimental evidence that miR-17-92 cluster has oncogenic activity [152]. 
Ancient replications have given rise to two mir-17-92 paralogues in mammals: 
mir-106b-25 and mir-106a-363. mir-17-92 cluster is undoubtedly the most 
studied class of miRNAs in cancer. 
miRNAs derived from mir-17-92 have shown to be oncogenic in lymphomas, 
leukemia, thyroid, colonic and lung cancer [152, 166-170], and been shown to 
act as a tumour suppressors in breast cancer, by down-regulating AIB1 and 
Table 1: Timeline of important discoveries of miRNA’s role in cancer. 
Modified from [87] 
 
           
50 
 
 
 
 
 
Cyclin D1 [171, 172]. In addition, it is been discovered that the genomic 13q31 
area, including mir-17-92, is associated with loss of heterozygosity in breast 
cancer [173].  
 
 
 
 
 
 
 
Figure 8: Primary miRNA transcript structures of the 3 paralogous 
families. Human mir-17–92, mir-106a-363 and mir-106b-25 clusters. Adapted 
from [1]  
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The miR-17-92 cluster first came under scrutiny when it was reported that 
transcription of this cluster is directly transactivated by c-Myc [153], a oncogenic 
transcription factor that is frequently overactive in cancer cells. These findings 
provided one of the first critical demonstrations that miRNAs are functionally 
incorporated into oncogenic pathways and are crucial to cancer development. 
Several independent bodies of research have further confirmed that the miR-17-
92 cluster and its paralogues can act as oncogenes [174-177]. It was also shown 
that the expression of the paralogue cluster miR-106a-363 is normally extremely 
low and  when ectopically transcribed, the miRNAs from this cluster may act in a 
similar manner to the miR-17-92 cluster [178]. All these findings suggest the 
important role of miR-17-92 cluster and its paralogue cluster in cancer biology.            
1.6.2  miR-17-92 Cluster in Breast Cancer 
Prior to this research, little evidence existed for the role of the mir-17-92 cluster 
in breast cancer, however, in recent years, many studies have shown that mir-
17-92 miRNAs have both an oncogenic and tumour suppressive role in breast 
cancer. For example, mir-19 has been shown to play an oncogenic role in breast 
cancer [179-183] whilst mir-18a can act as a tumour suppressor in breast cancer 
[1, 184, 185]. These findings suggest that the individual miRNAs derived from 
this cluster can be used as potential therapeutic target in breast cancer. 
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                 miR-17              CAAAGUGCUUACAGUGCAGGUAG 
                 miR-20a            UAAAGUGCUUAUAGUGCAGGUAG 
                 miR-20b            CAAAGUGCUCAUAGUGCAGGUAG 
                 miR-106a          AAAAGUGCUUACAGUGCAGGUAG 
                 miR-106b          UAAAGUGCUGACAGUGCAGAU 
                 miR-93              CAAAGUGCUCUUCGUGCAGGUAG 
 
                 miR-18a            UAAGGUGCAUCUAGUGCAGAUAG 
                 miR-18b            UAAGGUGCAUCUAGUGCAGUUAG 
 
                 miR-19a            UGUGCAAAUCUAUGCAAAACUGA 
                 miR-19b            UGUGCAAAUCCAUGCAAAACUGA 
 
                 miR-25              CAUUGCACUUGUCCUCGGUCUGA 
                 miR-92a            UAUUGCACUUGUCCCGGCCUGU 
                 miR-363            AAUUGCACGGUAUCCAUCUGUA 
 
 
 
 
 
Figure 9: MicroRNAs derived from miR-17-92 cluster and its paralogue 
clusters (mir-106a-363 and mir-106b-25). The seed sequences are 
highlighted in red - the regions considered most important for target selection. 
miRNAs of these clusters can be grouped into four families: the miR-17 family 
(miR-17, miR-20a/b, miR-106a/b, and miR-93); the miR-18 family (miR-18a/b); 
the miR-19 family (miR-19a/b); and the miR-25 family (miR-25, miR-92a, and miR-
363). Adapted from [178]. 
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1.7 RNA binding proteins 
RBPs play an important role in most aspects of RNA biology, transcription, pre-
mRNA splicing, mRNA export, translation and decay [186, 187].  They have also 
been shown to have a role in post-transcriptional modifications like 
polyadenylation and RNA editing [188-190]. Generally RNAs in cells have 
dynamic interactions with RNA-binding proteins (RBPs) to form ribonucleoprotein 
(RNP) Complexes [191]. Post-translational modifications are important for the 
stability of the proteins [192]. These modifications of RBPs cause additional 
layers of complexity, as they can alter the RNA-binding, function and localization 
of the RNP [188]. The three common types of modifications reported for RBPs 
that can change RNA binding are phosphorylation, arginine methylation and 
small ubiquitin-like modification (SUMO) [193-195]. For RNA-protein interactions, 
the sequence of the RNA target is very important and also the protein-protein 
interactions are crucial factors in shaping the formation of an RNP. Also, more 
than one RBP can bind to a specific sequence of the target RNA [196]. 
One of the important RBPs are heterogeneous nuclear ribonucleoproteins 
(hnRNPs) which are mostly present in the nucleus, involved in gene transcription 
and also in post-transcriptional modification of the newly synthesized pre-mRNA 
[197]. There are so many types of hnRNPs, and most of them tend to share the 
same type of RNA binding domain [198]. Some of the well-characterized RNA-
binding domains include the following: RNA binding domain, RNA recognition 
motif, K-homology (KH) domain (type I and type II), RGG (Arg-Gly-Gly) box, Sm 
domain, DEAD/DEAH box, zinc finger (ZnF), double stranded RNA-binding 
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domain (dsRBD), cold-shock domain, Pumilio/FBF (PUF or Pum-HD) domain and 
the Piwi/Argonaute/Zwille (PAZ) domain [188]. RBPs often contain multiple RNA-
binding domains and the functions of the RBPs are generally characterized by the 
presence these domains [199].  
 
1.8 MicroRNA regulation by RNA binding proteins 
The regulation of miRNA expression occurs at three levels:  pre-transcriptional, 
transcriptional, and post-transcriptional [107, 114, 139, 200].  Most of the 
microRNA regulation by RBPs occurs at the post-transcriptional level [201, 202]. 
Maturation of miRNAs requires coordinated post-transcriptional processing 
mechanisms where  DROSHA crops pri-miRNA transcripts to pre-miRNA hairpin 
structure and further DICER cleaves pre-miRNA to form mature miRNAs [203]. 
Apart from DROSHA and DICER being the main component of the 
microprocessor complex there have been several RBPs which are important for 
miRNA processing [204]. RBPs like DGCR8 and TRBP regulates the global miRNA 
processing; but there are also RBPs involved in processing of individual miRNA or 
subset of miRNAs. miR-18a is derived from pri-miR-17-92 transcript which also 
encodes for five other miRNAs (Fig. 8). Initially, it was shown that hnRNP A1, an 
mRNA splicing regulator, stimulates DROSHA processing of miR-18a from the 
miR-17-92 cluster. pri-miR-18a had two regions similar to the consensus hnRNP 
A1-binding site, UAGGGA/U, within its terminal loop and stem but these 
consensus site were not present with the other miRNAs of the cluster [205, 206]. 
The specific interaction of hnRNPA1 with pri-miR-18a leads to structural 
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rearrangement of the hairpin to produce a more favourable Drosha/DGCR8 
binding and cleavage site [206]. Therefore hnRNPA1 acts as a chaperone for 
specific cropping of pri-miR-18a by Drosha/DGCR8. Interestingly, further studies 
showed that approximately 14% of human miRNAs have highly conserved loop 
sequences, suggesting the regulation of miRNA processing by hnRNPA1 might 
extend well beyond miR-18a [206]. Lin-28 was the first RBP discovered to be a 
negative regulator of microRNA processing both at DROSHA and DICER 
processing. Lin-28 inhibited microprocessor-mediated cleavage of let-7 family in 
the nucleus [207], by competing with DROSHA [208, 209]. Further studies 
revealed Lin-28 also inhibited DICER-mediated cleavage of the pre-let-7 family in 
the cytoplasm [210] by recruiting a terminal uridylyl transferase (TUTase) to the 
precursor and thereby inhibiting the processing. Another important RBP 
regulating miRNA processing was the KH type splicing regulator protein (KSRP) 
which recognizes the G-rich regions (particularly GGG triplet) present within the 
terminal loops of a subset of pri-miRNAs, thereby promoting DROSHA processing 
[211]. KSRP was also shown to interact with the terminal loop of the miRNA 
precursors during nucleo-cytoplasmic transfer and thereby promoting the DICER 
processing of the target pre-miRNAs in the cytoplasm. This suggests that the 
sequence specific recognition by the RBPs is important to extend regulation of 
miRNA processing of the individual miRNAs. Recent studies also revealed the 
binding of RBPs to specific sequences in the terminal loop regions of miRNA 
precursors either competes for binding or stimulates recruitment of processing 
factors [212]. The table below shows all the RBPs known to regulate the 
microRNA processing till date. 
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Protein 
 
Motifs 
 
Known 
Activity 
 
Mechanisms 
Target 
miRNA 
                     
Referen
-ces 
 
 
DGCR8  
 
 
dsRBD 
Binding to 
Drosha 
Stabilizing 
Drosha 
Global  [118] 
 
TRBP  
 
dsRBD 
Binding to 
Dicer, MKK 
phosphorylation 
site 
Stabilizing 
Dicer 
 
Global 
 
[213] 
 
 
p53  
 
DNA binding 
Tumour 
Suppressor 
Binding to 
p68 and 
Promoting 
Drosha 
cleavage 
miR-16-
1, 
miR-143 
[214] 
 
SMADs 
 
DNA binding 
Signal 
transducers 
of TGFβ 
Binding to 
p68 and 
Promoting 
Drosha 
cleavage 
miR-21, 
miR-
199a 
[215] 
 
 
ERα 
 
 
DNA binding 
 
Nuclear 
Receptor 
Binding to 
p68/p72 and 
inhibiting 
Drosha 
cleavage 
 
A subset 
 
 
[216] 
 
hnRNP 
A1  
 
RRM, M9 
 
Pre-mRNA 
splicing 
Chaperone for 
Drosha/DGCR
8 binding 
miR-18a [205] 
 
KSRP  
 
KH 
 
mRNA decay 
Promoting 
Drosha 
and Dicer 
processing 
A subset [211] 
 
ARS2  
 
Plant 
SERRATE 
homolog 
Nuclear Cap-
binding  
 
Enhancing 
Drosha 
Processing 
Global  
 
[217, 
218] 
Exportin-
5  
RanBP Binding to 
tRNAs 
and pre-
miRNAs 
Nuclear 
transport 
of pre-miRNA 
 
Global  
 
[219, 
220] 
 
 
LIN-28  
 
CCHC-type 
zinc finger 
 
 
Promoting 
pluripotency 
Inhibition of 
Drosha 
and Dicer 
processing, 
and Recruiting 
TUT4 
let-7  
 
[133, 
208, 
221] 
[210] 
[207] 
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TUT4  
Poly(A) 
polymerase, 
CCHC-type 
zinc 
finger 
 
Terminal 
uridylation 
Binding to 
LIN-28 and 
inhibiting 
Dicer 
processing 
 
let-7  
 
[213, 
221, 
222] 
 
Mei-P26  
TRIM-NHL 
(RING 
finger) 
 
Ubiquitinylation Binding to 
miRISC and 
inhibiting 
miRNA activity 
A subset [223] 
 
Argonaut
es  
 
 
PAZ, PIWI 
 
Components of 
RISC 
 
Stabilizing 
associated 
miRNAs 
 
Global 
 
[220] 
 
 
 
SF2/ASF 
 
 
RNA 
recognition 
motif (RRM) 
 
 
SR protein 
splicing 
factor 
 
binds directly 
to pri-miR-7 
and promote 
its nuclear 
cropping. 
 
miR-7, 
miR-
29b, 
miR-
221, 
and 
miR-
222)  
 
[224] 
 
ADARs  
 
dsRBD 
 
 
A-I RNA editing 
Inhibition of 
Drosha 
and Dicer 
processing 
A subset [225, 
226] 
 
p68/p72  
 
 
DEAD-box 
Components of 
Microprocessor 
Promoting 
Drosha 
Cleavage 
A subset [122] 
 
XRN-2  
5’ to 3’ 
exoribonucle
ase 
 
 
Exoribonuclease 
Degrading 
miRNA  
 
 
Global 
 
[227] 
 
GLD2  
Poly(A) 
polymerase 
Terminal 
adenylation 
Stabilizing 
miRNA 
miR-122 [228] 
 
mLin41  
 
TRIM-NHL 
(RING 
finger) 
 
 
Ubiquitinylation 
Binding to 
Ago2 and 
targeting it for 
degradation 
Let-7 
and 
others 
in 
ES cells 
 
[229] 
 
NHL-2  
TRIM-NHL 
(RING 
finger) 
 
Ubiquitinylation Binding to 
miRISC and 
enhancing 
miRNA activity 
A subset [230] 
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NF90-
NF45 
 
 
dsRBD 
 
 
Transcription 
factor 
Binds to the 
Microprocesso
r complex 
(Drosha) and 
Inhibits the 
Drosha 
processing 
 
 
let-7a 
 
 
[231] 
 
 
AUF1 
 
RNA binding 
domain 
(RBD) 
 
RNA binding 
protein 
Suppresses 
the Dicer 
expression 
and blocks 
Dicer 
processing 
 
Global 
[232] 
 
 
PTEN 
 
 
Phosphatase 
domain, C2 
 
 
Tumour 
Suppressor 
Inhibits the 
Drosha 
processing 
indirectly by 
down 
regulating 
RNH1  
miR-21 [233] 
 
MBNL1 
 
Zinc finger 
domain 
 
Pre-mRNA 
splicing 
Positively 
regulates 
Dicer 
processing 
miR-1  [234] 
 
SNIP1 
Forkhead-
associated 
(FHA) 
domain 
Involved in 
TGF-β and NF-
KB signalling 
pathways 
Inhibits the 
Drosha 
processing 
Global [235] 
 
BRCA1 
 
RING finger 
 
E3 ubiquitin 
ligase 
Positively 
regulates 
Drosha 
processing 
let-7a-1, 
miR-16-
1, miR-
145, 
miR-34a 
[236] 
 
TUT2, 
TUT4 
and 
TUT7 
 
Zinc Finger 
CCHC 
Domain 
 
Terminal 
uridylation 
mono-
uridylate 
group- II pre-
miRNAs and 
regulates 
dicer 
processing 
 
Subset 
[134] 
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AR 
 
 
DNA binding 
 
 
Nuclear 
Receptor 
Positively 
regulates 
Drosha 
processing of 
pri-miR-
23a27a24-2 
cluster. 
Subset [237] 
 
BCDIN3D 
 
DNA binding 
 
Methylation 
Negatively 
regulates 
dicer 
processing 
miR-145 [238] 
 
 
 
MCPIP1 
 
 
Zinc Finger 
CCCH 
Domain 
 
 
 
Ribonuclease 
suppresses 
miRNA 
biogenesis 
via cleavage 
of the 
terminal loops 
of precursor 
miRNAs 
 
Global 
 
[239] 
 
TDP-43 
 
DNA binding 
 
DNA and RNA-
binding protein 
Interacts with 
Dicer complex 
and promote 
processing 
 
Subset 
[240] 
 
 
 
EGFR 
 
 
 
 
 
Ligand 
Binding, 
Tyrosine 
kinase 
domain 
 
 
Receptor 
tyrosine kinase 
binding ligands 
of the EGF 
family 
Phosphorylate 
AGO2 in 
response to 
hypoxic 
stress, which 
in turn 
reduces the 
binding of 
Dicer to AGO2 
 
Subset 
 
[241] 
 
c-Myc 
 
DNA binding 
DNA and RNA-
binding protein, 
transcription 
factor 
c-Myc binds 
directly with 
drosha and 
promote 
processing 
 
Global 
 
[242] 
 
 
SND1 
 
Staphylococ
al Nuclease 
Domain  
 
Transcriptional 
coactivator/ 
Important 
component of 
RISC complex 
SND1 
interacts with 
the precursors 
of mir-92a 
cluster and 
blocks the 
processing 
 
 
miR-92a 
 
 
[244] 
 
Table 2: Post-transcriptional Regulators in mammalian miRNA 
Biogenesis. Modified from [243]  
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It is established that RBPs like Dnd1 or HuR can regulate the function of miRNAs 
in different ways either by affecting the biogenesis of miRNAs or by directly 
interacting with the miRNA binding sites, competing with the miRNA binding sites 
on mRNAs and therefore regulating the miRNA function [245]. A relationship 
between miRNAs and RBPs clearly exists which is important for proper function 
of processes involved in differentiation, cell cycle, stress, and cell survival [246]. 
As miRNAs play a very important role in cancer, and RBPs regulate miRNA 
biogenesis and activity, it suggests that the interplay of miRNA and RBPs is 
important for the regulation of cancer pathways. 
 
1.9 Estrogen Receptor Phosphorylation 
Phosphorylation is one the most important post-translational modifications and 
has been shown to regulate many nuclear receptors including Estrogen Receptor. 
ERα has shown to be phosphorylated in the absence of a ligand as well as when 
bound to estrogen and anti-estrogens [247]. Functions of some of the important 
phosphorylation sites have been summarized below (table 3 and fig 10). 
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Site of 
Phosphorylation 
Function Kinase 
(putative) 
Reference 
Ser46/47 Transcription PKC [248] 
Tyr52 Transcription, Protein 
stability, Cell 
growth/invasion 
 
cABL 
 
[249] 
Ser104/106 Transcription, 
Coactivator binding 
Cyclin A/CDK2, 
ERK1/2, GSK3β 
[250-252] 
Ser118 Transcription, 
Coactivator binding, 
Protein stability, RNA 
splicing, Cell 
growth/invasion 
CDK7, ERK1/2, 
IKKα, GSK3β, DNA-
PK, 
 
[253-256] 
Ser167 DNA binding, 
Transcription 
p90 RSK1, S6 K1, 
AKT, IKKε, CK2 
[257-261] 
 
Tyr219 
DNA binding, 
Dimerization, 
Transcription, Protein 
stability, Cell 
growth/invasion 
 
 
cABL 
 
 
[249] 
 
Ser236 
DNA binding, 
Dimerization, 
Transcription 
 
 
PKA 
[262] 
Ser282 Transcription CK2 [248] 
 
 
Ser305 
DNA binding, 
Transcription, 
Coactivator binding, 
Interaction with other 
PTMs, Cell 
growth/invasion 
 
 
 
PAK1, PKA 
 
 
[263, 264] 
 
Thr311 
Transcription, 
Coactivator binding, 
Subcellular localization 
 
p38 SAPK 
[265] 
 
Tyr537 
Ligand binding, DNA 
binding, Dimerization, 
Transcription, 
Coactivator binding 
 
c-SRC 
[266] 
 
 
Table 3: ERα phosphorylation sites and its function 
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Figure 10: The known multiple phosphorylated sites in ERα have been 
identified and some of the well-known kinases that phosphorylates ERα. 
The different functional domains A/B, C and D promotes the non-classical signalling 
and domains E and F promotes the classical signalling of human ERα. Modified from 
[267, 268]. 
             
        
“Non-Classical” Signalling “Classical” Signalling 
CDK2/ cyclinA 
MAPK AKT 
PKA 
P38α/ SAPK2 Src ERK1/2 
Some of the well-known kinases regulating Estrogen Receptor 
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Resistance to endocrine therapy is a common problem and phosphorylation of 
ERα has a very crucial role in endocrine resistance [29]. Ser-118 is one the most 
important phosphorylation sites of ERα. It has been shown estrogen induces Ser-
118 phosphorylation [269], kinases such as CDK7, MAPKs and GSK3 have all 
been shown to phosphorylate ERα on Ser-118 (Table 3). Other phosphorylation 
sites like Ser-167, Ser-236, Ser-305, Thr-311 and Tyr-537 have an important role 
in endocrine resistance [267]. Previous clinical studies suggest that the 
phosphorylation status is associated with good prognosis and response to 
endocrine therapy [270, 271]. Therefore phosphorylation of ERα could be one of 
the key mechanisms of resistance to endocrine therapy. The investigation of 
novel kinases involved in ERα phosphorylation may elucidate potential strategies 
for combating resistance to endocrine therapy. 
 
1.10 siRNA Mediated Gene silencing or knockdown  
siRNAs are double stranded RNAs, usually 20 to 25 nucleotides, involved in post-
transcriptional gene silencing by binding to and promoting the degradation of 
mRNA at specific sequences [272, 273]. The discovery of small interfering RNAs 
(siRNAs) [274] has revolutionized our understanding of gene regulation. siRNA 
therapy is one the most powerful tools used in biological research over the last 
decade and has gained much attention for their ability to suppress gene 
expression by post-transcriptionally silencing a gene through mRNA degradation 
[275, 276]. siRNAs are able to suppress gene expression, without producing a 
significant cytotoxic response [277].  
64 
 
 
 
 
 
 
 
1.10.1 Mechanism of siRNA (RNA interference) 
In mammalian cells the RNase III enzyme Dicer recognises the siRNA duplex via 
the two nucleotide overhang and is incorporated into the RNA inducing silencing 
complexes (RISCs). Further, the ATP-dependent helicase unwinds the duplex and 
one of the strands independently recognizes mRNAs mediates siRNA mediated 
gene knockdown [278, 279]. The degree of complementarity between the 
guiding strand and the target mRNA determines whether mRNA silencing is 
achieved via the site-specific cleavage of the mRNA [280] or through a miRNA 
like mechanism by blocking the translation [281].  
Figure 11: Structure of a siRNA. Positions of each nucleotide in the 19nt 
duplexed region of the sense strand of an siRNA; a model which shows to design 
an effective siRNA molecule. Adapted from [278]. 
 
      
65 
 
 
 
 
 
1.10.2 Off-target effects of siRNA 
Initially it was thought siRNAs have laser-like specificity, but later expression 
profiling by Jackson et al. revealed the off-target effects of siRNAs [282]. It has 
been shown that a single siRNA duplex can target more than one mRNA 
transcript because of sequence homologies [283]. So therefore to minimise off-
target effects and to maximize gene silencing, a careful selection of sequences is 
needed. Off-target activity of siRNAs can lead to unexpected phenotypes and 
complicate the understanding of the gene expression. The off-target effects of 
siRNA delivery fall under three categories;  (a) siRNA mediated regulation of 
unintentional transcripts through partial sequence complementarity to their 3′ 
UTRs (microRNA-like off-target effects) [284] (b) an inflammatory reaction 
through activation of Toll-like receptors triggered by siRNAs or their delivery 
vehicles [285] and (c) widespread effects on microRNA processing and function 
through saturation of the endogenous RNAi machinery by exogenous siRNAs 
[286]. 
1.10.3  RNAi screening for the discovery of novel modulators 
Over recent years, the development of RNAi libraries (siRNA library) has changed 
the direction of drug target discovery and validation [287, 288]. RNAi technology 
has already influenced the strategies for drug development of many diseases 
including cancer [289]. Using RNAi libraries in various formats has led to the 
identification of novel regulators at genome wide level that alter the disease 
phenotype and also offers a better understanding of the mechanisms that trigger 
disease pathogenesis [290-293]. Earlier studies involving ‘kinome screens’ have 
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revealed critical kinases involved in the key pathogenesis of different cancers 
[294-298]. 
1.10.4  RNAi as the most potential therapeutic target  
Initially it was thought that non-coding RNAs played no role in gene expression 
and were considered to be ‘junk’ molecules in the genome.  However, the past 
20 years has brought many discoveries about non-coding RNAs which have 
changed this previously held view. The discovery of RNA interference (RNAi) has 
revolutionized the understanding of gene regulation [299]. siRNAs (exogenous) 
and miRNAs (endogenous) are the central players in RNAi; and are considered to 
be both a valuable tool in understanding biological mechanisms,  and also 
potential therapeutic targets. 
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1.11 Aims 
The aims of this research are: 
1. The first aim of this project was to identify specific miRNAs that are 
transcribed and then regulated in breast cancer in an estrogen dependent 
manner and to determine the contribution of post-transcriptional miRNA 
regulation to oncogenesis in breast cancer, in response to ERα’s 
transcriptional activity. Also, to establish the mechanisms of how miRNAs 
are regulated in breast cancer and identify any miRNA-binding proteins 
involved.  
2. The aim of the second part of the project was to screen the entire 
‘kinome’ family and identify novel kinases regulating estrogen receptor 
using RNAi technology, which may provide valuable information to design 
novel therapeutic strategies against ER positive patients. 
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Chapter 2: Methods and Materials 
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2.0 Methods and Materials 
2.1 Cell Culture and passaging cells 
MCF-7 and MELN cells were maintained in DMEM (Gibco, Invitrogen) 
supplemented with 10% FCS, 1% penicillin/streptomycin and 1% glutamine. 
MCF-7-Tet-Off (MCF-7-TO) cells (BD Biosciences, UK) were maintained in DMEM 
supplemented with 10% FCS, 100μg/ml G418 and 1μg/ml of doxytetracycline 
(Tet). MCF7-TO cells (BD Biosciences, UK) in DMEM supplemented with 10% 
FCS, containing 100 mg/ml G418 and 1 mg/ml of the more stable tetracycline 
analogue doxytetracycline (Tet). MCF7-TO-PLZF-ERα cells were maintained as 
previously described [300].  
Cells were cultured in 150cm2 flasks or 100-mm dishes or 6-well plates unless 
otherwise specified and maintained at 37°C in a humidified 5% CO2 incubator. 
Cells were routinely passaged when a confluency of ~90% was reached, 
depending on the growth curve of each cell line. To passage cells, medium was 
aspirated, cells were washed once with PBS solution and then trypsinised with 
EDTA-trypsin at 37°C for 3 to 10 minutes to allow them to detach. FCS was 
added to inactivate the trypsin (1:1 ratio) and cell clumps were disrupted 
through gentle pipetting. The resulting liquid suspension of deaggregated cells 
was pipetted out of flask, and transferred to 15 mL sterile centrifuge tube. The 
cell suspension was centrifuged for 5 min at 1300 rpm. After centrifugation, the 
supernatant was aspirated and the cell pellet resuspended in an appropriate 
volume of medium. The resulting suspension was split to the desired dilution into 
new flasks and fresh media was added. 
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2.2 Cell treatments and RNA isolation  
For E2 treatment, 1.5 x 106 of MCF-7 cells were deprived of hormones through 
growth in DMEM lacking phenol red (Gibco, Invitrogen), supplemented with 10% 
dextran-coated charcoal-treated FCS (DSS) for 72 h then stimulated with E2 (10 
nM) for 0, 3, 6 or 12 h, at which points total RNA was isolated using Trizol 
(Invitrogen, UK). For the MCF-7-TO and the MCF-7-TO-PLZF-ERα lines, 1.5 x 106 
cells were seeded in 10 cm plates. After 24 h, the cells were washed with PBS 
and DMEM lacking phenol red, supplemented with 10% DSS and G418. Cells 
were cultured for a further 72 h, at which time E2 (10 nM) and Tet (1 μg/ml) 
were added as indicated. These cells were maintained in E2 for 24 h before Trizol 
RNA extraction [1]. 
For separation of small (< 200 nt) and large (> 200 nt) RNA fraction the 
miRNeasy mini kit was used for obtaining the larger fraction, followed by the 
RNeasy MinElute Cleanup kit to isolate the smaller fraction, according to the 
manufacturer’s instructions (Qiagen, Crawley, UK). Separation of RNA between 
the large and small fractions was confirmed by gel electrophoresis. After 
extraction the quality and levels of RNA were determined using an Agilent 
Bioanalyzer (Agilent Technologies, Edinburgh, UK) and a NanoDrop® ND-1000 
Spectrophotometer (Thermo Scientific, Horsham, UK) [1]. 
Cells were lysed directly in the well by adding 1ml of Trizol reagent and the 
lysates were collected in Eppendorf tubes and mixed by pipetting.  200µl of 
chloroform per 1ml of Trizol reagent were added to the lysates. The samples 
were vortexed vigorously for 15 seconds, incubated at RT for 2 to 3 minutes, and 
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then centrifuged at 12,000 x g for 15 minutes at 2 to 8°C. Following 
centrifugation, each mixture separates into lower red, phenol-chloroform phase, 
an interphase, and a colorless upper aqueous phase. RNA remains exclusively in 
the aqueous phase. Each aqueous phase was transferred carefully without 
disturbing the interphase into fresh Eppendorf tubes. The total RNA was 
precipitated from the aqueous phases by mixing with 500µl of isopropyl alcohol 
and incubating for 10 minutes at RT. The mixtures were then incubated 
overnight at -80 °C to allow small RNA precipitation. After incubation, the RNA 
precipitates were centrifuged at 12,000 x g for 10 minutes at 2 to 4°C to form a 
pellet on the side and bottom of the tube. The supernatants were removed, and 
the RNA pellets were washed by adding 1ml of 75% ethanol and vortexing. The 
samples were centrifuged at 7,500 x g for 5 minutes at 2 to 8°C. The 
supernatants were removed and any residues of ethanol were air-dried. Finally 
the RNA pellets were resuspended in an appropriate volume of RNAse-free 
water. Subsequently, RNA concentration was measured at 260nm and 280nm 
wavelengths, using a NanoDrop ND-100-Spectrophotometer (NanoDrop 
Technologies).  
2.3 miRNA microarray 
The microarray was done in collaboration with Genomics Laboratory, 
Hammersmith Hospital, Imperial College London. Isolated RNA was labelled 
using the Agilent labelling kit following the manufacturer’s instruction (Agilent 
Technologies, USA). The Agilent human (V1) miRNA Microarray platform, 
containing probes for 470 human and 64 viral miRNAs from the Sanger database 
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v9.1, was used to perform miRNA expression profiling. After hybridization, 
microarrays were scanned with Agilent scanner (G2565BA) using Agilent Feature 
Extraction software. Raw data were imported and analyzed by the Resolver gene 
expression data analysis system version 4.0 (Rosetta Biosoftware, Seattle, WA). 
A two-tailed Student t-test was performed with a p-value cutoff of 0.01 was used 
to identify significantly changed miRNAs. Three biological replicates were used in 
each experiment. 
2.4  Transfection and luciferase reporter assays 
MELN cells (5 x 105) were plated in 24 well plates in medium containing 
DMEM/10 % DSS for 24 h, transfected with either the pre-miR miRNA precursor 
or an anti-miR miRNA inhibitor (Applied Biosystems) for 48 h using HiPerFect 
Transfection Reagent (Qiagen) and treated with E2 (10 nM) or vehicle (ethanol) 
for 24 h before luciferase measurement. For the 3'UTR reporter assay, 200 ng 
pMIR-REPORT firefly luciferase vector, including the various fragment of ERα 
3'UTR, 100 ng of Renilla luciferase vector (pRL-TK) and the pre-miRNAs or 
negative control oligonucleotide, were transfected using Lipofectamine 2000 
(Invitrogen). Forty eight hours after transfection, cells were harvested and 
luciferase activity measured using the Dual-Glo luciferase assay system 
(Promega).  
MCF7 cells were plated in 24-well tissue culture plates at a density of 5 x 104 
cells/well in 0.5mL of medium without antibiotics. Cells were allowed to adhere 
and grown at 37 °C with 5% CO2 for 24 hours and then transfected accordingly. 
After forty eight hours of transfection, cells were lysed with 50µl/well of the Cell 
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Culture Lysis Buffer (5x) (Promega) fivefold diluted in dH2O and placed on 
agitator at constant speed for 30 minutes. Luciferase assay was performed by 
using the Dual-Glo Luciferase assy system (Promega). The lysates were 
transferred in a Opti-plate 96-well and mixed with 50µl/well Dual-GloTM 
Luciferase Reagent. After 10 minutes, the 96-well plate was sealed and the firefly 
luciferase activity was measured by using a luminometer. Renilla luciferase 
luminescence was measured by adding 50µl/well of Dual-GloTM Stop & Glo® 
Reagent, prepared according to the manufacturer’s instructions, and after 10 
minutes, the reading of Renilla luminescence was taken by a luminometer. The 
ratio of luminescence from the experimental reporter to luminescence from the 
control reporter was then calculated. 
2.5 Protein Analysis 
2.5.1 Preparation of cell lysates 
Cells were plated in 100-mm tissue culture dishes or in 6-well tissue culture plate 
for the pre-miRNAs over-expression, allowed to adhere and grown for 48 hours. 
The dishes were placed on ice and cells were washed once with cold PBS. Cells 
were scraped in cold PBS and centrifuged for 5 minutes at 1300 rpm. The 
supernatant was removed and the cell pellets was lysed in NP-40 lysis buffer (50 
mM Tris/HCl, pH 8.0, 150 mM NaCl, 10 % (v/v) glycerol, 1 % NP40, 5mM 
dithiothreitol (DTT), 1 mM EDTA, 1 mM EGTA) + protease inhibitors cocktail 
solution (Roche). Eppendorf tubes containing cell lysates were placed on a 
rotator for 15 minutes at 4°C. A microcentrifugation of the lysates at maximum 
speed (13,000 rpm) for 15 minutes at 4°C allowed the separation of protein from 
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insoluble elements. The supernatants containing proteins were transferred in 
new Eppendorf tubes and subsequently subjected to protein quantification. 
2.5.2 Protein quantification  
The protein concentration in the supernatants was determined using the 
Bradford Reagent (BioRad) diluted tenfold in dH2O. In reading cuvettes, a 
standard solution and a solution used as “blank” were prepared by adding 1µl of 
1mg/ml BSA (Invitrogen) and 1µl of the NP-40 working lysis buffer, respectively, 
in 1ml of diluted Bradford Reagent. Protein samples were diluted 1:10 and 1µl 
was added in 1ml of diluted Bradford Reagent. Absorbance readings were 
measured at 595nm using a UV/Visible spectrophotometer (Beckman DU® 530 
Life Science). Upon collection of the data, the concentration of the unknown 
samples was determined based on standard absorbance value. The protein 
samples were then prepared with the SDS Loading Buffer (2x) and boiled at 95°C 
for 5 minutes. 
2.5.3  Western blots 
Both acrylamide (6-20%) resolving and 4% stacking gels were prepared 
manually as required. The rainbow marker (Fermentas, life science) and protein 
samples (10µl) were loaded, electrophoresis was carried out for 2 to 3 hours at 
80V. Proteins were separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) in 1X SDS running buffer.  
Proteins were transfered to Hybond C super nitrocellulose membrane (GE 
Healthcare) at 100V for one hour in 1X transfer buffer using a Mini-PROTEAN® 
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Tetra Cell (BioRad). Following brief incubation with Ponceau S solution (Fluka) to 
check sufficient transfer, membranes were washed in 0.1% TBS-Tween (TBST), 
and incubated in 5% BSA in 0.1% TBST on a rocker shaker at 4°C for 1 hour. 
Membranes were probed using antibodies diluted in 5% BSA in 0.1% TBST 
overnight. We probed with AIB1, ERα, β-actin, ALY (mouse monoclonal 
antibodies) purchased from Abcam (Cambridge, UK). TBST was used to wash the 
membrane for three times, 15 minutes each. An IgG/HRP secondary antibody 
(DAKO, UK) diluted in blocking solution was then added, and the membrane was 
incubated at room temperature for 1 hour. The membrane was washed 3 times 
with TBST and Enhanced Chemiluminescence (ECL) detection system (GE 
Healthcare) was used for visualization. The emitted fluorescence was detected 
using Hyperfilm ECL (GE Healthcare) on SRX-101A x-ray developer. Band 
intensities were measured by the image analysis program Image J software 
(NIH, Bethesda, MD).  
 
2.6 Northern Blotting 
RNA was extracted using Trizol, total RNA (30μg per lane) was loaded on 15% 
denaturing polyacrylamide gel and electophoresed at 300V until the bromophenol 
blue approached the bottom. After electrophoresis the RNA was transferred from 
the gel to Hybond-N+ (GE Healthcare) membrane using a wet transfer 
apparatus. DNA oligonucleotide probe complementary to miR-18a, mir-21, mir-
34a and U6 were 5’ -end labeled with [γ-32P] ATP, and hybridization was 
performed using Miracle hybridisation buffer according to the manufacturer’s 
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instructions (Thermo Scientific). After hybridization, membranes were washed 
three times with 2× SSC and 0.05% SDS, twice with 0.1× SSC and 0.1% SDS, 
and exposed from overnight up to 1 week depending on the expression of the 
miRNA. 
2.7 Reverse Transcription and Real Time PCR 
2.7.1      cDNA synthesis for Taqman probe 
The reverse transcription of mature miRNAs was performed using the TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems). 10ng of total RNA 
were mixed with 7µl of master mix and 3µl of microRNA-specific RT TaqMan 
Probes (Applied Biosystems) in a 48-well PCR plate (Thermo Scientific, 
Abgene®). The samples were incubated in the 7900Ht Thermal Cycler (Applied 
Biosystems) at 16°C for 30 minutes to allow primers to anneal, followed by 30 
minutes at 42°C for the elongation step, and 5 minutes at 85°C to inactivate the 
reverse transcriptase. After RT cycles, the cDNAs samples were placed in ice and 
then prepared for quantitative real-time PCR. 
2.7.2      Quantitative real-time PCR by Taqman probe 
In order to amplify mature miRNAs, for a single reaction, 1ng of relative cDNA 
template was distributed in a Fast Optical 96-well reaction plate (Applied 
Biosystems), followed by the appropriate volume of a master mix. The master 
mix was prepared by combining 10μl of 2x TaqMan® Universal PCR Master Mix, 
No Amperase® UNG (Applied Biosystems) with 1μl of the relative 20x Real Time 
TaqMan probe (Applied Biosystems), by adding ddH2O to a final volume of 
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15.57μl per single reaction. Each reaction was done in triplicate. The plate was 
then sealed using the Optical Adhesive Cover Starter Kit (Applied Biosystems) 
and centrifuged (2,000 x g) for 30 seconds at 4°C. Quantitative real-time PCR 
(qPCR) was performed with an ABI Prism 7900HT sequence detection system 
(Applied Biosystems) with a thermal cycling program as follow: a first stage of 10 
minutes at 95°C followed by 40 cycles of 15 seconds at 95°C and 1 minute at 
60°C. Finally, data were analyzed using SDS 3.1 software (Applied Biosystems).  
2.7.3   cDNA synthesis for Sybr green 
The reverse transcription of Primary (pri) and Precursor (pre) transcripts was 
performed using the SuperScript III First-Strand cDNA synthesis system 
(Invitrogen). 1µg of purified DNAse treated RNA were mixed with reverse 
primers in a 48-well PCR plate (Thermo Schientific, Abgene®). The samples were 
incubated in the 7900HT Thermal Cycler (Applied Biosystems) at 65°C for 10 
minutes to open up the secondary structures and also for primers to anneal. 
Then 6µl of master mix was added to make a final volume of 10µl. Cycling 
conditions for the reaction were 55°C for 30 minutes and 5 minutes at 85°C to 
inactivate the reverse transcriptase. After RT cycle, the cDNAs samples were 
placed in ice and then prepared for quantitative real-time PCR. 
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2.7.4      Quantitative real-time PCR by Sybr green 
In order to amplify the primary and precursor transcripts, 10ng of cDNA template 
was distributed in a Fast Optical 96-well reaction plate (Applied Biosystems), 
followed by the appropriate volume of a master mix. The master mix was 
prepared by combining 10μl of 2x Power SYBR green PCR master mix (Applied 
Biosystems) and 10μl of cDNA/ primers, add ddH2O to a final volume of 20μl per 
single reaction. Each reaction was done in triplicate. The plate was then sealed 
using the Optical Adhesive Cover Starter Kit (Applied Biosystems) and 
centrifuged (2,000 x g) for 30 seconds at 4°C. Quantitative real-time PCR (qPCR) 
was performed with an ABI Prism 7900HT sequence detection system (Applied 
Biosystems) with a thermal cycling program as follow: a first stage of 10 minutes 
at 95°C followed by 40 cycles of 20 seconds at 95°C 20 seconds, 20 seconds at 
60°C and 20 seconds at 72°C. Data were analyzed using SDS 3.1 software 
(Applied biosystems).  
 
2.8 ChIP (Chromatin Immunoprecipitation)  
MCF-7 cells were first cross-linked using 37% Formaldehyde.  The cells were 
then resuspended in solution 1 (0.25% Triton X-100, 10 mM EDTA, EGTA 0.5 
mM, 10 mM Tris-HCl pH 8), and fresh protease inhibitor cocktail (Roche) was 
added. The cells were rotated at 4oC 10 min, spun down and then solution 2 
(0.2 M NaCl, 10 mM EDTA, 0.5 mM EGTA, 10 mM Tris-HCl pH 8) was added. The 
cells were rotated at 4oC 10 min, spun down again and resuspended in 
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sonication buffer (SDS – 1%, EDTA – 10mM, Tris HCl pH 8 – 50 mM). The 
samples were sonicated (at a frequency predetermined to produce appropriately 
sized DNA fragments) and resuspended in ChIP buffer (0.01% SDS, 1.1% Triton-
X100, 1.2mM EDTA, 16.7mM Tris-HCl, pH8.1, 167mM NaCl). Each aliquot cross-
linked chromatin (20 μg) was precleared with 25 μl of Protein A-Sepharose beads 
(Amersham Biosciences). Aliquots were incubated overn 
ight with 2 µg of c-Myc (sc-764) and ERα (sc-543) antibodies (Santa Cruz 
Biotechnology, Heidelberg, Germany) or without (mock controls) in a total 
volume of 1 ml and immunoprecipitated. Reverse histone-DNA crosslinking was 
done by adding 5M NaCl (5µl) to the eluate and input samples and incubated at 
650C overnight. RNase (Qiagen, 100mg/ml) was added to samples (final 
concentration – 50µg/ul) to degrade RNA, incubated at 37 0C for 30 minutes and 
the DNA was purified with phenol chloroform extraction. Triplicate samples of 5 
µl of immunoprecipitated genomic DNA were amplified by real time PCR. Values 
are expressed as fold of enrichment with respect to input DNA. Primer sequences 
used in this assay are listed in Table 2. 
2.9 Breast cancer specimens 
Snap frozen breast cancers derived from post-menopausal women with strongly 
ERα positive (immunohistochemistry 3+) or negative (control group) primary 
invasive ductal carcinomas were included, as described [301]. Total RNA was 
extracted from ~500 µg of frozen tissue using Trizol (Invitrogen). For 
quantification of pre-miR-18a, U6 and HNRPA1, cDNA was synthesized from 1 μg 
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of purified DNAse treated RNA by the SuperScript III First-Strand cDNA synthesis 
system (Invitrogen) and qRT-PCR was performed on a 7900HT Thermocycler 
using the Power SYBR green PCR master mix (both from Applied Biosystems). 
Appropriate ethical approval was obtained. 
2.10 EMSA (Eletrophoeretic Mobility Shift Assay) 
EMSA were performed as described previously [302]. Briefly, binding reactions 
were carried out in (20 mM HEPES, pH 8.0, 100 mM NaCl, 10 mM MgCl2, 1 mM 
EDTA, 1 mM DTT, 1 µg/µl BSA and 10% glycerol), final reaction volume of 20 µl 
for 30 min at 37°C. γ-32P labeled single-stranded probes (Table 7) were added to 
a final concentration of 5nM together with recombinant Aly/Ref. Reactions were 
subjected to electrophoresis on 12% polyacrylamide gels containing 5% glycerol 
in TBE (0.5X) and run for 2 hours at 300V until the bromophenol blue 
approached the bottom of gel. After electrophoresis, gels were dried and 
exposed to Hyperfilm ECL (GE Healthcare).  
2.11 Co-Immunoprecipitation 
Co-immunoprecipitation (Co-IP) was performed to detect protein-protein 
interactions. MCF-7 cells were starved in DMEM lacking phenol red (Gibco, 
Invitrogen), supplemented with 10% dextran-coated charcoal-treated FCS (DSS) 
for 72 h and then stimulated with E2 (10 nM) for 3h with ethanol used as an (E2-
) control treatment (‘vehicle’). Cells were treated as indicated in the text and 
lysed by sonication in Marais' lysis buffer (25 mM HEPES [pH 7.8], 400 mM KCl, 5 
mM EDTA, 0.4% NP40, 10% glycerol freshly supplemented with 1 mM DTT, 
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protease, and phosphatase inhibitors). The extracts were diluted fourfold to bring 
KCl concentration to 100 mM and NP40 to 0.1%, supplemented with 0.5% BSA 
(Roche, UK) and 10 mM MgCl2. The extracts were incubated on ice for 15 
minutes and spun at the max speed (13,000 rpm) at 4°C; the supernatant 
(lysates) was removed and transferred to a new eppendorf. The lysates were 
further with incubated with protein-A sepharose beads and 5µg of flag-Dicer ab 
(M2 clone, sigma-aldrich, USA) for immunoprecipitation, overnight at 4°C. Beads 
were quickly washed three times at RT with wash buffer (100 mM KCl, 0,05% 
NP40) and subjected to centrifugation (13,000 rpm) to remove the supernatant. 
The beads were then boiled at 95°C for 5 minutes with Laemmli buffer before 
separation on a SDS-PAGE gel. 
2.12 Mass Spectrometry Analysis by HPLC MS/MS 
The Mass Spectrometry was done in collaboration with Dr. Robin Wait, Charing 
Cross Hospital, Imperial College London. This protocol was kindly provided by Dr. 
Robin Wait.  
Protein identification and relative quantitation were performed by liquid 
chromatography mass spectrometry using the isobaric tags for relative and 
absolute quantitation (iTRAQ) method. This is an amino tagging strategy which 
employs up to eight isobaric but isotopically distinguishable derivatization 
reagents, which are coupled to free amino groups of sample peptides. We 
performed a series of duplex comparisons [Estrogen stimulation (E2) vs Vehicle 
(E2-); pre-miR-18a over expression vs pre-miR-34a over expression (control 
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bait)]. MCF7 cells (2 X 107) were lysed in 250 µl 0.5 M triethylammonium 
bicarbonate /0.05% SDS at 4° C, centrifuged and protein quantified by Bradford 
assay. After cysteine reduction and alkylation 100 µg aliquots of protein were 
digested with trypsin overnight at 37° C. Each 50-100 µg sample will then be 
derivatised with 1 unit of label (iTRAQ-4plex; Applied Biosystems, Warrington 
UK) for 1 h at room temperature.   
The samples resulting from each binary comparison experiment were pooled, 
and fractionated prior to LC MS by off line strong cation exchange 
chromatography. Eight fractions from 50mM to 500mM salt were collected, 
resuspended in 0.1% formic acid and loaded onto a 15 cm x 75µ C18 column (LC 
Packings pepmap) installed in a Dionex Ultimate 3000 HPLC system. Peptides 
were separated with acetonitrile 0.1% formic acid gradient into a Q-Star XL mass 
spectrometer (Applied Biosystems) fitted with a nanoflow ESI source 
(Protana/Applied Biosystems), and tandem mass spectra obtained by automated 
data dependant acquisition. Protein identification and quantitation were 
performed using both proQuant software (Applied Biosystems) and our local 
Mascot server using 4-plex iTRAQ reagents as fixed modifiers [303] [304] 
2.12.1 Identification of gel separated proteins 
Proteins bands were excised from the gels and digested with trypsin as described 
previously [304] and analysed using a Q-Tof spectrometer (Micromass, 
Manchester, UK) interfaced to a Micromass CapLC capillary chromatograph fitted 
with a 300 µm x 5 mm Pepmap C18 column (LC Packings, Amsterdam, NL). Data 
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dependent acquisitions were performed on precursor masses with charge states 
of 2, 3 or 4, over the m/z range 400-1300 using argon collisional activation, and 
proteins were identified by correlation of uninterpreted spectra to entries in 
SwissProt/TrEMBL, using Mascot version 2.2 (Matrix Science, London). 
2.13 Transfection of Plasmid DNA 
Cells were seeded in 10cm dishes to confluency of approximately 90% with 
DMEM medium without any antibiotics. Lipofectamine® 2000 (Invitrogen) was 
used as the transfection reagent. The ratio 3:1 (ul of Lipofectamine® 2000: μg 
of DNA) was used, as recommended by the manufacturer. To begin, 975 μl of 
optimem was pipetted into a sterile eppendorf tube. 18μl of Lipofectamine® 
2000 were then carefully added and the mixture was shaken slightly and left at 
RT for 5 minutes. To this 6μg of plasmid DNA was added, gently mixed and left 
at room temperature for 20 minutes. The mixture was then pippetted dropwise 
into the 10cm dish while gently being shaken for uniform distribution of the 
transfection complex. Overexpression of desired proteins was confirmed 48h 
after transfection, by real-time and western blot analysis 
2.14 RNA Interference (RNAi) – Kinome Screening 
siRNA library (Human Kinase siRNA Set V3.0, Qiagen) containing 691 kinases was 
used to specifically repress the expression of entire kinome. In this study, all 
siRNAs used were pooled siRNAs which had 2 siRNAs targeting two independent 
sites on the same gene. HiPerFect (Qiagen) was used as the transfection 
reagent. MCF7 cells 40,000 per well of a 24-well plate, were plated in DMEM 
84 
 
 
 
 
 
lacking phenol red (Gibco, Invitrogen), supplemented with 10% dextran-coated 
charcoal-treated FCS (DSS) 24h prior to transfection. For each well, 20nM of 
siRNA was added to 85μl of neat DMEM medium to clean eppendorf and then 3μl 
of HiPerFect was added to each tube. The mix was incubated at room 
temperature for 10min. After incubation, the mix was added drop-wise to the 
wells and the plates were shaken for uniform distribution of the transfection 
complex. Cells were also transfected with appropriate controls provided together 
with the siRNA libarary. After 48h of transfection, the cells were treated with 
Estradiol (E2) and Vehicle (Ethanol) respectively. Further after 24h of E2 
stimulation the cells (in total 72h of transfection) were subjected to total RNA 
extraction. 
2.15 Total RNA Extraction – for Kinome Screening 
After 60h of transfection with siRNAs, total RNA was isolated from MCF7 cells 
using the RNeasy Kit (Qiagen, Crawley, UK). The protocol was performed in line 
with the manufacturer’s instructions using QIAcube (Qiagen, USA). Cells were 
resuspended in 350μl of RLT buffer (containing 10% ßmercaptoethanol), 
homogenised with 1000 μl pipette and the lysates were transferred to the 
QIAshredder spin column and 350 μl of 70% ethanol was added, mixed by 
pipetting. The total mixture was added to the provided column placed in a 2ml 
collection tube and spun at 13,000rpm for 30s, and the flow through was 
discarded. 700μl of buffer RW1 was added to the column and was spun at 
13,000rpm for 30s, the flow through was again discarded. Next, 500 μl of RPE 
buffer was added to the column and microcentrifuged at 13,000 rpm for 30s, the 
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flow through was discarded and the column, spun for an additional 2 minutes at 
13,000 rpm to extract any waste from the column. The column was then 
transferred to a clean eppendorf tube. 30μl of RNase-free water was carefully 
added to the centre of the column and was spun for 1 minute at 13,000 rpm to 
elute the extracted RNA. The purity and concentration of the RNA was then 
determined using Nanodrop, which measures the spectrometric absorption at 
260nm and 280nm. RNA samples were then stored at -80ºC. 
2.15.1 Reverse Transcription and Real Time PCR – Kinome screening 
The Reverse transcription was performed using high capacity cDNA reverse 
transcription kit (Applied Biosystems). 1µg of total RNA were mixed with 
MultiScribe™ Reverse Transcriptase, dNTPs and random primer mix in a 48-well 
PCR plate (Thermo Schientific, Abgene®). The samples were incubated in the 
Veriti® 96-Well thermal Cycler (Applied Biosystems) at 25°C for 10 minutes to 
allow primers to anneal, followed by 120min at 37°C for the elongation step, and 
5 minutes at 85°C to inactivate the reverse transcriptase. After RT cycles, the 
cDNAs samples were placed in ice and then prepared for quantitative real-time 
PCR. 
2.15.2 Quantitative real-time PCR by taqman probe - Kinome screening  
In order to amplify single gene expression, 5ng of cDNA template was distributed 
in a Fast Optical 96-well reaction plate (Applied Biosystems), followed by the 
appropriate volume of a master mix. The master mix was prepared by combining 
10μl of 2x TaqMan® Universal PCR Master Mix (Applied Biosystems) with 1μl of 
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the relative 20x Real Time TaqMan probe (primers for TFF1, PGR, GREB1, 
LMTK3, and GAPDH, purchased from Applied Biosystems), and finally by adding 
appropriate volume of ddH2O to make final volume of 20μl per single reaction. 
Each reaction was done in triplicate. The plate was then sealed using the Optical 
Adhesive Cover Starter Kit (Applied Biosystems) and centrifuged (2,000 x g) for 
30 seconds at 4°C. Quantitative real-time PCR (qPCR) was performed with an 
ABI Prism 7900HT sequence detection system (Applied Biosystems) with a 
thermal cycling program as follow: a first stage of 10 minutes at 95°C followed 
by 40 cycles of 20 seconds at 95°C, 20 seconds at 60°C and 20 seconds at 72°C. 
Finally, data were analyzed using SDS 3.1 software (Applied biosystems).  
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2.16 Materials  
2.16.1 Buffers and Solutions 
 
 
Reagent Recipe Storage 
 
PBS (Phosphate 
 buffered Saline) 
 
EDTA-Trypsin 
 
1M DTT 
(Dithiothreitol) 
 
5 PBS tablets (Sigma) dissolved  
in 500ml of ddH20 
 
2.5g/l Trypsin in 0.02% EDTA 
(Sigma-Aldrich) 
 
1.54g of DTT in total of 10ml ddH20 
(double distilled MilliQ water) 
 
 
4°C 
 
 
4°C 
 
100μl aliquots at -
20°C 
75% Ethanol 
 
1M Tris-HCl 
 
 
 
Laemmli’s buffer 
 
 
 
 
75ml Ethanol added to 25ml of ddH20 
 
60.5g Tris in total of 500ml ddH20 
and adjusted to desired pH with pure 
HCl 
 
50mM Tris-HCl pH 6.8, 15% glycerol, 
0.1% (w/v) bromophenol blue,  
4% SDS (BioRad) 
 
 
Room 
temperature 
 
Room 
temperature 
 
 
Room 
temperature 
 
 
 
Table 4: Lists of buffer and reagents  
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SDS (Sodium Dodecyl 
Sulphate) loading 
buffer (2x) 
 
 
10x SDS PAGE  
Running buffer 
 
 
10x Transfer buffer 
 
 
TBS 10x 
(Tris-Buffered Saline) 
 
 
TBST buffer 
(TBS/ Tween® 20) 
 
Blocking solution  
 
125mM Tris-Cl pH 6.8, 20% glycerol,  
4% SDS, 100mM DTT,  
0.04% (w/v) bromophenol blue 
 
 
10g SDS, 30.3g Tris, 144.1g glycine 
dissolved in  
1l of ddH20 
 
30.3g Tris, 144,1g glycine dissolved  
in 1l of ddH20 
 
24.23g Trizma HCl, 80.06 g 
NaCl dissolved in 1l of ddH20 and 
adjusted pH to 7.6 with pure HCl 
 
100ml of TBS 10x, 900ml ddH20,  
1ml Tween® 20 (BDH) 
 
5% dried skimmed milk powder  
in TBS/ Tween 
 
500μl aliquots at 
4°C 
 
 
 
Room 
temperature 
 
 
Room 
temperature 
 
Room 
temperature 
 
 
Room 
temperature 
 
 
Prepared as 
required 
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2.16.2  Primers 
Most of the Primers were synthesized from Eurofins and some of them by Sigma-
Aldrich. 
 
Gene Forward primer Reverse primer 
GREB1 CAAAGAATAACCTGTTGGCCCTGC GACATGCCTGCGCTCTCATACTTA 
GAPDH TGAAGGTCGGAGTCAACGGATTT GCCATGGAATTTGCCATGGGTGG 
U6 CTCGCTTCGGCAGCACA AACGCTTCACGAATTTGCGT 
HNRPA1 ATACTGTGAATGGCCACAA AACCACTTCGACCTCTTTG 
ERα GAATCTGCCAAGGAGACTCGC ACTGGTTGGTGGCTGGACAC 
AIB1 CGTCCTCCATATAACCGAGC TCATAGGTTCCATTCTGCCG 
TIF2 GCCCGATTTCTCTTGGATTTG TGGAGGGGTCAGAGGTATTT 
SRC1 ATGGTGAGCAGAGGCATGACA AAACGGTGATGCTCATGTTG 
ER1 CGCACTAGTAAATGGCTCTAAGAATAAGC CGCACGCGTAGTGCTATTTTGTCTACTGT 
ER2 CGCACGCGTGATGCCTATTGTTGGATACT CGCACGCGTAATTGTTTACAGGTGCTCGA 
ERup CGCACGCGTAGTGCTATTTTGTCTACTGT CGCACTAGTCCACACGGTTCAGATAAT 
ERfl CGCACGCGTAGTGCTATTTTGTCTACTGT CGCACGCGTAATTGTTTACAGGTGCTCGA 
TFF1 promoter CACCCCGTGAGCCACTGT CTGCAGAAGTGATTCATAGTGAGAGAT 
mir-17-92 
promoter 
AAAGGCAGGCTCGTCGTTG CGGGATAAAGAGTTGTTTCTCCAA 
pri-miR-17-92 CAGTAAAGGTAAGGAGAGCTCA CATACAACCACTAAGCTAAAGAA 
pre-miR-18a TAAGGTGCATCTAGTGCAGATAG GAAGGAGCACTTAGGGCAGT 
pri-miR-34a CAACCAGCTAAGACACTGCCAA CCTCCTGCATCCTTTCTTTCCT 
pre-miR-34a TGGCAGTGTCTTAGCTGGTTG GGCAGTATACTTGCTGATTGCTT 
pri-miR-342 GCCATTGCATCCTTCTCT TCAATCACAGATAGCACCC 
Table 5: Primer sequences 
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RBM34 GCCTGTGCCTAAACAAACC CTTGCGAAAGTGGTCTTTCA 
TNRC6B GTTTCAAAGAAGGGTGCTG ACAAACATCCTCATGCTTCA 
METTL3 TCGTTAGAAGCTGAAGGAAG ACAGGTTCAGTTCAATCACA 
CTTN TCCCAGAAAGACTACTCCA TGTCGATACCGTATTTGCC 
SF3B3 GCCCGACTTACCAATTCA TGTCTGCTTCCTCATAATCC 
ANKRD17 AGTCCCTCAGGTATTGTCA CATCGTACCTCCTGAAATGT 
DAZAP1 GAAGGAAGGATGGCAGAAA GGAAGGATGGCAGAAAGG 
ALY/REF CGTGGAGACAGGTGGGAAAC GCACAGCCGCCTTCTTCAG 
DICER GTACGACTACCACAAGTACTTC ATAGTACACCTGCCAGACTGT 
 
 
miR Northern Blot primers 
miR-18a TATCTGCACTAGATGCACCTT 
miR-21 TCAACATCAGTCTGATAAGCT 
miR-34a  ACAACCAGCTAAGACACTGCC 
U6 GAATTTGCGTGTCATCCTTGCGCAGGGGCCATGCTAA 
 
 
MiR Nucleotides Used in EMSA 
miR-18a ss UAAGGUGCAUCAAGUGCAGAUAG 
miR-18a* ACUGCCCUAAGUGCUCCUUCUGG 
miR-18a TL 
(Terminal loop) 
UGAAGUAGAUUAGCAUCU 
Pre-18a CCAGAAGGAGCACTTAGGGCAGTAGATGCTAATCTACTTCACTAT 
 
Table 6: Northern Blot Primer sequences 
 
      
 
Table 7: Nucleotides Used in EMSA assay 
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Gene Gene Description siRNA sequence 
ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1 ACGCACGGACATCACCATGAA 
ACVR1 activin A receptor, type I CTGGTCTGTCTTTGGATAATA 
ACVR2
B activin A receptor, type IIB TACGGTCATGTGGACATCCAT 
AK1 adenylate kinase 1 CCGGGATGCCATGGTGGCCAA 
AKAP1 A kinase (PRKA) anchor protein 1 AGCGCTGAACTTGATTGGGAA 
AKAP1
3 A kinase (PRKA) anchor protein 13 CACGGTCATTATGAGAAACAA 
AKT2 v-akt murine thymoma viral oncogene homolog 2 CAAGCGTGGTGAATACATCAA 
AKT3 v-akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma) ACCAGAGGTGTTAGAAGATAA 
ATM ataxia telangiectasia mutated (includes complementation groups A, C and D) AAACTACTGACTCGTGTATTA 
ATR ataxia telangiectasia and Rad3 related GACCGGATACTTACAGATGTA 
BCR breakpoint cluster region CAGCATTCCGCTGACCATCAA 
CAMK1
G 
calcium/calmodulin-dependent protein 
kinase IG CAGGTCTTGTCGGCAGTGAAA 
CAMK2
A 
calcium/calmodulin-dependent protein 
kinase (CaM kinase) II alpha CAGGAACTTCTCCGGAGGGAA 
CDC2L
1 
cell division cycle 2-like 1 (PITSLRE 
proteins) CAGGATCGAGGAGGGCACCTA 
CDKN2
A 
cell division cycle 2-like 1 (PITSLRE 
proteins) CAGGATCGAGGAGGGCACCTA 
CIT citron (rho-interacting, serine/threonine kinase 21) CAGGATATACCGTAACACGAA 
CKMT1
B creatine kinase, mitochondrial 1B ACGGATCTAGATGCCAGTAAA 
DAPK1 death-associated protein kinase 1 AAGCATGTAATGTTAATGTTA 
EPHB1 EPH receptor B1 ATGGCCCTGGATTATCTACTA 
GALK1 galactokinase 1 CCGCCTCATGGTGGAGAGCCA 
GRK6 G protein-coupled receptor kinase 6 AAGGATGTTCTGGACATTGAA 
IKBKA
P 
inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase complex-
associated protein 
CAGCGGTTTACTATAGACAAA 
KSR1 kinase suppressor of ras 1 CAAGGCGAAGCTGGTCCGTTA 
LMTK3 lemur tyrosine kinase 3 CAAGTTCATCTCGGAAGCACA 
MAP3K mitogen-activated protein kinase kinase AAGATGGTATATACCAAGTTA 
Table 8: siRNA sequence of the kinases whose knockdown down-
regulated TFF1  expression 
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7 kinase 7 
MAP3K
7IP2 
mitogen-activated protein kinase kinase 
kinase 7 interacting protein 2 CAGTCAATAGCCAGACCTTAA 
MAPKA
P1 
mitogen-activated protein kinase 
associated protein 1 CTCCCTTATTCAGGTGGACAA 
MARK4 MAP/microtubule affinity-regulating kinase 4 CTGCAGCCTGTTGCCCAATAA 
MAST4 microtubule associated serine/threonine kinase family member 4 TTCCCAGTTGTAACCGGTAAA 
PIK3C2
B 
phosphoinositide-3-kinase, class 2, beta 
polypeptide CAGGGTGGTCCAGTCCGTCAA 
PRKAR
1B 
protein kinase, cAMP-dependent, 
regulatory, type I, beta GACAACGAGAGGAGTGACATA 
TAOK2 TAO kinase 2 ACCTACAAACTTCGCAAGGAA 
TYRO3 TYRO3 protein tyrosine kinase AACGGTGACCTTTAGTGCCAA 
 
 Gene Gene Description      siRNA sequence 
BMPR1
B 
bone morphogenetic protein receptor, 
type IB ACGGATATTGTTTCACGATGA 
CCRK cell cycle related kinase TGGCGAGATAGTTGCCCTCAA 
CLK3 CDC-like kinase 3 CACGAAGATCTCGGTCCAGAA 
DDR1 
discoidin domain receptor family, 
member 1 ACGGTGTGAATCACACATCCA 
DGKZ diacylglycerol kinase, zeta 104kDa CAAGAGGAACGACTTCTGTAA 
FN3KR
P fructosamine-3-kinase-related protein TAGGTAGACGGAGCCACACTA 
   
LATS2 
LATS, large tumor suppressor, homolog 
2 (Drosophila) AAGGATGTCCTGAACCGGAAT 
NEK3 
NIMA (never in mitosis gene a)-related 
kinase 3 ACGATAGAGGTGGTTCTGTAA 
NEK8 
NIMA (never in mitosis gene a)- related 
kinase 8 ACGGACAGTTGGGCACCAATA 
PANK2 
pantothenate kinase 2 (Hallervorden-
Spatz syndrome) CTGTGTGTGAACTTACTGTAA 
PIP5K2
B 
phosphatidylinositol-4-phosphate 5-
kinase, type II, beta CACGATCAATGAGCTGAGCAA 
RIOK1 RIO kinase 1 (yeast) GCCCAACAAGATAATATTCTA 
RPS6K
A6 
ribosomal protein S6 kinase, 90kDa, 
polypeptide 6 GGCGAGGTAAATGGTCTTAAA 
Table 9: siRNA sequence of the kinases whose knockdown up-
regulated TFF1  expression 
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Chapter 3: Results 
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3.1 Chapter-1 
ERα is one of the most studied proteins in breast cancer and is largely 
responsible for endocrine therapy resistance in breast cancer [305]. miRNAs are 
small non-coding RNA molecules involved in gene regulation and the modulation 
of many biological mechanisms. We were interested to explore which miRNAs 
could be regulated by the estrogen receptor and vice versa. At the outset of this 
study, no other publications existed regarding regulation of miRNAs by estrogen 
receptor, but over recent years many studies have revealed the ‘cross-talk’ 
between miRNAs and estrogen receptor (which is discussed later in chapter 4.1). 
We wanted to perform miRNA microarray to reveal all of the possible miRNAs 
regulated by ERα after the estrogenic response.  
3.1.1 GREB1 modulation by ERα in an E2 dependent manner 
We wanted to perform a time course experiment after E2 treatment at 3, 6 and 
12 hours and evaluate the miRNA expression profile. In order to do so we first 
carried out initial experiments to optimise the conditions before performing the 
microarray experiment using GREB1 as a positive control. GREB 1 is a critical 
regulator of estrogen induced growth of breast cancer cells [306]. To do so, 
MCF-7 cells were grown in 10% FCS and then switched to a starved condition 
using DMEM (phenol red free) supplemented with 10% double charcoal stripped 
FCS (DSS) for 72 hours. After this period the cells were either treated with 
vehicle or treated with 10nM E2 for the above mentioned time periods. After total 
RNA extraction from each treated sample, expression of GREB1 was analysed by 
qRT-PCR using SYBR green and normalized to the GAPDH housekeeping gene, 
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which remains stable throughout treatment (Fig 12A).  We observed the 
expected fold expression change of GREB1 at 3h, 6h and 12h of E2 treatment 
when compared to the untreated sample (vehicle) [306].  
As a further control we used JP13 cell lines, MCF-7 cells mutated to conditionally 
over-expresses a protein composed of the zinc finger transcriptional repressor 
PLZF fused to ERα (PLZF-ERα) when tetracycline (Tet) is removed from the 
growth medium (Tet-off system). This fusion protein acts as a dominant-negative 
that inhibits the expression of estrogen-regulated genes and estrogen-stimulated 
growth of MCF-7 cells [300]. The JP13 cells were kindly provided to us by Dr. 
Laki Buluwela. 
When compared with the control MCF7-TO cell line (an MCF-7 derived cell line 
that expresses the tetracycline-regulated transactivator Tet-Off), GREB1 
expression was decreased in the JP13 cells when Tet was removed from the 
medium (Fig. 12B) [307]. These control experiments indicate that treatment with 
E2 and reduced expression of ER regulated genes with PLZF-ER, these were 
optimized conditions for producing a miRNA expression profile and identifying ER 
regulated miRNAs.   
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3.1.2 Microarray to reveal ERα regulated miRNAs 
To determine whether ERα regulates the expression of miRNAs, MCF-7 cells were 
maintained in starved condition using DMEM (phenol red free) supplemented 
with 10 % DSS for 72 hours; then E2 was added at 3h, 6h, 12h respectively as 
described above, and miRNA chip hybridization was performed to elucidate early 
(0-3 h) and delayed (>6 h) regulation of miRNAs by ERα. As a control we used 
the JP13 and MCF-7-TO (MCF-7-Tet-Off) derived cell line. After hybridization, the 
raw data were imported into the Rosetta Resolver software system for data 
analysis. Following microarray analysis we did not reveal any miRNAs with 
expression changes greater than 2 fold comparing 0 h to 3h, 6h and 12 h (P < 
0.05). Moreover, we found that those miRNAs that increased following E2 in 
MCF-7 cells (Fig.13A) were decreased in the JP13-Tet-Off system used as a 
control (Fig.13B). Interestingly, most of the ERα up-regulated miRNAs were 
derived from mir-17-92 and its paralogue clusters mir-106a-363 and mir-106b-25 
(Fig. 8) which are known to be important in cancer biology. 
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Figure 13: Microarray analysis revealed ERα regulated miRNAs. Graphical 
representation of upregulated and downregulated genes after 6h of estradiol treatment 
compared to the vehicle treated. (A) MCF-7 cell lines underwent E2 stimulation (10 nM) 
after 72 h of hormone deprivation. After total RNA extraction and labelling we used a 
microarray platform containing probes for 470 human miRNAs. After hybridization and 
scanning, raw data were imported into the Rosetta Resolver system for analysis. P < 0.01 
was used as cut-off for identification of miRNAs up-regulated or down-regulated between 
0 h versus 6 h.  
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Figure 13: Microarray analysis revealed ERα regulated miRNAs. Graphical 
representation of upregulated and downregulated genes after 6h of estradiol treatment 
compared to the vehicle treated in JP13 cells. (B) JP13 cells were cultured in the 
presence or absence of Tet for 72 h, followed by the addition of 10 nM E2 for 24 h prior 
to microarray analysis. Once again P < 0.01 was used as cut-off for identification of 
miRNAs down-regulated in JP13 Tet (+) versus JP13 (Tet-).  
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Table 10 shows miRNAs up- and down-regulated with significant p-value (P < 
0.01). 
miRNA name Fold change 
(oh vs 3h) 
P value Fold change 
(oh vs 6h) 
P value Fold change 
(JP13+Tet  vs 
jp13)- 6h 
P value 
hsa-miR-489         1.28 5.15E-03     
hsa-miR-32           1.54 3.28E-03   
hsa-miR-424   1.48 2.00E-05 -1.16 4.77E-03 
hsa-miR-101   1.45 1.73E-03   
*hsa-miR-19a   1.36 4.04E-03 -1.26 1.44E-03 
hsa-miR-92b     -1.32 4.81E-02 
*hsa-miR-20b 1.16 9.13E-02 1.31 9.52E-08 -1.28 5.32E-06 
hsa-miR-450   1.24 1.14E-03   
*hsa-miR-19b 1.17 5.69E-03 1.29 5.02E-06 -1.28 2.62E-08 
*hsa-miR-20a 1.13 1.55E-02 1.29 1.73E-07 -1.28 4.63E-13 
hsa-miR-7 1.23 4.01E-03 1.27 2.59E-14   
*hsa-miR-92     -1.27 2.62E-03 
*hsa-miR-106a 1.16 3.95E-03 1.29 3.90E-04 -1.26 4.00E-05 
hsa-miR-429   1.26 2.00E-05   
*hsa-miR-17-5p   1.25 4.35E-03 -1.25 6.96E-06 
*hsa-miR-18a   1.10 2.78E-01 -1.25 2.46E-07 
*hsa-miR-93 1.13 4.46E-03 1.12 1.00E-05 -1.15 3.41E-06 
hsa-miR-301     -1.13 1.00E-04 
*hsa-miR-25 1.10 2.36E-06 1.15 4.91E-03 -1.14 3.65E-07 
*hsa-miR-106b     -1.13 4.21E-06 
hsa-miR-181a -1.11 2.60E-04 -1.10 2.30E-03   
hsa-miR-181b   -1.13 4.58E-03   
hsa-miR-181d   -1.15 9.51E-03   
hsa-miR-181a -1.36 2.60E-03     
hsa-miR-22 -1.20 1.00E-05     
hsa-miR-30a-5p -1.24 1.72E-03     
hsa-miR-487b -1.32 1.26E-03 -1.25 8.56E-03   
hsa-miR-494 -1.27 1.75E-03     
hsa-miR-198   -1.34 3.77E-03   
hsa-miR-500   -1.37 5.87E-03   
       
Table 10: List of upregulated and downregulated miRNAs from microarray with 
significant p-value. MiRNAs encoded by the 3 paralogous clusters (miR-17–92, miR-106a-
363, and miR-106b-25) are indicated by *. In our experiments, for each individual miRNA 
atleast 2 or 3 probes were spotted on the platform and data are shown for a representative 
miRNA, but interestingly all the probes abundantly reach our statistical thresholds. 
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3.1.3 Validation of microarray results by Real-time PCR  
To confirm the change of expression detected by the microarray, we performed 
RT-qPCR from the same RNA samples choosing those miRNAs modulated 
between 1.2 to 2 fold in cells treated with E2 and those repressed similarly by 
PLZF-ERα in JP13 cell lines.  To validate the results we choose miR-18a, miR-19a 
and miR-20a from the miR-17-92 cluster and miR-19b, miR-20b and miR-92 from 
the miR-106a-363 cluster. We also chose miR-424 and miR-181b encoded from 
different genomic locations, which were up-regulated and down-regulated 
respectively in the microarray. Finally, we chose miR-342 as negative control as 
miR-342 levels did not change in the microarray after E2 induction.  
RT-qPCR showed that miR-19a (1.5 fold) and miR-20a (1.3 fold) were 
upregulated although downregulated in JP13 cells (Fig 14b & c). Also, miR-19b 
(1.5 fold) and miR-20b (1.5 fold) were upregulated but downregulated in JP13 
cells (Fig 14d & e). miR-424 was shown to be upregulated (>1.5 fold) and  miR-
181b was downregulated (0.75 fold). miR-342 (which was used as negative 
control) did not change with either estradiol treatment or in JP13 cells. 
Therefore, RT-qPCR showed comparable results to those obtained from the 
microarray, reaching significance (P<0.05) in most cases. These results confirm 
the precision of the miRNA profiling results from the microarray experiment.  
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Figure 14: Validation of microarray results by qRT-PCR. miRNAs up or down regulated 
were validated by Taqman qRT-PCR after 0h, 3h, 6h and 12 h of E2 treatment and after PLZF-
ERα over-expression (a) miR-18a (b) miR-19a (c) miR-20a 
 
        
103 
 
 
 
 
 
 
 
Figure 14: Validation of microarray results by qRT-PCR. miRNAs up or down 
regulated were validated by Taqman qRT-PCR after 0h, 3h, 6h and 12 h of E2 treatment 
and after PLZF-ERα over-expression (d) miR-19b (e) miR-20b (f) miR-92. 
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Figure 14: Validation of microarray results by qRT-PCR. miRNAs up or down 
regulated were validated by Taqman qRT-PCR after 0h, 3h, 6h and 12 h of E2 treatment 
and after PLZF-ERα over-expression (g) miR-424, (h) miR-181b and (i) miR-342 which 
was used as negative control. The mean of three experiments each performed in 
triplicate are presented, error bars represent s.e.m. * represents P<0.05 in comparison 
to time 0 h, ** represents P<0.005. P value obtained using a one-tailed Student's t-test.   
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3.1.4 ERα induction reveals pri-mir-17-92 up-regulation 
We further went on to examine the expression of the unprocessed pri-mir-17-92 
and family members using RT-qPCR. Pri-mir-17-92 appeared up-regulated within 
3h of E2 treatment reaching a 4-5 fold change in comparison to 0h (Fig. 15A) 
defining it as a new early ERα up-regulated gene. As expected, their expression 
levels were significantly repressed by PLZF-ERα (Fig. 15B). Pri-mir-342, a 
negative control showed no changes (Fig. 15A & B) 
 
 
  
Figure 15: Pri-mir-17-92 is increased by E2 and decreased by over-
expression of PLZF-ERα. (A) MCF-7 cells were maintained in DMEM (minus phenol 
red) supplemented with 10 % charcoal-dextran FBS for 3 days and then were either left 
untreated or treated with 10 nM E2 for the indicated time periods. After total RNA 
extraction, expression of pri-mir-17-92 and pri-miR-342 was analyzed by RT-qPCR using 
SYBR green and normalized to GAPDH.  (B) JP13 and MCF-7-TO cells were cultured in 
the presence or absence of Tet for 72 h, followed by the addition of 10 nM E2 for 24 h. 
Once again, after total RNA extraction, expression of pri-mir-17-92 and pri-miR-342 
were analyzed by RT-qPCR using SYBR green and normalized to GAPDH. The mean of 
three experiments each performed in triplicate are presented, error bars represent 
s.e.m. For RT-qPCR data, the asterisk indicates P < 0.05 in comparison to time 0 h, the 
double asterisk represents P < 0.005 in comparison to time 0 h. P values obtained using 
a two-tailed Student's t-test. 
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We obtained the same results normalizing the value of expression for several 
housekeeping genes (GAPDH, snRNA U6 and snRNA U47) (Fig. 16 A&B). 
 
 
 
 
 
 
 
 
 
Figure 16: miR-17-92 expression levels after E2 treatment normalized by two 
housekeeping small RNAs. After MCF7 hormone starvation and treatment with 10 nM 
of E2 for 0h, 3h, 6h and 12h, expression of miR-17-92 was analysed by qRT-PCR. (A) 
miR-17-92 expression levels normalized to U6. (B) miR-17-92 expression levels 
normalized to U47. Average of three experiments each performed in triplicate are 
presented, error bars represent s.e.m.  
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3.1.5 Pri-mir-17-92 is negatively regulated following DROSHA 
cleavage delaying miRNA maturation over time 
Remarkably, the pri-mir-17-92 expression were strikingly upregulated compared 
to the miRNAs that are produced by its processing (miR-17, miR-18a, miR-19a, 
miR-19b and miR-20a), indicative of modulation of miRNAs biogenesis at the 
post-transcriptional level (Fig. 15A and 17A). A primary transcript undergoes a 
dual processing event, the first in the nucleus by DROSHA (pre-miRNA 
production), the second in the cytoplasm by DICER. In order to define the steps 
of miRNA biogenesis in which this regulation occurs, we measured levels of the 
pri-miR-17-92 derived pre-miR-18a after E2 treatment. DROSHA pri-mir-17-92 
cleavage to pre-miR-18a was not a regulatory or ‘rate-limiting’ step here because 
both were induced at similar levels (Fig. 17B).  
These data demonstrate that pri-mir-17-92 is induced by the E2-ERα complex, 
then it is processed by DROSHA releasing the pre-miR-18a, but the passage 
between pre-miR-18a and miR-18a is blocked until at least 12h following initial 
E2 stimulation. Furthermore, using RT-qPCR, we found that both miR-18a and 
miR-20a mature forms increase their levels of expression from 24 - 72 h after E2 
stimulation (Fig. 17C & D). Northern blot analysis also confirmed that miR-18a 
increase their levels of expression from 24 - 72 h after E2 stimulation (Fig. 17E). 
Analys ing the levels of the pri-mir-17-92 and the pre-miR-18a from 0 - 72h, we 
observed that pri-mir-17-92 is transcriptionally up-regulated after 3h, then 
DROSHA promptly processes the pri- to the pre-miR-18a, whereas the formation 
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of the mature form from the pre-miR-18a is delayed (Fig. 17F). In addition while 
the miR-18a levels start to increase at 24 h, both pri-mir-17-92 and pre-miR-18a 
levels decline, indicative of the processing delay we observed (Fig. 17F). 
 
  
Figure 17: Pri-mir-17-92 is negatively regulated following DROSHA cleavage 
delaying miRNA maturation over time. (A) Comparison of the levels of expression 
between pri-mir-17-92 (normalized to GAPDH) and miRNAs encoded from this cluster 
(normalized to U47). The mean of three experiments each performed in triplicate are 
presented, error bars represent s.e.m. (B) After starvation, expression levels of both pri-
mir-17-92 and pre-miR-18a have been analysed by RT-qPCR using SYBR green and 
normalized to U6 snRNA following E2 treatment as indicated. The mean of three 
experiments each performed in triplicate are presented, error bars represent s.e.m. * 
indicates P < 0.05 in comparison to time 0 h, ** represents P < 0.005 in comparison to 
time 0 h. P values obtained using a two-tailed Student's t-test. 
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Figure 17: miR-18a, miR-20a and miR-342 levels after estradiol treatment. 
(C) After starvation expression levels of miR-18a, miR-20a and miR-342 was analysed 
by RT-qPCR and normalized to U47 snRNA. The mean of three experiments each 
performed in triplicate are presented, error bars represent s.e.m. * indicates P < 0.05 in 
comparison to vehicle treatment; ** represents P < 0.005 in comparison to vehicle 
treatment. P  values obtained using a two-tailed Student's t-test. (D) Representation of 
miR-18a, miR-20a and miR-342 levels (normalization to U47 snoRNA) from 0 to 72 h of 
E2 treatment by RT-qPCR. The mean of three experiments each performed in triplicate 
are presented, error bars represent s.e.m. (E) Northern blotting of miR-18a from 0 to 72 
h of E2 treatment. The values represent densitometric scanning of the miR-18a bands 
normalized to the loading levels (Ethidium bromide staining of the small RNA fraction). 
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Figure 17: Levels of miR-17-92, pre-miR-18a and miR-18a after estradiol 
treatment. (F) Representation of the miR-18a (normalization to U47), pre-miR-
18a and pri-mir-17-92 levels (normalization to U6) from 0 to 72 h of E2 
treatment. The mean of three experiments each performed in triplicate are 
presented, error bars represent s.e.m.  
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The primers used to amplify the pre-miR-18a would also amplify pri-mir-17-92. 
Therefore, to show that we could distinguish between pri- and pre-miRNA, we 
stimulated the cell lines with E2 and then separated the small RNA fraction from 
the large RNA fraction. We used the large RNA fraction to measure pri-mir-17-92 
and the small RNA fraction to measure pre-miR-18a (Fig. 18). As a further 
control we measured the pri-mir-17-92 from the small RNA fraction without 
obtaining any amplification product. 
 
Figure 18: Pri- miR-17-92 is promptly processed by DROSHA complex that 
releases pre-miR-18a. After MCF7 hormone starvation and treatment with 10 nM of E2 
for 0h, 3h, 6h and 12h, RNA fractions were separated and used for qRT-PCR. MiR-17-92 
expression levels from large RNA fraction (>200 nt), normalized to GAPDH levels are 
presented with white columns, whereas pre-miR-18a expression levels from small RNA 
fraction (<200 nt), normalized to U6 are presented with dark columns. Average of three 
experiments each performed in triplicate are presented, error bars represent s.e.m.  
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Cycloheximide is an inhibitor of protein biosynthesis and exerts its effect by 
interfering with translational elongation during the translocation step therefore 
blocking protein synthesis [308]. Using cycloheximide (CHX), we demonstrated 
that new protein synthesis is not required exclusively for pri-mir-17-92 
expression. 
 
 
 
 
 
 
Figure 19: New protein synthesis is not required exclusively for E2-induced 
mir-17–92 expression. MCF-7 cells were maintained in DMEM (minus phenol red) 
supplemented with 10% charcoal-dextran FBS for 3 days and then pretreated with either 
CHX or DMSO (vehicle) as indicated, 1h before 10 nM E2 treatment. After total RNA 
extraction, the expression of mir-17–92 was analysed by qRT-PCR using SYBR green and 
normalized to GAPDH. The mean of 3 experiments each performed in triplicate are 
presented, error bars represent SEM. * indicates P<0.05 in comparison to time 0h, ** 
represents P<0.005 in comparison to time 0h. P values were obtained using a 2-tailed 
Student’s t-test. 
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3.1.6 C-MYC directly regulates the pri-mir-17-92 upon estrogenic 
stimulation 
It has already been proven that pri-mir-17-92 is transcriptionally regulated by c-
MYC in the P493-6 B cell line during the G1-S cellular transition phase [153]. 
Since c-MYC mRNA is up-regulated by ERα within 1 h of E2 treatment in breast 
cancer cells [309], c-MYC could contribute to the increased transcription of the 
pri-mir-17-92 upon E2 stimulation. Interestingly, we observed a half site 
conserved estrogen response element (ERE) 70 bp upstream of the c-MYC 
consensus site (E-box) of the mir-17-92 promoter (Fig. 20). 
  
 
 
Figure 20: Putative ERE and c-MYC consesus elements in mir-17–92 
promoter are located in close proximity and conserved among species. 
Alignment between human, mouse, and rat of the genomic sequence of mir-17–
92 promoter, containing both a putative half-site ERE and the E-box (c-MYC 
binding site).   
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The putative half-site ERE is indicated in red, the E-box in green. Since it has 
been demonstrated that estrogen responsive genes can contain both ERα and c-
MYC binding elements located within close proximity (13-214 bp) of the promoter 
and regulated by both transcription factors in a E2 dependent manner [310], we 
performed chromatin immunoprecipitation (ChIP) assays for both ERα and c-
MYC, and co-precipitated DNA was analysed by amplifying the genomic region 
containing both consensus sites (Fig. 21A) by real time PCR (Fig. 21B & C). 
Although TFF1, a known estrogen regulated gene, is confirmed here as regulated 
by ERα (Fig. 21B), we observed only c-MYC interacting with the mir-17-92 
promoter region analysed (Fig. 21B & C). We demonstrated that c-MYC is 
recruited to the mir-17-92 promoter in breast cancer cells upon E2 stimulation. 
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Figure 21: c-MYC directly regulates the pri-mir-17-92 upon estrogenic 
stimulation. (A) Schematic representation of the mir-17-92 cluster genomic region. 
Both the c-MYC binding site and a putative ERE half site are indicated.  (B) MCF-7 cells 
were maintained in estrogen-free medium for 3 days (starvation) and then either left 
untreated (vehicle) or treated with 10 nM E2 for 3 h after which ChIP was performed, 
followed by real time PCR. The c-MYC interaction site genomic region is presented. (C) 
After starvation, MCF-7 cells were treated with E2 for 12 h prior to ChIP.  
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3.1.7 Pri-mir-17-92 expression is correlated with ERα levels in 
ERα-positive primary breast cancers 
To evaluate ERα modulation of the pri-mir-17-92 at the physiologic level, we 
examined a correlation between ERα mRNA and pri-mir-17-92, and ERα mRNA 
and pre-miR-18a, in breast cancer tissues by RT-qPCR. Levels of pri-mir-17-92 
were correlated with ERα mRNA in tissues (r2 = 0.97, P = 0.0002, Fig. 22A), 
further indicating that ERα regulates the expression of this primary miRNA. 
However pre-miR-18a was less well correlated with ERα (r2 = 0.54, P = 0.21, 
Fig. 22B). Next, we addressed whether pre-miR-18a and miR-18a were 
differentially expressed in primary breast cancer tissues, comparing the average 
expression levels between ERα-positive and negative tumours. Pre-miR-18a 
levels were significantly higher in ERα-positive tumours (2.52 + 0.30) compared 
with negative tumours (0.90 + 0.08, P = 0.006, Fig. 22C) supporting our data. 
Moreover, expression levels of miR-18a showed no significant difference between 
the two groups of samples (Fig. 22D), indicating that impaired pre-miR-18a 
processing to miR-18a occurs in tumours. 
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Figure 22: ERα modulates pri-mir-17-92 in breast cancer tissues. (A) 
Expression levels of ERα and pri-mir-17-92 (Pearson correlation 0.97) or (B) pre-miR-
18a (Pearson correlation 0.54) was measured by RT-qPCR in ERα-positive breast 
cancers.  (C) RT-qPCR showed that expression levels of pre-miR-18a is significantly 
higher in ERα-positive then in ERα-negative tumours (unpaired, two-tailed Student’s t-
test P = 0.006). Error bars represent s.e.m. (D) RT-qPCR showed that expression levels 
of miR-18a are not different between ERα-positive and ERα-negative tumours 
(unpaired, two-tailed Student’s t-test P = 0.18). Error bars represent s.e.m. 
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3.1.8 miR-18a, miR-20b and miR-19b negatively modulate the 
ERα transcriptional activity after estrogen stimulation 
Using available miRNA target prediction software (TargetScan [311], miRBase 
[312], Pictar [313] and Pita [314]), we looked to see if ERα is a potential target 
of some or all of these miRNAs.  
 
 
 
 
 
 
 
 
 
 
Figure 23: Prediction of the miRNAs targeting 3’UTR of ERα using targetscan. 
miRNAs targeting ERα from mir-17-92 and paralogue clusters have been highlighted in 
red rectangles. 
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Surprisingly, we found that miR-18, miR17/20/106 and miR-19 family members 
were predicted to target ERα (Fig. 23 & Fig.24A). To experimentally validate this 
prediction, we chose miR-18a encoded by pri-mir-17-92, miR-19b encoded by 
both pri-mir-17-92 and the pri-mir-106a-363, and miR-20b encoded by the pri-
mir-106a-363. First, we assessed whether these miRNAs influence ERα 
transcriptional activity. MELN cells (MCF-7 cells, stably transfected with a 
luciferase reporter gene under the control of an ERE using the β-globin 
promoter) were transfected with pre-miR-18a, pre-miR-20b and pre-miR-
negative control (pre-miR-n.c). E2 stimulated reporter activity was significantly 
reduced when MELN cells were transfected with pre-miR-18a and pre-miR-20b, 
whereas the level of induction was not affected by pre-miR-n.c. (Fig. 24B). 
Remarkably, anti-miR-18a, anti-miR-20b and anti-miR-19b molecules able to 
silence their miRNA function, significantly increased reporter activity (Fig. 24C). 
The effect of miRNA silencing on luciferase reporter activity was similar to 
treatment with anti-miR-17-5p, previously reported to reduce the transcriptional 
activity of ERα by down-regulating the co-activator AIB1 [171] (Fig. 24C). 
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Figure 24: miR-18a, miR-19b and miR-20b suppress ERα mediated 
signalling. (A) MiRNAs predicted to target the ERα 3'UTR using target prediction 
software.  (B) Luciferase activity in MELN cells untransfected or transiently transfected 
for 48 h with pre-miR-18a, pre-miR-20b and pre-miR-n.c in the absence or presence of 
10 nM of E2 for 24h (C) Luciferase activity in MELN cells transiently transfected for 48 
h with anti-miR-17-5p, anti-miR-18a, anti-miR-19b, anti-miR-20b, anti-miR-n.c or 
untransfected in the absence or presence of 10 nM of E2 for 24h.  
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3.1.9 miR-18a, miR-20b and miR-19b suppresses ERα and its co-
activator AIB1 at the translational level 
The results presented so far indicate that any of the composer or ER 
transcriptional machinery could be directly targeted by these miRNAs. mir-17-5p, 
miR-106b and miR-20a are able to negatively regulate AIB1 protein translation 
by a direct interaction with the 3'UTR of AIB1 mRNA [171, 172, 174]. Since we 
observed that miR-17/20/106 and the miR-18 family members potentially target 
ERα, we evaluated if the reduction in ERα transcriptional activity induced by miR-
20b over-expression was due to the contemporary negative regulation of AIB1 
and ERα. In addition, if the reduction in ERα transcriptional activity induced by 
over-expression of miR-18a was due to a reduction of ERα protein levels.  
In order to address if these miRNAs negatively regulate either ERα and/or its co-
activator partner AIB1, we over-expressed pre-miR-18a, pre-miR-19b, pre-miR-
20b and pre-miR-n.c. and measured their protein levels. Notably, ERα was 
markedly reduced by the over-expression of all three pre-miRs analysed in 
comparison to either untransfected or pre-miR-n.c transfected cells although the 
reduction with pre-miR-19b was less pronounced (Fig. 25A & B). Furthermore, 
miR-20b reduced AIB1 protein levels (Fig. 25A & C).  
We further transfected pre-miR-18a, pre-miR-19b, pre-miR-20b, and pre-miR-n.c 
for 48h and checked RNA levels of ERα, AIB1 and also the ER co-activator TIF2. 
We did not observe reduction for either ERα or AIB1 mRNA levels after 
transfection of these precursors, suggesting that these miRNAs regulate these 
genes at the protein translation step (Fig. 26A, B &C). 
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Figure 25: ERα and AIB1 protein levels reduces upon pre-miRNA 
overexpression. (A) Western blot showing ERα, AIB1 and β-actin in MCF-7 cells 
untransfected or transiently transfected with pre-miR-18a, pre-miR-19b, pre-miR-20b and 
pre-miR-n.c. (B) Densitometric analysis of ERα Western blot (shown in panel A) (C) and 
Densitometric analysis of AIB1 Western blot (shown in panel A), both normalized to β-
actin. The mean of three independent experiments are presented, error bars represent 
s.e.m. 
 
           
B C 
A 
123 
 
 
 
 
 
 
 
To check if these miRNAs had an effect on AIB1 after estradiol treatment, we 
transfected with 10nM of anti-miR-18a, anti-miR-20b, anti-miR-n.c. at different 
time points and measured the protein levels. AIB1 proteins levels were increased 
due to the inhibition of miR-20b over prolonged treatment (72h) of estradiol and 
no significant changes were found after inhibiting miR-18a and miR-n.c (Fig. 
27A). Furthermore, transfection of anti-miR-20b in a dose dependent manner 
increased AIB1 protein levels (Fig. 27B).  
Figure 26: ERα and AIB1 mRNA levels do not change upon pre-miRNA 
overexpression. qRT-PCR analyses showing (A) AIB1, (B) ERα, and (C) TIF2 
(negative control) in MCF-7 cells untransfected or transiently transfected with 
pre-miR-18a, pre-miR-19b, pre-miR-20b, and pre-miR-n.c for 48h. The mean of 
three independent experiments are presented, error bars represent s.e.m. 
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Figure 27:  Inhibition of miR-20b leads to increase in AIB1 protein levels. (A) 
Western Blot showing the time point analysis of AIB1 and β-Actin in MCF7 cells 
transfected with anti-miR-20b, anti-miR-18a and anti-miR-n.c. at 10nM concentration. β-
Actin was used as the loading control. One representative experiment from three 
independent experiments is shown. β-Actin was used as the loading control. 
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Figure 27:  Inhibition of miR-20b leads to increase in AIB1 protein levels in a 
dose dependent manner. (B) Western blots showing AIB1 and β-actin in MCF-7 cells 
transfected with anti-miR-n.c and anti-miR-20b at 10, 30 and 100 nM concentrations. β-
Actin was used as the loading control. One representative experiment from two 
independent experiments is shown. 
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Next we wanted to address whether these miRNAs negatively regulate ER by 
interacting with the predicted seed regions on its 3’UTR. To this end, we inserted 
into the luciferase reporter vector 4 fragments of the 3'UTR of ERα: the full 
length (FL containing all the putative miRNAs interaction sites); the first half of 
the 3'UTR (ERup for miR-17/20/106 and miR-18); a fragment containing just the 
putative miR-18 family interaction sites (ER1); and a fragment corresponding to 
the second half of the 3’UTR, containing the miR-19 family interaction sites (ER2) 
(Fig. 28A).  
Transfection of miR-18a, miR-19b and miR-20b, derived from pri-mir-17-92, 
were used to investigate direct interactions with the 3'UTR of ERα constructs and 
we demonstrated that these miRNAs profoundly down-regulate luciferase activity 
for the constructs containing miRNA interaction sites, but not for the ones in 
which these sites are absent (Fig. 28B). This indicates direct targeting of ERα by 
a number of miRNAs derived from these paralogous primary miRNAs. We did not 
observe any down-regulation of luciferase reporter activity upon miR-17-5p over 
expression, according to a recent report [315]. 
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3.2 Chapter - 2 
3.2.1 Hypothesis 
We have established that ER induces the transcriptional expression of mir-17-92 
after E2 stimulation and this primary transcript is then processed by DROSHA in 
the nucleus, but the Dicer processing of the precursors derived from it is delayed 
over-time. Hence we hypothesized that E2 inducible factor may interact with the 
miRNA precursors derived from the mir-17-92 temporarily inhibiting their 
processing from Dicer in the cytoplasm. With this in mind, we aimed to establish 
the identity of the estrogen-inducible factors that could eventually cause this 
inhibition of miRNA processing. We used pre-mir-18a as a representative 
because it exerts the greatest effect on the ERα protein translational inhibition 
(Fig. 26). On the other hand, it is also possible that ER inducible factors interact 
with these precursors within the nucleus, retaining them inside this 
compartment, and avoiding exportation to the cytoplasm where Dicer can 
process them to mature miRNAs (Fig. 29).  In summary these are our 
hypotheses: 
Hypothesis 1: The microprocessor complex processes the primary transcript of 
the miR-17-92 following estrogen induced transcription, but these pre-miRNAs 
then remain in the nucleus and are not transported to the cytoplasm, preventing 
further processing by Dicer. 
Hypothesis 2: The miR-17-92 derived pre-miRNAs are processed by the 
microprocessor complex and are actively transported out of the nucleus into the 
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cytoplasm where an inhibitor, interacting with the pre-miRNAs, inhibits further 
Dicer processing. 
 
 
 
 
Figure 29:  Diagramatic representation of the proposed hypothesis.  We showed 
that after estrogenic activation, ERα upregulates the transcription of mir-17-92 via c-MYC 
but observed an inhibition at the processing of precursor to mature miRNAs Levels, 
implicating post-transcriptional regulation. We propose two possibilities: precursor 
molecules derived are retained into the nucleus thereby no Dicer processing (Hypothesis 
1) or precursors is been transported from the nucleus to the cytoplasm where an inhibitor 
binds to it and inhibits Dicer processing (Hypothesis 2). 
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3.2.2 pre-miR-18a is been transported to cytoplasm 
To check whether the precursors were retained in the nucleus after 
transcriptional upregulation of the cluster by estrogen receptor, we performed 
cytoplasmic RNA extraction and total RNA extraction (which includes nuclear and 
cytoplasmic extracts) after estradiol treatment.  
We first treated MCF-7 cells with estradiol at timepoints 3h and 48h and then 
half of the cells were subjected to cytoplasmic extraction and half to total RNA 
extraction. We then went on to measure pre-miR-18a levels by RT-qPCR and 
found that the levels of pre-miR-18a was exactly the same when compared 
between cytoplasmic and total RNA extracts (Fig. 30A & B). There was an 
upregulation of pre-miR-18a levels after 3h of estradiol induction (2.5 fold) and 
subsequent reduction at 48h. This suggests that the pre-miR-18a molecule is 
transported into the cytoplasm, but Dicer mediated processing does not occur 
because an inhibitory factor interacts with the precursor (hypothesis 2). 
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Figure 30: Cytoplasmic and Total RNA extracts after early (3h) and late (48h) 
estradiol induction. MCF-7 cells were maintained in DMEM (minus phenol red) 
supplemented with 10 % charcoal-dextran FCS for 3 days and then were either left 
untreated or treated with 10 nM E2 for 3h and 48h. (A) After cytoplasmic RNA 
extraction, expression of pre-mir-18a was analysed by RT-qPCR using SYBR green and 
normalized to GAPDH. (B) After total RNA extraction, expression of pre-mir-18a was 
analysed by RT-qPCR using SYBR green and normalized to GAPDH. The mean of three 
independent experiments are presented, error bars represent s.e.m. 
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3.2.3 Inhibitory molecule of mir-17-92 processing could be a 
protein shuttling between nucleus and cytoplasm 
We transfected one set of MCF-7 cells with CMV promoter driven plasmid 
expressing mir-17-92 that expresses the primary transcript containing all the 
miRNAs derived from it and the other set with pre-miR-18a synthetic precursor. 
We then measured the levels of both the intermediates pri-mir-17-92 and pre-
miR-18a and in addition the mature miR-18a molecules, by RT-qPCR. Although 
pri-mir-17-92 is processed to pre-miR-18a with high efficiency (Fig. 31A & B), 
pre-miR-18a to mir-18a processing was inhibited (Fig. 31C) when compared to 
the mock transfection, further validating our hypothesis that pre-mir-18a Dicer 
processing is inhibited in these breast cancer cells. Moreover, synthetic pre-miR-
18a transfected alone was completely processed to miR-18a (Fig. 32A & B) when 
compared pre-N.C. This indicates that the factor(s) that inhibit the mir-17-92 
processing are probably recruited either during transcription or during DROSHA 
processing in the nucleus and the formed miRNP complex gets transported to the 
cytoplasm. In this compartment the interacting inhibitor probably impedes the 
action of DICER on the pre-miRNA. A molecule that shuttles between the two 
main cellular compartments could be involved in this process. 
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Figure 31: Overexpression of miR-17-92 cluster confirms the Dicer processing 
block of the cluster. MCF-7 cells were transfected with 1µg of pcmv-mir-17-92 and 
empty pcmv vector (mock) for 48h and then subjected to total RNA extraction. (A) 
Expression of mir-17-92 was analysed by RT-qPCR using SYBR green and normalized to 
U6 snRNA (B) Expression of pre-miR-18a was analysed by RT-qPCR using SYBR green 
and normalized to U6 snRNA. (C) Expression of miR-18a was analysed by RT-qPCR 
using Taqman assay and normalized to U6 snRNA. The mean of three independent 
experiments are presented, error bars represent s.e.m. 
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Figure 32: Overexpression of synthetic pre-miR-18a shows pre-miR-
18a is completely processed to miR-18a. MCF-7 cells were transfected with 
5nM of pre-miR-18a and pre-N.C for 48h; also untreated (mock) was included 
and then subjected to total RNA extraction. (A) Expression of pre-miR-18a was 
analysed by RT-qPCR using SYBR green and normalized to U6 snRNA (B) 
Expression of miR-18a was analysed by RT-qPCR using Taqman assay and 
normalized to U6 snRNA The mean of three independent experiments are 
presented, error bars represent s.e.m. 
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3.2.4 Preliminary investigation of RNA binding proteins by Mass 
spectrometry 
To identify the miRNA regulating factor we took advantage of a mass 
spectrometry approach. The complexity and dynamic nature of the proteome 
presents massive technological challenges. Mass spectrometry is a powerful 
analytical technology that enables interpretation of protein sequences. Over 
recent years improved mass spectrometry approaches like increased sensitivity 
and higher resolving power have been developed to characterize the proteome, 
indicating it as powerful approach for identification of factors that could inhibit 
miRNA biogenesis[316]. In addition, mass spectrometry based proteomics has 
been previously employed to identify several critical components of the miRNA 
biogenesis pathway and their post-translational modifications, amongst which is 
LIN-28 [317-319]. 
In order to discover such a molecule using this approach, we performed an 
affinity chromatography approach followed by mass spectrometry, using miRNA 
precursor molecules joined with beads as bait. We used pre-miR-18a as the 
specific molecule, and pre-miR-34a, as negative control.  This approach allowed 
us to obtain a list of proteins containing RNA binding domains that specifically 
interact with pre-miR-18a alone, pre-miR-34a alone or both molecules, and in 
response to E2 treatment.  
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Figure 33: A schematic to illustrate the overall outline of the mass 
spectrometry experiment. MCF-7 cells were maintained in DMEM (minus phenol 
red) supplemented with 10 % charcoal-dextran FCS for 3 days and then were either 
left untreated or treated with 10 nM E2 for 6h. Cells were then subjected to protein 
extraction and subsequent treatment with agarose beads bound with the pre-miRs 
accordingly (shown above). Proteins were separated on 4-12% gradient gels before 
purification of the protein bands and mass spectrometry for their identification (Figure 
34).  
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3.2.5 Idenfication and Screening of selected RBPs 
We chose proteins based on the number of peptides bound to the beads. 
Proteins were identified by LC-MS were specifically chosen from estradiol treated 
pre-miR-18a and pre-miR-18a/ pre-miR-34a samples; and not in control samples 
are listed. Ribosomal proteins and cyto-skeletal proteins are excluded from this 
list. 
Pre-miR-18a (E2+) Pre-miR-18a/Pre-miR-34a (E2+) 
Accession Description Accession Description 
TNRC6B 
_HUMAN 
Trinucleotide Repeat-
Containing Gene 6B 
Protein 
 
PC4_HUMAN 
  
Pheochromocytoma Cell-
4 
ZNF225 _HUMAN C2-H2 Type Zinc Finger 
Protein 
TOE1_HUMAN 
  
Target Of EGR1 Protein 1 
hnRNPA1 
_HUMAN 
Heterogeneous Nuclear 
Ribonucleoprotein A1 
ANKRD17_HUMAN Ankyrin Repeat Domain 
17 
THOC4/ALY 
_HUMAN 
  
THO Complex Subunit 4 
 
ASB7_HUMAN 
  
 
Ankyrin Repeat And 
SOCS Box Containing 7 
FGD1 _HUMAN FYVE, RhoGEF And PH 
Domain Containing 1 
 
NONO_HUMAN 
  
Non-POU Domain 
Containing, Octamer-
Binding 
CTTN _HUMAN Src substrate cortactin SF3B3_HUMAN Splicing Factor 3b, 
Table 11: List of selected RBPs from Mass Spectrometry experiment 
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  Subunit 3, 130kDa 
ZNF168 _HUMAN Zinc Finger Protein 168 STK19_HUMAN 
  
Serine/Threonine Kinase 
19 
DAZAP1 _HUMAN DAZ Associated Protein 
1 
U2AF1_HUMAN 
  
U2 Small Nuclear RNA 
Auxiliary Factor 1 
EDC4 _HUMAN Human Enhancer Of 
Decapping Large 
Subunit 
RPL35_HUMAN 
  
Ribosomal Protein L35 
CPSF6 _HUMAN Cleavage And 
Polyadenylation Specific 
Factor 6 
METTL3_HUMAN 
  
Methyltransferase Like 3 
STAT3 _HUMAN Signal Transducer And 
Activator Of 
Transcription 3 
RBM34_HUMAN 
  
RNA Binding Motif 
Protein 34 
HSPA1A _HUMAN Heat Shock 70kDa 
Protein 1A 
PCF11_HUMAN 
  
Polyadenylation and 
cleavage Factor Subunit 
HSPA8 _HUMAN Heat Shock 70kDa 
Protein 8 
    
HSPB1 _HUMAN Heat Shock 27kDa 
Protein 1 
    
 
Interestingly, we found a few important heat shock proteins in the list 
(particularly in E2 treated pre-miR-18a beads samples only) so we went on to 
investigate any involvement of heat shock proteins in the miRNA biogenesis of 
mir-17-92 family or even global biogenesis. We did not identify any change of 
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miR-18a, miR-19a, miR-20a and miR-34a levels after silencing of the three HSP 
proteins (HSPA1A, HSPA8 and HSPB1). 
 
 
Figure 35: Silencing of HSP proteins (HSPA1A, HSPA8 and HSPB1) does not 
affect miRNA biogenesis. MCF-7 cells were transfected with 20nM of siRNAs targeting 
HSPA1A, HSPA8 and HSPB1 for 72h and then subjected to total RNA extraction. (A) 
Expression of mRNAs levels of HSPA1A, HSPA8 and HSPB1 were analysed by RT-qPCR 
using SYBR green and normalized to GAPDH (B) Expression of miR-18a, miR-19a, miR-
20a and miR-34a were analysed by RT-qPCR using Taqman assay and normalized to U6 
snRNA. One representative experiment from two independent experiments is shown in 
figure 35. 
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3.2.6 ALY, possible regulator of miRNA biogenesis? 
We subsequently performed siRNA based screening for other possible RBPs that 
could be involved in the mir-17-92 biogenesis. We screened selected RBPs 
based on the number of peptides bound to pre-miR-18a and pre-miR-18a/ pre-
miR-34a to check whether it is involved in either mir-17-92 or global processing. 
The following RBPs were chosen: ALY, ANKRD17, DAZAP1, SF3B3, CTTN, 
hnRNPA1. We did not find any significant changes after silencing these RBPs 
(Fig. 36A). We did observe a slight decrease in miR-18a, miR-21 and miR-34a 
after silencing of ALY, indicating a possible involvement in global processing. We 
were finding it extremely difficult to get consistent results using RT-qPCR (which 
is further discussed in chapter 4.2). Hence we performed northern blotting, a 
recognised and superior technique for quantification of miRNA levels. Expression 
of miR-18a and miR-34a is low in MCF7 cells so levels were undetectable, unlike 
miR-21, which is quite highly expressed in most cancer cells. We found that 
silencing of ALY decreased miR-21 levels when compared to the negative control 
(Fig. 36B); hence raising the possibility of its involvement as a positive regulator 
of miRNA processing. 
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Figure 36: Screening of selected RBPs using RT-qPCR and northern blotting. 
MCF-7 cells were transfected with 20nM of siRNAs targeting ALY, ANKRD17, DAZAP1, 
SF3B3, CTTN, hnRNPA1 and N.C (negative control siRNA) for 72h and then subjected to 
total RNA extraction. (A) miRNA levels of miR-18a, miR-21 and miR-34a was analysed 
by RT-qPCR using Taqman assay and normalized to U6 snRNA. The mean of six 
independent experiments are presented, error bars represent s.e.m. (B) Northern blot 
analysis (30µg of total RNA was used) of miR-21 after silencing ALY, ANKRD17, DAZAP1, 
SF3B3, CTTN, hnRNPA1 and N.C for 72h and normalized to U6 snRNA. One 
representative experiment from two independent experiments is shown. 
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In our previous chapter (chapter 3.1) we showed an inhibitory effect of Dicer 
processing on all miRNAs that arise from the mir-17-92 transcript, but here 
silencing of ALY decreased levels of miR-18a, miR-21 and miR-34a (Fig. 36A&B). 
This raises the possibility that ALY could be involved in global miRNA biogenesis. 
We also wanted to ensure that the effect observed was not due to transcriptional 
regulation but instead, regulation at the post-transcriptional level, indicative of 
processing regulation. Therefore, in the same samples, we quantified the levels 
of two other miRNA biogenesis products (primary transcript and precursor) in 
addition to the miRNA, using RT-qPCR. Using the primary transcript and 
precursor of miR-18a and miR-21, we showed that silencing of ALY only altered 
miRNA levels but not primary transcript or precursor levels, revealing a possible 
regulation at the Dicer step (Fig. 37 A&B). 
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Figure 37: primary transcript and precursors levels did not change after 
silencing of ALY. MCF-7 cells were transfected with 20nM of siRNAs targeting ALY for 
72h and then subjected to total RNA extraction. (A) Primary transcript and precursor 
levels of miR-18a were analysed by RT-qPCR using SYBR green and normalized to U6 
snRNA. (B) Primary transcript and precursor levels of miR-21 were analysed by RT-qPCR 
using SYBR green and normalized to U6 snRNA.  The mean of two independent 
experiments are presented, error bars represent s.e.m. 
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Interestingly, ALY seems to be one of the key factors involved in the nuclear 
transport of mRNA (Fig. 37) and it is a protein known to shuttle between the 
nucleus and cytoplasm [320-322]. It acts as a molecular adaptor for key proteins 
like UAP56, TAP/NXF1 involved in the mRNA transport [323]. 
 
 
 
 
 
Figure 38: Key factors involved in the mRNA transport. ALY acts as a molecular 
adaptor for the important proteins involved in mRNA transport. Modified from [324]. 
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We checked the ALY mRNA and proteins levels after its silencing to make sure 
that we obtained a good silencing level (Fig. 39 A&B). 
 
 
 
 
 
 
Figure 39: mRNA and protein levels of ALY after silencing using siRNA. MCF-7 
cells were transfected with 20nM of siRNAs targeting ALY, N.C and mock (untransfected) 
for 48h and 72h respectively; then subjected to total RNA and protein extraction. (A) 
mRNA levels of ALY after silencing were analysed by RT-qPCR using SYBR green and 
normalized to GAPDH. The mean of two independent experiments are presented, error 
bars represent s.e.m. (B) Western blot analysis of ALY after silencing for 48h and 72h; 
β-Actin was used as the loading control. One representative experiment from two 
independent experiments is shown. 
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We next wanted to investigate whether ALY interacts directly with the miRNA 
precursors or indirectly through other RBPs.  We performed electrophoretic 
mobility shift assay (EMSA) using recombinant ALY protein and radiolabeled γ-32P 
pre-miR-18a to show that the formation of this RNA-protein complex was 
specific. We did see that ALY formed a complex together with pre-miR-18a and 
did not form any complex in the absence of pre-miR-18a, indicating that the 
interaction is specific (Fig. 40A). We further went on to investigate the potential 
sites of the precursor for ALY interaction. We performed EMSA again with entire 
precursor (pre-miR-18a), terminal loop (TL) of the precursor, double strands of 
the precursor, miRNA strand of the precursor (miR-18a) and complementary 
stand of the precursor (miR-18a*). We found that ALY requires the entire 
precursor molecule (pre-miR-18a) to interact, there was no complex formed with 
any other parts of the precursor molecule (Fig. 40B).  
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Figure 40: EMSA revealing interaction of ALY with the pre-miR-18a. EMSA 
performed using γ-32P labelled pre-miR-18a and recombinant ALY. Reactions were 
subjected to electrophoresis on 12% polyacrylamide gels containing 5% glycerol in 
TBE (0.5X). Protein: RNA complexes were detected by nondenaturing gel 
electrophoresis and autoradiography. (A) Specific binding of pre-miR-18a by ALY (B) 
ALY binds to entire pre-miR-18a not any other specific part of the precursor molecule. 
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We went on to perform in vitro pre-miRNA processing assay to enable us 
characterize the role of ALY in the processing of pre-miRNAs to mature miRNAs 
but unfortunately we were unable to identify any role of ALY involved in the 
processing (data not shown). Overexpression of ALY with a plasmid also failed to 
show any change in the mature miRNA levels or the precursor levels. 
Furthermore, we performed RNA immunoprecipitation to see the interaction of 
ALY with pri-, pre- and mature miR-18a but again did not find an interaction 
between any of the biogenic products (data not shown). We were finding it 
extremely difficult to have consistent results and I have discussed these 
problems in chapter 4.2.  
We carried screening for other RBPs which may be involved in the processing. 
Further screens using RT-qPCR and northern blotting to assess levels of miRNAs 
after silencing of RBPs identified one potentially interesting candidate, RBM34 . 
RBM34 is an RNA binding protein of unknown function. We also used two 
different siRNA controls to minimize the false positive results. 
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Figure 41: Screening of selected RBPs using RT-qPCR. MCF-7 cells were 
transfected with 20nM of siRNAs targeting RBM34, TNRC6B, METTL3, hnRNPA1, 
N.C and all star N.C for 72h and then subjected to total RNA extraction. miRNA 
levels of (A) miR-18a (B) miR-34a (C) miR-21 were analysed by RT-qPCR using 
Taqman assay and normalized to U6 snRNA. The mean of three independent 
experiments are presented, error bars represent s.e.m.  
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Figure 41: Screening of selected RBPs using RT-qPCR and northern blotting. 
(D) Northern blot analysis (50µg of total RNA was used) of miR-18a, miR-21 and miR-
34a after silencing RBM34, TNRC6B, METTL3, hnRNPA1, N.C and all star N.C for 72h 
and normalized to U6 snRNA. One representative experiment from two independent 
experiments is shown. 
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RBM34 silencing increased mature levels of both miR-18a and miR-34a (Fig. 
42A), without effect on precursors levels (Fig. 42B). This indicates that RBM34 is 
able to reduce the expression of both miRNAs at DICER processing step. In our 
previous chapter (chapter 3.1) we showed an inhibitory effect of Dicer 
processing relating to all miRNAs that arise from the mir-17-92 transcript, and we 
appreciated here an effect of RBM34 on both miR-18a and miR-34a (Fig. 42A). 
Reviewing the mass spectrometry data, this protein was present in both the pull-
down with the beads (pre-miR-18a and pre-miR-34a). Although we cannot rule 
out the possibility that the inhibitory mechanism that we previously 
demonstrated is acting also on miR-34a, further experiments will demonstrate if 
the inhibitory action of RBM34 on these miRNAs is related to the estrogenic 
response. 
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Figure 42: RBM34 silencing increases miR-34a and miR-18a levels. MCF-7 cells 
were transfected with 20nM of siRNAs targeting RBM34 for 72h and then 
subjected to total RNA extraction. Expression levels of (A) miR-34a and miR-18a 
were analysed by RT-qPCR using Taqman assay and normalized to U6 snRNA. 
(B) pri-17-92, pri-34a, pre-miR-18a and pre-miR-34a by RT-qPCR using SYBR 
green and normalized to U6 snRNA.  The mean of three independent 
experiments are presented, error bars represent s.e.m. 
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We carried out further experiments with overexpression of RBM34 plasmid and 
again we did not find any change in the mature miRNA levels or the precursor 
levels. We also performed RNA immunoprecipitation to see the interaction of 
RBM34 with pri-, pre- and mature miR-18a but again unfortunately we couldn’t 
find interaction between any of the biogenic products (data not shown).  
We decided not to carry on with the project as we were finding it extremely 
difficult with the inconsistent results and technical difficulties we had during this 
time, I have discussed these problems later in chapter 4.2. 
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Chapter-3 Results 
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3.3 Chapter-3 
3.3.1 Introduction 
As previously mentioned, most breast tumours express ERα [325] and patients 
with ERα positive disease respond to anti-estrogens (tamoxifen), estrogen 
withdrawal (aromatase inhibitors) and direct targeting of the receptor 
(fulvestrant) [29]. The introduction of these treatments has had a profound 
impact on patient survival [326]. However, resistance to these therapies is 
common [327]. Since phosphorylation is one of the most important post-
translational modifications most of the proteins undergo and has critical roles in 
the regulation of many cellular processes. In vitro evidence points to the 
importance of ERα phosphorylation [328] in the development of endocrine 
resistance [329, 330]. RNA interference (RNAi) screens in drug discovery are a 
commonly used technique, particularly in the search for anti-cancer drugs. 
Hence, kinomes have become a target for large scale genomics, enabling the 
systematic screening for a role for individual kinases in regulating different 
proteins. We wanted to perform ‘Kinome’ screening using an siRNA library which 
targeted all kinases in the genome and identify a novel kinase regulator of ERα. 
Thus, our intention was to find a new novel kinase that regulates ERα that could 
possibly be involved in endocrine resistance mechanisms.  
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3.3.2 Kinome Screen set-up 
The kinase library [Human Kinase Set V3.0 siRNA library (Qiagen)] used in the 
following study has siRNAs which target 691 kinases with each well having two 
pooled siRNAs targeting every individual kinase to have silencing efficacy. We 
decided to perform our screen in the most well characterised ER positive cell line, 
MCF-7. We further carried on preliminary experiments checking the transfection 
efficiency using transfection reagent, HiPerfect and also siRNA silencing efficacy 
by choosing 5 random kinases from the library FRK, FYN, HCK, BTK and CSF1R. 
We transfected the chosen siRNAs in 24-well format (which will be used for the 
screen) for 72h and was subjected to total RNA extraction using RNeasy Kit 
(Qiagen). We checked the mRNAs levels of the individual kinases using RT-qPCR 
and expression of all the five genes were supressed suggesting the efficacy of 
siRNAs from the library (Fig. A,B,C,D & E). We observed more than 80% of the 
gene silencing in all five genes transfected with respective siRNAs, when 
compared to the negative control (CT siRNA) indicating that the entire library can 
be safely used to perform the planned screening.   
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Figure 43: Silencing of the selected kinases using the siRNAs from the 
library. MCF-7 cells were transfected with 20nM of siRNAs targeting FRK, FYN, HCT, 
BTK and CSF1R for 72h respectively; then subjected to total RNA extraction. mRNA 
levels of (A) FRK (B) FYN (C) HCT (D) BTK (E) CSF1R after silencing was analysed by 
RT-qPCR using Taqman assay and normalized to GAPDH. Error bars represent standard 
deviation of 2 experiments each in triplicate. 
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To check estrogenic induction by estradiol (E2), we chose two genes well known 
to be upregulated by ERα transcriptional activity, TFF1 [331] and GREB1 [332]. 
We performed estradiol induction with the kinases we chose for the previous 
experiment (Fig. 43). We transfected MCF-7 with the chosen siRNAs and after 
48h of transfection the cells were replaced with the media either treated with E2 
or untreated and incubated for another 24h. We quantified the mRNAs levels of 
the TFF1 and GREB1 using RT-qPCR and expression of both genes was 
appropriately increased, confirming that the treatment was effective (Fig. 44 
A&B). We then silenced the well-known kinases that regulate ERα activity, 
mitogen-activated protein kinase-3 (MAPK3) and AKT which phosphorylate 
ERα at Ser118 and Ser167 respectively [253, 330]. We transfected MCF-7 with 
MAPK3 and AKT siRNAs, after 48h of transfection the cells were replaced with 
the media either treated with E2 or untreated and incubated for another 24h. As 
expected, silencing of MAPK3 and AKT kinases led to reduction of TFF1 mRNA 
levels after estrogenic induction when compared to the mock and negative siRNA 
control, indicating that the screening can detect new kinases involved in 
estrogenic signalling (Fig. 44C). We decided to consider the estrogen-responsive 
gene TFF1 as readout after silencing of all the kinases. 
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Figure 44: Estradiol induction and silencing of the selected kinases using the 
siRNAs from the library. MCF-7 cells were transfected with 20nM of siRNAs targeting 
FRK, FYN, HCT, BTK, CSF1R, MAPK3 and AKT, after 48h of transfection the cells were 
replaced with the media either treated with E2 or untreated, incubated for another 24h 
and then subjected to total RNA extraction. (A) mRNA levels of TFF1 was analysed by 
RT-qPCR using Taqman assay and normalized to GAPDH. (B) mRNA levels of GREB1 
was analysed by RT-qPCR using Taqman assay and normalized to GAPDH. Error bars 
represent standard deviation of 2 experiments each in triplicate. 
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Figure 44: Estradiol induction and silencing of known kinases that regulate 
TFF1 expression using the siRNAs from the library. (C) Transfection of MCF7 cells 
with MAPK or AKT siRNAs followed by treatment with E2 significantly inhibited the 
expression levels of TFF1. Error bars represent standard deviation of 2 experiments each 
in triplicate [* p < 0.05 compared to siControl (Student's t test)]. 
 
 
 
 
 
 
 
 
C 
163 
 
 
 
 
 
3.3.3 Screening of the Kinome 
To identify kinases that regulate ERα activity, we performed the siRNA screen 
using expression of the estrogen-responsive TFF1 gene as readout for altered 
ERα activity and also using appropriate controls provided in the library. The 
schematic representation below (Fig. 45) displays the way we performed the 
screening. 
 
Figure 45: Schematic representation of the experimental procedure for the 
screening. MCF-7 cells were plated in a 24-well plates and transfected with 20nM of 
siRNAs targeting the entire kinome (691 kinases) and appropriate controls were used 
which was provided in the library. After 48h of transfection, the cells were replaced with 
the media treated with E2 or untreated (as control to check the estradiol induction), 
incubated for another 24h, which makes in total 72h of transfection and then subjected 
to total RNA extraction. Further proceeded with cDNA preparation and then the mRNA 
levels of TFF1 was analyzed by real-time PCR using Taqman assay and normalized to 
GAPDH (Fig. 46).  
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Data analysis showed many interesting candidates, so we subsequently screened 
again using only the interesting candidates (280 kinases) using the same 
experimental conditions as the first experiment. We screened again for the third 
time all the interesting candidates (130 kinases) which had consistently 
significant changes, again using the same experimental conditions.  
Following three rounds of kinase screenings, we were left with 46 potentially 
interesting candidates (both up- and down-regulated). The identified kinases 
included MAPK3 and AKT, which phosphorylate ERα at S118 and S167 
respectively, confirming that the screen could successfully identify regulators of 
estrogen-responsive gene expression [253, 259, 271, 329, 330]. 
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Figure 46: Graphical representation of the entire screening. Graphical 
representation of the entire screening (691 kinases and the controls). Those highlighted in 
red circles are Kinases which upon silencing, down-regulated (<50%) TFF1 expression; 
those highlighted in purple diamond are the kinases which upon silencing, did not result in 
an altered expression of TFF1; and those highlighted in black triangle are the Kinases which 
upon silencing up-regulated (>100%) TFF1 expression; finally those in yellow squares are 
the controls used throughout screening. 
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3.3.4 Interesting candidates (kinases) upon silencing, up- or 
down-regulates TFF1 expression  
We screened the most interesting candidates (46 kinases) (Fig. 46) with TFF1 
again, along with the other estrogen-responsive genes PGR and GREB1. MCF-7 
cells were transfected with siRNAs targeting the interesting candidates and 
appropriate controls were used, which were provided in the library. The 
estrogen-responsive genes TFF1 (Fig. 47A&B), PGR and GREB1 (data not shown) 
were used as a read-out. The interesting candidates whose knockdown 
suppressed TFF1 levels included AKT, MAPK3, ABL1 and BCR which are known 
regulators of ERα activity and hence were used as positive controls (Fig. 47A). 
Furthermore, the interesting candidates whose knockdown increased TFF1 levels 
did not have any positive controls in our screen results as there are not many 
known kinases which act as a negative regulator for ERα activity. Interestingly, 
we found a kinase ‘LMTK3’ whose function was completely unknown and its 
silencing significantly down-regulates TFF1 expression which suggests that it 
could act as positive regulator for ERα activity. 
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Figure 47: Expression of TFF1  after silencing of the interesting candidates. MCF-7 
cells were plated in 24-well plates and transfected with 20nM of interesting candidate. GFP 
control and scramble control (negative controls) were used, which were provided in the 
library. After 48h of transfection, the cells were replaced with the media treated with E2, 
incubated for another 24h, which makes in total 72h of transfection and then subjected to 
total RNA extraction. mRNA levels of TFF1 were analysed by real-time PCR using Taqman 
assay and normalized to GAPDH. (A) List of selected kinases upon silencing decreased the 
TFF1 expression (B) List of selected kinases upon silencing decreased the TFF1 expression. 
Error bars represent standard deviation of three independent experiments is presented.  
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Group A (up-regulation)               FOLD CHANGE (+) 
 
siRNA pool                                   Gene name                                         TFF1              PGR              GREB1    
     LATS2                       large tumor suppressor, homolog 2                               2.98                1.34              2.05 
      NEK3             NIMA (never in mitosis gene a) - related kinase 3                  2.96                   -                 
 1.14 
      NEK8             NIMA (never in mitosis gene a) - related kinase 8                  2.35                1.19               1.59 
   PIP5K2B     phosphatidylinositol-4-phosphate 5-kinase, type II, beta          2.11                1.80               1.40 
      CCRK      cell cycle related kinase                                         2.03                2.56    
           1.73   
Group B (down-regulation)                                                                                      FOLD CHANGE (-) 
 
siRNA pool                                 Gene name                                           TFF1              PGR              GREB1    
 
  ACVR2B                          activin A receptor, type IIB                                         4.65                 2.81                 1.53 
      BCR                               breakpoint cluster region         3.53                   -                       - 
  AKAP13                          A-kinase anchor protein 13        3.33                3.22                 1.76 
   TYRO3           TYRO3 protein tyrosine kinase                                     3.28                5.35                 5.59 
   LMTK3                              lemur tyrosine kinase 3             2.96                4.57                 2.98 
 PRKAR1B     protein kinase, cAMP-dependent, regulatory, type I, beta      2.87        -                       - 
 MAP3K7          mitogen-activated protein kinase kinase kinase 7                 2.51                1.24                 1.71                 
  CDC2L1              cell division cycle 2-like                                      2.38                1.65                1.45                  
    GRK6                  G protein-coupled receptor kinase 6                                  2.30               1.82                1.67 
 CDKN2A                cyclin-dependent kinase inhibitor 2A                                  2.26               1.66                1.17 
 MARK4          MAP/microtubule affinity-regulating kinase 4                          2.25               1.44                1.10 
MAPK3                     mitogen-activated protein kinase 3                                   2.25                   -                       - 
CKMT1B                    creatine kinase, mitochondrial 1B                                    2.22                1.09                 1.87 
   KSR1                              kinase suppressor of ras 1                                           2.19                6.94                 6.80 
  AKT3            v-akt murine thymoma viral oncogene homolog 3                   2.18                   -                       - 
MAPKAP1    mitogen-activated protein kinase associated protein 1            2.13                   -                       - 
 
 
- = not measured 
 
 
 
Table 12: List of selected Kinases regulating ERα chosen from siRNA 
screening  
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3.3.5 Brief summary of the screening 
Overview of the Kinome screen which we performed showing the sequential 
steps in the selection of hits based on the TFF1 expression. After the third round 
of screening, in addition to TFF1 expression, we also used the ERα regulated 
genes PGR and GREB1 as a read-out. We ultimately decided that ‘LMTK3’ was an 
exciting kinase on which to focus because of its potential for regulating ERα 
activity. 
 
 
 
  
  
 
 
            
                                              
 
 
Figure 48: Schematic representation of the screening work. 
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3.3.6 Validation of LMTK3 as new novel modulator of ERα activity 
We wanted to validate that the effect of LMTK3 on ERα activity observed in the 
screen was not due to an off-target effect of the siRNAs used.  Hence we 
silenced LMTK3 using 4 different siRNAs, all targeting different sites of LMTK3. 
We transfected MCF-7 cells with 4 different siRNAs targeting LMTK3 and after 
48h of transfection the cells were replaced with the media either treated with E2 
or untreated and incubated for another 24h. We checked the mRNAs levels of 
the TFF1, PGR and GREB1 using RT-qPCR. Three siRNAs (siRNA 1, 2 and 3) out 
of 4 siRNAs supressed the expression of LMTK3 (Fig. 49D) and there was 
subsequent reduction of estrogen-responsive genes TFF1, PGR and GREB1 (Fig. 
49A, B &C). In doing so, we showed that this effect on ERα was not an off-target 
effect but one associated with LMTK3.  
LMTKs are a family of serine-threonine-tyrosine kinases [333-335]. A function 
has not previously been recognized for LMTK3, although screens have suggested 
a putative role in the β-catenin pathway [336] and leukemic cell survival [337]. 
We silenced the other two isoforms of the family LMTK1 and LMTK2, by silencing 
of either of these two isoforms did not change TFF1 expression levels (Fig. 50A) 
suggesting that this effect on ERα activity is very specific to LMTK3. We 
confirmed that silencing actually resulted in supressed expression of LMTK1 and 
LMTK2 (Fig. 50B). 
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Figure 49: Expression of TFF1, PGR and GREB1 after silencing LMTK3 using 
four different siRNAs. Validation of the effects of LMTK3 silencing on the E2-induced 
expression of TFF1, PGR and GREB1 genes. Gene expression of (A) TFF1 (B) PGR and 
(C) GREB1 in MCF7 cells transfected with 4 individual LMTK3 siRNAs. (D) Validation of 
down-regulation of LMTK3 mRNA levels after treatment with 4 individual LMTK3 siRNAs. 
Error bars represent standard deviation of three independent experiments is presented. 
[* p < 0.05 compared to siControl (Student's t-test)]. 
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Figure 50: Effects of LMTK1 and LMTK2 silencing on TFF1 expression 
levels. (A) Gene expression of TFF1 in LMTK1 and LMTK2 siRNA transfected in MCF-7 
cells. (B) RT-qPCR validation of down-regulation of LMTK1 and LMTK2 mRNA levels 
after treatment with 20nM of siRNA. GAPDH was used for normalization. Error bars 
represent standard deviation of three independent experiments is presented. [* p < 
0.05 compared to siControl (Student's t test)].  
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We carried out LMTK3 silencing again and also overexpressed the LMTK3 plasmid 
to validate our findings. We transfected MCF-7 cells with siRNAs targeting LMTK3 
and after 48h of transfection the cells were replaced with the media either 
treated with E2 or untreated and incubated for another 24h. We also transfected 
MCF-7 cells with 2µg of LMTK3 plasmid and empty vector, after 24h of 
transfection the cells were replaced with the media either treated with E2 or 
untreated and incubated for another 24h. We checked the mRNAs levels of the 
TFF1, PGR and GREB1 using RT-qPCR. LMTK3 silencing consistently inhibited the 
expression of estrogen-regulated genes effectively (Fig. 51A). Also, 
overexpression of LMTK3 increased the levels of the estrogen-induced genes 
confirming that LMTK3 acts as a positive regulator of ERα activity (Fig. 51B).  
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Figure 51: Effects of LMTK3 on expression of estrogen-regulated genes TFF1, 
PGR and GREB1. (A) Transfection of MCF7 cells with LMTK3 siRNA followed by 
treatment with E2, significantly inhibited the expression of estrogen-regulated genes 
(TFF1, PGR and GREB1) while (B) over-expression of LMTK3 increased the mRNA levels 
of these genes. Error bars represent standard deviation of three independent 
experiments is presented. [* p < 0.05 compared to siControl (Student's t test)].  
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Chapter 4: Discussion 
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4.0 Discussion 
4.1 Regulation of miRNAs by Estrogen receptor 
More than 70% of all breast cancers overexpress the estrogen receptor (ER), 
providing a target for drugs like Tamoxifen, the aromatase inhibitors and other 
anti-estrogen therapies. Despite most initially responding to such treatment, 
40% will subsequently become resistant to this hormone therapy and the patient 
will relapse [338]. The ERα receptor, a well-studied protein, is known to play an 
important role in the development of resistance to endocrine therapy [339]. 
Since their discovery twenty years ago, miRNAs have been proven to be vital 
modulators of many biological mechanisms. Hence, we decided to focus our 
research efforts on finding the miRNAs regulated by the estrogen receptor.  
We performed a microarray to reveal miRNAs that are regulated by estrogenic 
response. Prior to the microarray experiment, we optimized the conditions using 
GREB1 as a positive read-out (Fig.12 A&B). Remarkably, most of the ERα up-
regulated miRNAs in the microarray were derived from mir-17-92 and its 
paralogue clusters mir-106a-363 and mir-106b-25 (Fig. 13 A&B) which has 
proved to be important in cancer biology [152, 174, 340-347]. The microarray 
analysis did not reveal any upregulated miRNAs greater than two fold. Validation 
of some of the microarray results by RT-qPCR showed the precision of the 
microarray experiment (Fig. 14a-i).  
In addition to our research, several other groups have published their findings of 
estrogenic induction of microRNAs; reporting up and down regulation of several 
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miRNAs. In summary, the following miRNAs were shown to be up-regulated after 
early induction (< 6h): miR-206 [348], miR-15a, miR-200a, miR-30b and miR -
26b [349], miR-424 and miR-760 [350], miR-193b and miR-301b [351]. The 
miRNAs reported to be down-regulated after early induction (< 6h) are the miR-
181 family, miR-26 family and miR-23 family [352], miR-424, miR-10b and miR-
128 [353], miR-21 [98], miR-221 and miR-222 [354]. These corroborate the 
findings of our microarray data (Table 10) and suggest the involvement of 
estrogen receptor in the regulation of miRNA expression.  
As our microarray analysis failed to show significant changes in miRNA levels, we 
were interested to see the expression of their primary transcripts. Using qPCR we 
showed that mir-17-92, responsible for the production of miR-17, miR-19a, miR-
20a, miR-19b-1 and miR-92-1 was upregulated following estrogen treatment, 
indicating that estrogen plays a role in the regulation of these miRNAs at the 
transcriptional level (Fig. 15 A&B). To ensure that the changes observed were 
not due to variations in the expression of the housekeeping gene GAPDH (used 
for normalization) we used two further housekeeping genes, the small RNAs U6 
and U47, that are reported not to change with estrogenic treatment (Fig. 16 
A&B). The increase in mir-17-92 expression remained consistent using all three 
different endogenous controls, hence confirming that this cluster is 
transcriptionally upregulated by the E2 treatment (Fig 16 A&B).  
Having shown that pri-mir-17-92 was considerably more upregulated than the 
miRNAs it produces, we hypothesized that an inhibition of biogenesis occurred 
following estrogen mediated transcription (Fig. 17A). In order to define the 
step(s) of miRNA biogenesis in which this regulation occurs, we then measured 
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levels of pre-miR-18a and found that DROSHA mir-17-92 cleavage to pre-miR-
18a was not the regulatory or ‘rate-limiting’ step because both are induced at 
similar levels (Fig. 17B). The primers used to amplify the pre-miR-18a also 
amplify the pri-miRNAs. To establish that we could distinguish between pri- and 
pre-miRNA, we used the large RNA fraction to measure mir-17-92 and the small 
RNA fraction to measure pre-miR-18a. We demonstrated that the levels of the 
pre-miR-18a were induced similarly to mir-17-92. These data demonstrate that 
mir-17-92 is induced by the E2-ERα complex, then it is processed by DROSHA 
releasing the pre-miR-18a, but the passage between pre-miR-18a and miR-18a is 
attenuated following initial E2 stimulation (Fig. 18).  
Such regulation however has been described in let-7 family members during 
stem cell differentiation. LIN-28 is able to interact with pri-let-7 and/or pre-let-7, 
impairing its processing [207, 210]. It has also been reported that c-MYC down-
regulates let-7 maturation increasing the transcription of LIN-28b in P493-6 B cell 
lines [355]. Furthermore, it has been shown that when the RNA binding protein 
KSRP interacts with DICER and  promotes the biogenesis of a subset of miRNAs 
comprising of miR-20a and miR-106a, in both HeLa and NIH-3T3 cells [211]. This 
suggests that the miRNA biogenic process is finely regulated by specific proteins 
interacting with either Drosha or Dicer individually, or both together. Since we 
observed no evidence of estrogen mediated up-regulation of LIN-28 and/or 
expression of LIN-28b, or evidence of estrogen mediated down-regulation of 
DICER and/or KSRP in our models, our data indicates that these known RBPs are 
not responsible (data not shown). Although regulation of pri-mir-17-92-derived 
microRNAs could not be explained by the candidate factors we tested, the 
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apparent incidence of regulated miRNA maturation strongly suggests 
involvement of additional proteins in this process.  
Simultaneously,  similar research has been undertaken by Bhat-Nakshatri et al. 
[356]. They showed that after stimulation of MCF7 cells for 4 hours with E2, 
three miRNAs were up-regulated: let-7f, miR-98 and miR-21. They also found 
that miR-17-5p, a member of the miR-17-92 member was up-regulated, which 
agrees to our data. Since some of these miRNAs are already known to regulate 
the estrogen responsive c-MYC, the authors suggested that the estrogenic 
response is regulated by miRNAs: thereby E2F2 another E2 modulated gene was 
found to be a new target of the let-7/miR-98 miRNA family [353]. Accordingly, 
we also found that let-7g, miR-98 and miR-21 were significantly up-regulated by 
E2 between 3 and 6h after E2 stimulation. In support of their data, we found 
that miR-27a and miR-27b were among the miRNAs down-regulated by E2 and in 
addition all the miR-181 family members were included (Table 10).  
We found that the modulation of the pri-mir-17-92 by ERα appears to be 
mediated by the c-MYC oncogene via its direct interaction with the mir-17-92 
promoter (Fig. 21 B&C). It has been reported that, in P493-6 B cells, c-MYC 
directly up-regulates the expression of mir-17-92 and down-regulates the 
expression of a set of other miRNAs [357]. Since we have not observed any 
reduction of those miRNAs after estrogenic stimulation, we conclude that the 
ERα-c-MYC is specifically inducing the expression of mir-17-92 in breast cancer 
cells.  
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The importance of miRNA activity in breast cancer biology is also highlighted by 
the finding that a number of miRNAs show a differential expression between ERα 
positive and ERα negative breast cancers [358, 359]. We demonstrated that pri-
mir-17-92 expression is highly correlated with the level of ERα in breast cancers, 
and that pre-miR-18a, derived from DROSHA-pri-mir-17-92 cleavage, is also 
significantly more expressed in ERα positive compared to ERα negative tumours 
(FiG. 22 A&B). This indicates that a specific increase of this pri-miRNA also 
occurs in physiologic conditions. It is interesting that miR-18a produced by pri-
mir-17-92 is not expressed preferentially in ERα positive tumours (Fig. 22 C&D). 
This further suggests that ERα positive tumours escape the inhibitory targeting of 
ERα caused by miRNAs by in turn down-regulating Dicer processing of those 
miRNAs during tumour progression. Here we demonstrate that the factors 
implicated in attenuation of miRNA processing are also active in cancer tissues. 
Individual miRNAs had smaller effects on targeting the transcripts, but as 
multiple mature molecules derived from these primary transcripts target ERα 
and/or AIB1 this increases both the overall level of the miRNAs regulating these 
two proteins after E2 induction and the effects of silencing; it is known that 
multiple molecules affecting a single target increase their inhibitory effect [360].  
By forming a complex with several co-activators or co-repressors, ERα 
transcriptionally modulates several genes implicated in cell proliferation and 
apoptosis such as BCL2, c-MYC and Cyclin D1. SRC1, TIF2 and AIB1 belong to 
the same family of co-activators that interact and cooperate with ERα in the 
transcriptional regulation of target genes [361].  
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miR-17-5p and miR-20a encoded by pri-mir-17-92, and the homologue miR-
106b, down-regulate the translation of AIB1 [171, 172, 174]. Given that E2 
mediated up-regulation of miR-18a, miR-19b and miR-20b results in down-
regulation of ERα (Fig. 25 A&B) and up-regulation of miR-20a, miR-17-5p, miR-
106a and miR-20b results in down-regulation of  AIB1 (Fig. 27 A&B), we 
conclude that both primary transcripts are implicated in the regulation of ERα 
transcriptional activity upon estrogenic stimulation. 
Several studies have indicated that after estrogenic induction, both ERα and AIB1 
are rapidly down-regulated. This attenuation occurs at transcriptional, post-
transcriptional and post-translational levels [75, 76, 78, 79]. We have proved 
that ERα is regulated by these miRNAs (miR-18a, miR-19b and miR-20b) directly 
by interacting with 3’UTR of ERα (Fig. 28B). We thereby propose the translational 
regulation by miRNAs as a further step of ERα transcriptional activity attenuation 
after estradiol mediated ERα activation. Interestingly, this regulation occurs at a 
later time and in a negative feedback loop since DICER pri-mir-17-92 processing 
appeared inhibited after early ERα up-regulation.  
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Figure 52: Model of the negative feedback loop and miRNA maturation delay 
promoted by activated ERα in MCF-7 cells. After ligand binding, ERα induces 
the transcription of c-MYC that in turn directly activates pri-mir-17-92 
transcription. The primary miRNA is promptly cleaved by DROSHA in the 
nucleus, but the processing from precursor to miRNA is delayed in an E2-
dependent manner. The miRNAs derived from the precursors down-regulate ERα 
and AIB1, therein fine tuning the ERα transcriptional response. 
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4.2 Possible Estrogen-inducible factor(s) affecting miRNA 
biogenesis of mir-17-92 
We identified the miRNA processing block of the miR-17-92 cluster is due to the 
involvement of an inhibitor, possibly a molecule that shuttles between the 
nucleus and cytoplasm (Fig. 31 & 32). By a Mass spectrometry approach (Fig. 
33), we tried to identify the RNA binding proteins that could play a role in the 
processing of microRNAs derived from mir-17-92. It has become more evident 
that miRNA activity can also be affected by RBPs [362]. Recent studies have 
introduced a paradigm shift in our understanding of the miRNA biogenesis 
pathway, which was previously believed to be universal to all miRNAs. It has now 
been proven that maturation steps of individual miRNAs could be specific for 
subsets of microRNAs (Table 2). RBPs like hnRNPA1, KSRP, Lin-28 and many 
more have proved important for the biogenesis of miRNAs and this regulation is 
crucial, as variations in miRNA expression have been linked to several cancers 
[196].  
Lin-28 was the first negative regulator discovered in miRNA processing but over 
recent years there have been lot of RBPs involved in negative regulation of the 
miRNA biogenesis. Interestingly, it has been shown that the RNA 
methyltransferase, BCDIN3D has a role in miRNA biogenesis by negatively 
regulating DICER processing of pre-miR-145 [238]. MCPIP1 is an endo-RNase 
that cleaves the loops of multiple miRNAs, leading to their degradation and 
hence preventing their processing to mature miRNAs [239, 363].  
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We screened few RBP candidates, identifying ALY as most interesting candidate 
(Fig. 36). We showed that ALY did indeed interact effectively with pre-miR-18a in 
vitro (Fig. 40) but further inconsistency in our results suggested that it may not 
be involved in the miRNA processing. Although the principal function of ALY is to 
transport mRNAs from the nucleus to the cytoplasm it has been already 
demonstrated that the nuclear receptor XPO-1 is also implicated in miRNA 
biogenesis in C. elegans and D. melanogaster [364]. On the other hand we 
cannot exclude that the changes we found in the initial experiments could be an 
indirect effect due to ALY function in the mRNA transport from nucleus to 
cytoplasm [320, 322]. Therefore silencing ALY could have trapped one of the 
important proteins involved in miRNA biogenesis in the nucleus, thereby affecting 
the process. An alternative explanation would be the effect of variation in the 
snoRNA house-keeping gene U6 as we had different results with different house-
keeping genes (u44, u19, u47). In summary, these data suggest that ALY may 
not be involved in the processing. Hence, we continued our search for other 
RBPs playing an important role in the processing.  
Very recently it was discovered that SND1, a known regulator of edited RNAs, 
negatively regulates the processing of mir-17-92, particularly the processing of 
miR-92a in endothelial cells [365]. This was identified by performing mass 
spectrometry using pre-miR-92a and pulling all of its possible interactors. It 
would be interesting to see if SND1 has any role in the processing of mir-17-92 
via the estrogenic response. On the other hand it has been shown that the 
estrogenic regulated transcription factor c-Myb positively regulates the 
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transcription of SND1 in MCF-7 cells in response to E2 treatment [366]. We 
performed a similar mass spectrometry approach, but using pre-mir-18a instead 
of pre-mir-92a as bait in an affinity chromatography experiment followed by 
mass spectrometry.  There was no presence of SND1 in our mass spectrometry 
identified candidates, which could indicate that either our assay was not 
performed perfectly or that SND1 is not the cause of pri-17-92 miRNA inhibition 
in MCF-7 cells.   
One of the problems we faced was the technical replicates for mass spectrometry 
experiment. We performed the experiment with appropriate controls and 
appropriate treatment (estradiol induction) but we lacked technical replicates of 
the experiment.  Although mass spectrometry is specific and accurate, other 
groups that have identified important microRNA processing factors have used at 
least three replicates [121, 130, 207, 211] and in some cases they have even 
used six independent biological replicates [131]. Therefore, we would need to 
repeat the mass spectrometry experiment with at least three independent 
replicates and again with all the controls used previously (Fig. 33).  
As DICER and TRBP are the most important components for processing 
precursors to mature miRNAs (Fig. 7), we silenced these two proteins in the 
MCF-7 and the HEK293 cell lines for at least 3 days as positive control of our 
procedures. We then checked the levels of three miRNAs (miR-18a, Let-7a, miR-
21) derived from 3 different clusters, located on different genomic loci. 
Interestingly, we did not see low levels of miRNAs after 3 days of silencing (Fig. 
52 A&B). The miRNA levels which were detected after Dicer depletion could be 
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due to either residual Dicer protein after siRNA treatment, or may represent 
persistence of mature miRNAs over the relatively short time period of these 
experiments [130]. We further silenced again DICER and TRBP in MCF-7 and 
HEK293 cells for 9 days (transient transfection with siRNAs every 3 days), we 
observed much lower levels of miRNAs after 9 days of silencing compared to the 
silencing after 3 days (Fig. 52 C&D). This data suggests that prolonged silencing 
of the RBPs is needed to observe the significant changes in miRNA levels and 
hence longer siRNA silencing techniques are required to see the effect of new 
factors. 
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4.3 Kinome Screening 
Success of breast cancer treatment has been transformed by therapies targeting 
the estrogen receptor α (ERα, encoded by ESR1). However, large numbers of 
women with breast cancer will relapse, emphasizing the need for the discovery of 
new regulatory targets modulating ERα pathways [2, 29, 367, 368]. ERα 
phosphorylation is associated with endocrine therapy resistance, particularly the 
most commonly used drug tamoxifen [328]. Phosphorylation is one of the most 
important post-translational modifications that the proteins undergo and kinases 
are the enzymes that catalyse this process; they therefore have a major role in 
cell function. RNAi screens have become one of the most powerful tools used in 
drug discovery efforts, particularly in the search for anti-cancer drugs [369].  
In response to 17β-estradiol (E2), ERα regulates a wide range of cellular 
functions by acting as a transcription factor. Apart from the significant 
widespread role of E2 in various physiological processes, it is also associated with 
the progression of several types of cancers (breast, prostate, endometrial and 
ovarian). The proteins encoded by the E2 responsive genes regulate different E2 
dependent cellular functions and therefore tight regulation of ERα transcriptional 
activity is of enormous importance. The regulation of ERα transcriptional activity 
is highly complex and not yet fully understood. Previously, some kinases have 
been reported to exert significant impact on ERα transcriptional activity [267, 
370, 371].  Previously, RNAi screens have identified important kinases like CDK10 
and PDK1 that have a significant role in endocrine resistance [372, 373]. 
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Recently, RNAi screens revealed kinases like EphB4 (as a positive regulator) and 
JAK2 (as a negative regulator) of ERα transcriptional activity [374, 375].  
We decided to do an RNAi screen to identify new kinases that regulate ERα 
transcriptional activity. We chose the expression of TFF1 as a read-out for the 
screen as it is the best characterized ERα-regulated gene. TFF1 transcription is 
strongly controlled by the binding of ERα to an ERE within the TFF1 promoter 
[376]. Prior to the screening experiment we checked for the silencing efficacy 
(Fig. 43) and estrogenic induction (Fig. 44).  
We performed the siRNA screen to identify kinases that regulate ERα activity, 
using expression of the estrogen-responsive TFF1 gene as readout for altered 
ERα activity (Fig. 46). We identified 5 genes whose knockdown stimulated TFF1 
>100% and 16 genes whose knockdown reduced TFF1 <50% (Table 12). Two 
further independent replicate screenings confirmed these findings. Among the 
other important candidates we chose LMTK3, which upon silencing, down-
regulated all the estrogen-responsive genes (TFF1, PGR and GREB1) and it was 
also a kinase of unknown function. 
The off-target effects of siRNA are a common problem (as discussed in chapter 
1.10.2), in addition to silencing specific transcripts they can also target other 
random transcripts [377]. It was shown that the phenotype caused by at least 
two siRNAs targeting different sites of the transcripts is unlikely to be due to an 
off-target effect [378]. We wanted to validate the specificity of the effects 
observed after silencing LMTK3. We used 4 different individual siRNAs that target 
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LMTK3. We observed 3 out of the 4 siRNAs down-regulated LMTK3 expression 
and they had significant effects on the estrogen-responsive genes; therefore 
suggesting that it was not an off-target effect that we observed (Fig. 49). We 
also overexpressed the LMTK3 protein and it increased the mRNA levels of TFF1, 
PGR and GREB1 (Fig. 51) revealing LMTK3 as a positive regulator of ERα activity. 
LMTKs are a family of serine–threonine–tyrosine kinases and have three isoforms 
LMTK1, LMTK2 and LMTK3; the physiological function for LMTK3 is unknown. 
Silencing of LMTK1 and LMTK2 did not change the levels of estrogen-responsive 
gene TFF1 (Fig. 50), suggesting the effect of LMTK3 is very specific within the 
LMTK family.  
Further studies carried out simultaneously by colleagues in our group revealed 
LMTK3 as a positive regulator of ERα transcriptional activity. It has been shown 
that LMTK3 knockout led to an 80% reduction of ERα protein. LMTK3 knockout 
increased the ubiquitination of ERα and, in contrast, the overexpression of 
LMTK3 phosphorylated ERα, thereby stabilising the ERα protein by protecting it 
from proteasomal degradation. Silencing of LMTK3 also reduced significantly the 
protein levels of ERα regulator, FOXO3. Further, Chromatin immunoprecipitation 
studies revealed LMTK3 increases the binding of FOXO3 to the ESR1 promoter by 
decreasing the activity of protein kinase C (PKC) and the phosphorylation of AKT  
[2, 369].  
Subsequent studies about LMTK3 expression in breast cancer have revealed both 
nuclear and cytoplasmic expressions of LMTK3 are implicated with several factors 
of more aggressive breast cancers. It has been shown that nuclear LMTK3 
expression is directly associated with a high tumour grade in both a large 
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European cohort and an Asian cohort from Singapore. High baseline LMTK3 
expression was correlated with decreased overall survival [369, 379]. Recently, 
Genome-wide studies revealed that LMTK3 has a crucial role in endocrine 
resistance via different signalling pathways [380]. All of these studies reveal that 
LMTK3 is a potential therapeutic target and also a new biomarker in ER positive 
breast cancer. 
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5.0 Conclusion and Future Studies 
In the first part of the project, we identified specific miRNAs (mir-17-92 and 
paralogue clusters) that are transcribed and then regulated in breast cancer in an 
estrogen dependent manner. Remarkably, miRNAs belonging to mir-17-92 and 
its paralogous pri-miRNAs, target and down-regulate ERα, while a subset of 
miRNAs derived from the paralogue cluster mir-106a-363 inhibits protein 
translation of AIB1, in an autoregulatory negative feedback loop. Interestingly, 
we found that levels of pri-mir-17-92 increase earlier than the mature miRNAs 
derived from it, implicating post-transcriptional regulation of miRNA precursors as 
a new mechanism of miRNA biogenesis.  
Based on these data, we hypothesised that post-transcriptional regulation is a 
general mechanism of miRNA biogenesis with relevance to breast cancer and an 
estrogen-inducible mechanism is responsible for the processing inhibition of 
mature miRNA molecules. Therefore, we aimed to demonstrate the involvement 
of miRNA binding factors in this process, and also implicate these as potential 
new therapeutic targets. We performed mass spectrometry to identify the 
inhibitor that could be involved in the inhibition of Dicer processing. 
Unfortunately, due to technical and experimental problems we could not find the 
inhibitory molecule. In the future we would like to repeat the mass spectrometry 
experiment with at least 3 biological replicates (although ideally more) and 
further validate the interesting RNA binding proteins (RBPs) revealed from mass 
spectrometry by screening the potential RBPs based on the interactions 
discovered from the mass spectrometry experiment. Most importantly, we wish 
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to elucidate the mechanisms underlying miRNA biogenesis in breast cancer. This 
is also likely to reveal new RNA binding factors and ultimately these may serve as 
druggable targets.  
We will then investigate the clinical relevance of the mir-17-92 family of miRNAs 
in breast cancer. We aim to perform an extensive study of the expression of the 
primary miRNA transcripts, the pre-miRNAs derived from these and their mature 
molecules in well characterised sets of breast cancer specimens in order to 
determine their relative expression. We will study whether this ERα regulated 
miRNAs correlate with outcome including survival, comparing ERα-positive and 
ERα-negative tumours.  
In the second part of the project, we screened the entire kinome and identified a 
novel kinase, LMTK3 that positively regulates ERα transcriptional activity. 
Furthermore, research conducted by colleagues from our group showed LMTK3 
to be  a biomarker in breast cancer as well as being involved in endocrine 
resistance signalling, and hence a potential future therapeutic target [2, 379, 
380]. It will be interesting to explore the mechanism of action of LMTK3 as the 
functions of LMTK3 were previously unknown. We would like to identify any 
miRNAs that regulate LMTK3 and vice versa (if any) and examine their effects on 
the regulatory pathways, using a variety of reporter assays [1]. We plan to 
explore the post-transcriptional mechanisms of LMTK3 activity on ERα. We will 
make every effort to determine the exact ERα phosphorylation sites of LMTK3 in 
vitro and in vivo, and study their biochemical and functional consequences, 
including effects on proliferation/apoptosis, ERα stability, function and sub-
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cellular localisation. We also aim to identify the LMTK3-ERα interacting domain 
and investigate the involvement of LMTK3 in the ERα transcriptional machinery 
(co-activators and co-suppressors). Importantly, we will investigate the clinical 
relevance of our findings by correlating identified LMTK3-driven ERα 
phosphorylation sites with single nucleotide polymorphisms (SNPs) in ESR1 and 
clinical outcomes in large cohorts. This also aims to further validate our existing 
biomarker data. Together, these aim to establish the mechanism of ERα 
regulation by LTMK3 in breast cancer, which could be important for 
understanding endocrine resistance in the clinic.  
In addition to LMTK3, our group has also identified LATS2, another kinase 
detected in our kinase screen, as being an important modulator of ERα activity 
[381]. Hence, it will be important to research on other kinases identified in the 
screen (Table 12) and validate their role in the regulation of ERα activity. 
This research has identified novel modulators of ERα at both the transcriptional 
and translational level. We propose that miRNAs derived from mir-17-92 and the 
novel kinase LMTK3 are potential diagnostic/prognostic biomarkers in ER positive 
breast cancer. More research is required to validate these observations and their 
application in clinical practice. 
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6.0 Appendices 
 
 
Figure 52: Silencing of DICER and TRBP for 3 days in MCF-7 cells. MCF-7 cells 
were transfected with 20nM of siRNAs targeting DICER, TRBP and two negative controls 
(N.C and all star N.C) for 3 days and then subjected to total RNA extraction. (A) 
Expression of miRNA levels of miR-18a, let-7a and miR-21 was analyzed by RT-qPCR 
using Taqman assay and normalized to U44 snRNA. The mean of two independent 
experiments are presented, error bars represent s.e.m. 
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Figure 52: Silencing of DICER and TRBP for 3 days in HEK293 cells. HEK293 
cells were transfected with 20nM of siRNAs targeting DICER, TRBP and two negative 
controls (N.C and all star N.C) for 3 days and then subjected to total RNA extraction. (B) 
Expression of miRNA levels of miR-18a, let-7a and miR-21 was analyzed by RT-qPCR 
using Taqman assay and normalized to U44 snRNA. The mean of two independent 
experiments are presented, error bars represent s.e.m. 
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Figure 52: Silencing of DICER and TRBP 9 days in MCF-7 cells. MCF-7 cells were 
transiently transfected after every 72h with 20nM of siRNAs targeting DICER, TRBP and 
two negative controls (N.C and all star N.C) for 9 days in total and then subjected to 
total RNA extraction. (C) Expression of miRNA levels of miR-18a, let-7a and miR-21 was 
analyzed by RT-qPCR using Taqman assay and normalized to U44 snRNA. The mean of 
two independent experiments are presented, error bars represent s.e.m. 
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Figure 52: Silencing of DICER and TRBP for 9 days HEK293 cells. HEK293 cells 
were transiently transfected after every 72h with 20nM of siRNAs targeting DICER, TRBP 
and two negative controls (N.C and all star N.C) for 9 days in total and then subjected to 
total RNA extraction. (D) Expression of miRNA levels of miR-18a, let-7a and miR-21 was 
analyzed by RT-qPCR using Taqman assay and normalized to U44 snRNA. The mean of 
two independent experiments are presented, error bars represent s.e.m. 
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Following estrogenic activation, the estrogen receptor- (ER) di-
rectly regulates the transcription of target genes via DNA binding.
MicroRNAs (miRNAs) modulated by ER have the potential to fine
tune these regulatory systems and also provide an alternate mech-
anism that could impact on estrogen-dependent developmental and
pathological systems. Through a microarray approach, we identify
the subset of microRNAs (miRNAs) modulated by ER, which include
upregulation of miRNAs derived from the processing of the paralo-
gous primary transcripts (pri-) mir-17–92 and mir-106a-363. Charac-
terization of themir-17–92 locus confirms that the ER target protein
c-MYC binds its promoter in an estrogen-dependent manner. We
observe that levels of pri-mir-17–92 increase earlier than the mature
miRNAs derived from it, implicating precursor cleavage modulation
after transcription. Pri-mir-17–92 is immediately cleaved by DROSHA
to pre-miR-18a, indicating that its regulation occurs during the for-
mation of the mature molecule from the precursor. The clinical
implications of this novel regulatory system were confirmed by
demonstrating that pre-miR-18a was significantly upregulated in
ER-positive compared to ER-negative breast cancers. Mechanisti-
cally, miRNAs derived from these paralogous pri-miRNAs (miR-18a,
miR-19b, and miR-20b) target and downregulate ER, while a subset
of pri-miRNA-derived miRNAs inhibit protein translation of the ER
transcriptional p160 coactivator, AIB1. Therefore, different subsets of
miRNAs identified act as part of a negative autoregulatory feedback
loop. We propose that ER, c-MYC, and miRNA transcriptional pro-
grams invoke a sophisticated network of interactions able to provide
the wide range of coordinated cellular responses to estrogen.
AIB1  autoregulatory feedback loop  primary transcript  processing
Upon 17--estradiol (E2) binding, estrogen receptors (ERs)mediate transcription by interacting directly to specific
estrogen response elements (EREs) located in the promoter/
enhancer region of its target genes or indirectly by tethering to
nuclear proteins, such as AP1 and SP1 transcription factors
(2–4). The cellular response to estrogen is highly regulated at
multiple levels including transcription, RNA stability, and post-
translational modifications (5–8). Following treatment with E2,
ER transcription and mRNA stability is substantially reduced
within 1 h of stimulation (7). Furthermore, E2–ER interactions
accelerate receptor degradation through the ubiquitin–
proteasome pathway, an effect associated with its major coac-
tivator AIB1 (8).
MicroRNAs (miRNAs) are a class of noncoding short RNAs,
21–24 nucleotides (nt) in length, that play a role in gene regulation.
They downregulate expression of their target genes by base pairing
to the 3-UTR of target messenger RNAs (mRNAs) (9). During
their biogenesis most miRNAs are transcribed as part of a longer
transcript named pri-miRNA (10). These molecules are processed
inside the nucleus by DROSHA, producing a pre-miRNA that is a
70-nt ‘‘imperfect’’ stem loop RNA actively transported into the
cytoplasm. In the cytoplasm the pre-miRNA is cleaved by DICER,
a dual processing event that releases a small double stranded RNA,
about 22 nt in length. Here, nuclear processing activity is thought
to be regulated at early stages of development and in a variety of
tumor cells (11–13). There is also evidence of regulation at the next
step, pre-miRNA precursor processing (14, 15). After formation of
the small duplex RNA, only 1 strand is loaded onto a miRNA
induced silencing complex (RISC). These RISCs, guided by their
miRNA, interact with the 3-UTR or sometimes with the coding
region of targetmRNAs, inhibiting protein translation or degrading
the mRNA target (10).
Substantial data associate changes in miRNA activity with car-
cinogenesis and progression (16–19). The humanmir-17–92 cluster
is a polycistronic gene with a chromosomal location 13q31-q32 that
encodes 6 miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-
19b-1, and miR-92–1). Ancient duplications have given rise to 2
mir-17–92 paralogues in mammals: mir-106b-25 and mir-106a-363.
Mir-17–92 is thought to be oncogenic in lung cancer and lympho-
mas (17, 20) or function as a tumor suppressor in breast cancer by
downregulating AIB1 and/or cyclin D1 (21, 22). Furthermore, the
genomic 13q31 area including mir-17–92 is correlated with loss of
heterozygosity in breast cancer (23).
By a genome wide approach, we have elucidated the miRNAs
regulated by ER in breast cancer. Here, we show that among the
few miRNAs upregulated by ER, miR-18a encoded by the pri-
mir-17–92, miR-19b encoded by both this primary transcript and its
evolutionary paralogue pri-mir-106a-363, and miR-20b encoded by
pri-mir-106a-363, downregulate ER expression at the protein
translational level, correlating the induction of these 2 genes during
cell proliferation with a negative feedback loop. Remarkably,
miR-20b also downregulates and targets theER coactivatorAIB1.
Since ER can act as a ligand-activated oncogene, we suggest that
the pri-mir-17–92 acts as a tumor suppressor in breast cancer, not
only by downregulating cyclin D1 and AIB1 via the miR-17/20/106
family, but also by downregulation of ER by miR-18, miR-19, and
miR-17/20/106 members. For the first time we correlate ER
translational control by miRNAs as a further regulatory process
involved in ER transcriptional activity after ligand stimulation.
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Results
ER Induction Reveals pri-mir-17–92 Upregulation. To determine
whether ER regulates the expression of miRNAs, E2 was added
to MCF-7 cells and miRNA chip hybridization was performed to
elucidate early (0–3 h) and delayed (6 h) regulation of miRNAs
by ER. As a control we used an MCF-7-TO (MCF-7-Tet-Off)-
derived cell line, JP13, that conditionally overexpresses a protein
composed of the zinc finger transcriptional repressor PLZF fused
to ER (PLZF-ER), acting as a dominant-negative that inhibits
expression of estrogen-regulated genes and estrogen-stimulated
growth of MCF-7 cells (24). Following E2 stimulation and before
microarray hybridization, we assessed the reliability of the system
using quantitative real time PCR (RT-qPCR) to reveal expression
levels of the ER-regulated gene GREB1 [supporting information
(SI) Fig. S1A and ref. 25]. GREB1 expression was reduced in
PLZF-ER cell lines treated without doxytetracycline (Tet) com-
pared to cell lines that do not express the fusion protein (Fig. S1B).
Although following array analysis we did not reveal any miRNAs
with expression changes greater than 2-fold comparing 0 h to 3, 6,
and 12 h (P  0.05) (Table S1), we found that those miRNAs that
increased following E2 in MCF-7 cells decreased in the JP13-Tet-
Off system used as a control (Fig. 1 A and B and Table S1). The
ER-upregulated miRNAs were generated by the processing of 3
paralogous primary miRNAs: pri-mir-17–92, pri-mir-106a-363, and
pri-mir-106b-25 (Fig. 1 A and B, Table S1 and Fig. S2).
To confirm the change of expression detected by the microarray,
we performed RT-qPCR choosing those miRNAs modulated be-
tween 1.2- to 2-fold in cells treated with E2 and those repressed
similarly by PLZF-ER in JP13 cell lines. Firstly, we examined the
expression of the unprocessed pri-mir-17–92 and family members.
Pri-mir-17–92 appeared upregulated within 3 h of E2 treatment
reaching a 4- to 5-fold change in comparison to 0 h (Fig. 1C)
defining it as a new early ER-regulated gene. Levels of expression
were significantly repressed by PLZF-ER (Fig. 1D). Pri-mir-342,
a negative control, showed no changes (Fig. 1 C and D), and we
obtained the same results normalizing the value of expression for
GAPDH, for the snRNAU6 and for the snoRNAU47.We excluded
from this analysis the paralogous pri-mir-106b-25 because the fold
change of the miRNAs encoded by it were considered too low by
our pre-established criteria (Table S1). Furthermore, levels of
expression of the pri-mir-106a-363 inMCF-7 cells appeared too low
to detect (we were not able to amplify it using 7 different sets of
primers from 7 genomic regions). However, it is known that in the
P493–6 B cell line that although there is c-MYC-regulated expres-
sion of typical miRNAs encoded by both pri-mir-17–92 and pri-
mir-106a-363, it is possible to detect the pri-mir-17–92 but not
pri-mir-106a-363, indicating that the latter could either be less
expressed or alternatively processed more rapidly (26). Further-
more, miR-424, miR-450, and miR-542–3p located within 6 kb of
the same genomic region, appeared significantly upregulated by E2
and significantly repressed by PLZF-ER in a perfectly reciprocal
manner (Table S1). We also observed a subset of miRNAs
that were subtly downregulated by the E2-ER complex from 0 to
12 h, and the majority of these belonged to the miR-181 family
(Table S1).
Next, we performed RT-qPCR for miR-18a, miR-19a, miR-19b,
miR-20a,miR-92 (derived frompri-mir-17–92),miR-19b,miR-20b,
miR-92 (from pri-mir-106a-363), miR-424, and miR-181b; the 2
techniques showed an overall correlation (Fig. S3 A–I and Table
S1). Comparing the low levels of expression of the miRNAs to the
higher levels of the pri-miRNAafter stimulation, therewas negative
regulation of miRNA biogenesis, following transcriptional induc-
tion by ER (Fig. 1C and Fig. S3).
C-MYC Directly Regulates the pri-mir-17–92 upon Estrogenic Stimula-
tion. It has already been demonstrated that pri-mir-17–92 is tran-
scriptionally regulated by c-MYC in the P493–6 B cell line during
the G1–S cellular transition phase (26). Since c-MYC mRNA is
upregulated by ER within 1 h of E2 treatment in breast cancer
cells (27), c-MYC could contribute to the increased transcription of
the pri-mir-17–92 upon E2 stimulation. Interestingly, we observed
a half site conserved ERE 70 bp upstream of the c-MYC consensus
site (E-box) of the mir-17–92 promoter (Fig. 2A and Fig. S4). Using
cycloheximide (CHX), we demonstrated that new protein synthesis
Fig. 1. Pri-mir-17–92 is increased by E2 and de-
creased by overexpression of PLZF-ER. (A) MCF-7
cell lines underwent E2 stimulation (10 nM) after
72 h of hormone deprivation. After total RNA ex-
traction and labeling we used a microarray platform
containing probes for 470 human miRNAs. After
hybridization and scanning, raw data were imported
into the Rosetta Resolver system for analysis. A P 
0.01 was used as cut-off for identification of miRNAs
upregulated or downregulated between 0 h versus
6 h. (B) JP13 cells were cultured in the presence or
absence of Tet for 72 h, followed by the addition of
10 nM E2 for 24 h before microarray analysis. Once
again a P 0.01 was used as cut-off for identification
of miRNAs downregulated in JP13  Tet versus
JP13  Tet. (C) MCF-7 cells were maintained in
DMEM (minus phenol red) supplemented with 10%
charcoal-dextran FBS for 3 days and then were either
left untreated or treated with 10 nM E2 for the
indicated time periods. After total RNA extraction,
expression of pri-mir-17–92 and pri-miR-342 was an-
alyzed by RT-qPCR using SYBR green and normalized
toGAPDH. (D) JP13 and MCF-7-TO cells were cultured
in the presence or absence of Tet for 72 h, followed
by the addition of 10 nM E2 for 24 h. Once again,
after total RNA extraction, expression of pri-mir-17–92 and pri-miR-342 were analyzed by RT-qPCR using SYBR green and normalized to GAPDH. The
mean of 3 experiments each performed in triplicate are presented, error bars represent SEM. For RT-qPCR data, the asterisk indicates P  0.05 in
comparison to time 0 h, the double asterisk represents P  0.005 in comparison to time 0 h. P values were obtained using a 2-tailed Student’s t-test.
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is not required exclusively for pri-mir-17–92 expression (Fig. S5)
and because it has been demonstrated that estrogen responsive
genes can contain both ER and c-MYC binding elements located
within close proximity [13–214 bp within the promoter and regu-
lated by both transcription factors in an E2-dependent manner
(28)], we performed chromatin immunoprecipitation (ChIP) assays
for both ER and c-MYC: coprecipitated DNA was analyzed by
amplifying the genomic region containing both consensus sites (Fig.
2A and Fig. S4) by real time PCR (Fig. 2B andC). Although TFF1,
a known estrogen-regulated gene, is confirmed here as regulated by
ER (Fig. 2B), we observed only c-MYC interacting with the
mir-17–92 promoter region analyzed (Fig. 2 B and C). We dem-
onstrated that c-MYC is recruited to the mir-17–92 promoter in
breast cancer cells upon E2 stimulation.
Pri-mir-17–92 Is Negatively Regulated Following DROSHA Cleavage
Prolonging miRNA Maturation over Time. Remarkably, the pri-mir-
17–92 expression is striking compared to the miRNAs that are
produced by its processing (miR-17, miR-18a, miR-19a, miR-19b,
and miR-20a), indicative of modulation of miRNAs biogenesis at
the posttranscriptional level (Figs. 1C, 3A, and Fig. S3). A primary
transcript undergoes a dual processing event, the first in the nucleus
by DROSHA (pre-miRNA production), the second in the cyto-
plasm by DICER. To define the step(s) of miRNA biogenesis in
which regulation occurs, we measured levels of the pri-miR-17–92-
derived pre-miR-18a after E2 treatment. DROSHA pri-mir-17–92
cleavage to pre-miR-18awas not a regulatory or ‘‘rate-limiting’’ step
here because both were induced at similar levels (Fig. 3B). How-
ever, the primers used to amplify the pre-miR-18a also amplify
pri-mir-17–92. Therefore, to establish that we could distinguish
between pri- and pre-miRNA, we stimulated the cell lines with E2
and then separated the small RNA fraction from the large RNA
fraction.We used the largeRNA fraction tomeasure pri-mir-17–92
and the small RNA fraction to measure pre-miR-18a (Fig. S6). As
a further control we measured the pri-mir-17–92 from the small
RNA fraction without obtaining any amplification product. These
data demonstrated that pri-mir-17–92 is induced by the E2–ER
complex, then it is processed by DROSHA releasing the pre-miR-
18a, but the passage between pre-miR-18a and miR-18a is atten-
uated until at least 12 h following initial E2 stimulation. Further-
more, using RT-qPCR, we found that both miR-18a and miR-20a
mature forms increase their levels of expression from 24 to 72 h
after E2 stimulation (Fig. 3 C and D). Analyzing the levels of the
pri-mir-17–92 and the pre-miR-18a from0 to 72 h, we observed that
pri-mir-17–92 is transcriptionally upregulated after 3 h, then DRO-
SHA promptly processes the pri- to the pre-miR-18a, whereas the
formation of themature form from the pre-miR-18a is delayed (Fig.
3E). In addition while the miR-18a levels start to increase at 24 h,
both pri-mir-17–92 and pre-miR-18a levels decline, indicative of the
processing delay we observed (Fig. 3E).
Pri-mir-17–92 Expression Is Correlated with ER Levels in ER-Positive
Primary Breast Cancers. To evaluate ER modulation of the
pri-mir-17–92 at the physiologic level, we examined a corre-
lation between ER mRNA and pri-mir-17–92, and ER
mRNA and pre-miR-18a, in breast cancer tissues by RT-qPCR.
Levels of pri-mir-17–92 were correlated with ER mRNA in
tissues (r2  0.97, P  0.0002, Fig. 4A), further indicating that
ER regulates the expression of this primary miRNA. How-
ever pre-miR-18a was less correlated with ER (r2 0.54, P
0.21, Fig. 4B). Next, we addressed whether pre-miR-18a,
miR-18a, and miR-20a were differentially expressed in pri-
mary breast cancer tissues, comparing the average expression
levels between ER-positive and -negative tumors. Pre-miR-
18a levels were significantly higher in ER-positive tumors
(2.52 0.30) compared with negative tumors (0.90 0.08, P
0.006, Fig. 4C), supporting our data. Moreover, expression
levels of miR-18a showed no significant differences between
the 2 groups of samples (Fig. 4D), indicating that impaired
pre-miR-18a processing to miR-18a occurs in tumors.
MiR-18a, miR-20b, and miR-19b Negatively Modulate the ER Tran-
scriptional Activity After Estrogen Stimulation. Using the available
miRNA target prediction software [TargetScan (29), Pictar
(30), and Pita (31)], we observed whether ER is a potential
target of some or all of these miRNAs. Surprisingly, we found
that miR-18, miR17/20/106, and miR-19 family members were
predicted to target ER. To experimentally validate this
prediction, we chose miR-18a encoded by pri-mir-17–92, miR-
19b encoded by both pri-mir-17–92 and the pri-mir-106a-363,
and miR-20b encoded by the pri-mir-106a-363 (Fig. S2). First,
we addressed whether these miRNAs inf luence ER tran-
scriptional activity. MELN cells (MCF-7 cells, stably trans-
fected with a luciferase reporter gene under the control of an
ERE using the -globin promoter) were transfected with
pre-miR-18a, pre-miR-20b, and pre-miR-negative control
(pre-miR-n.c.). E2-stimulated reporter activity was signifi-
cantly reduced when MELN cells were transfected with pre-
miR-18a and pre-miR-20b, whereas the level of induction was
not affected by pre-miR-n.c. (Fig. 5A). Remarkably, anti-miR-
18a, anti-miR-20b, and anti-miR-19b molecules able to silence
their miRNA function significantly increased reporter activity
(Fig. 5B). The effect of miRNA silencing on luciferase reporter
activity was similar to treatment with anti-miR-17–5p, previ-
ously reported to reduce the transcriptional activity of ER by
downregulating the coactivator AIB1 (21) (Fig. 5B).
Mir-17–5p, miR-106b, and miR-20a are able to negatively reg-
ulate AIB1 protein translation by a direct interaction with the
3-UTR of AIB1 mRNA (21, 22, 32). Because we observed that
miR-17/20/106 and the miR-18 family members potentially target
ER, we evaluated whether the reduction in ER transcriptional
activity induced by miR-20b overexpression was the result of the
contemporary negative regulation of AIB1 and ER and in addi-
tion, whether the reduction in ER transcriptional activity induced
by overexpression of miR-18a was the result of a reduction of ER
protein levels. To address if these miRNAs negatively regulate
either ER and/or AIB1, we overexpressed pre-miR-18a, pre-miR-
19b, pre-miR-20b, and pre-miR-n.c. and measured protein levels.
ER was markedly reduced by the overexpression of all 3 premiRs
analyzed in comparison to either untransfected or pre-miR-n.c.
Fig. 2. c-MYC directly regulates the pri-mir-17–92 upon estrogenic stimula-
tion. (A) Schematic representation of the mir-17–92 cluster genomic region.
Both the c-MYC binding site and a putative ERE half site are indicated. (B)
MCF-7 cells were maintained in estrogen-free medium for 3 days (starvation)
and then either left untreated (vehicle) or treated with 10 nM E2 for 3 h after
which ChIP was performed, followed by real time PCR. The c-MYC interaction
site genomic region is presented. (C) After starvation, MCF-7 cells were treated
with E2 for 12 h before ChIP.
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transfected cells although the reduction with pre-miR-19b was less
pronounced (Fig. 5 C and D). Furthermore, miR-20b downregu-
lated AIB1 because transfection of pre-miR-20b into MCF7 cells
reduced AIB1 protein levels (Fig. 5 C and E). On the other hand,
the transfection of anti-miR-20b increased AIB1 (a dose–response
was also observed here; Fig. 5F). Because a reduction in eitherER
or AIB1 mRNA levels after transfection of precursors was not
observed, it appears likely that this regulation occurs at the protein
translation step (Fig. S7 A and B).
To confirm whether these miRNAs directly target ER, we
inserted into the luciferase reporter vector 4 fragments of the
3-UTR of ER: the full length (FL, containing all of the putative
miRNAs interaction sites), the first half part of the 3-UTR (ERup
for miR-17/20/106 and miR-18), a fragment containing just the
putative miR-18 family interaction sites (ER1), and finally a frag-
ment corresponding to the second half section, containing the
miR-19 family interaction sites (ER2) (Fig. 6A). Transfection of
miR-18a, miR-19b, and miR-20b, derived from pri-mir-17–92 and
pri-mir-106a-363, were used to investigate direct interactions with
the 3-UTR of ER constructs and we demonstrated that these
miRNAs profoundly downregulate luciferase activity for the con-
structs containing miRNA interaction sites, but not for the ones in
which these sites are absent (Fig. 6B). This indicates direct targeting
of ER by a number of miRNAs derived from these paralogous
primary miRNAs. We did not observe any downregulation of
luciferase reporter activity upon miR-17–5p overexpression, ac-
cording to a recent report (33).
Discussion
In this study we were able to classify miRNAs upregulated by
estrogen as the members encoded by the paralogous tran-
scripts pri-mir-17–92 and pri-mir-106a-363. For individual
miRNAs small changes were observed, but as multiple mature
molecules derived from these primary transcripts target ER
and/or AIB1 this increases both the overall level of the
miRNAs regulating these 2 proteins after E2 induction and the
effects of silencing; it is known that multiple molecules affect-
ing a single target increase their inhibitory effect (34).
Changes in pri-mir-17–92 were significantly greater than the
miRNAs derived from it, implicating inhibition during miRNA
biogenesis: DROSHA cleavage of pri- to pre-miRNAs occurred
rapidly, indicating that this step is not rate limiting (Fig. S8). Such
regulation however has been described regarding let-7 family
members during stem cell differentiation: LIN-28 is able to interact
with pri-let-7 and/or pre-let-7 impairing its processing (12, 15). It
has also been reported that c-MYC downregulates let-7 maturation
increasing the transcription of LIN-28b in P493–6 B cell lines (35).
Furthermore, it has been shown that the RNA binding protein
KSRP, interacting with DICER, promotes the biogenesis of a
subset of miRNAs comprising miR-20a and miR-106a in both
HeLa and NIH 3T3 cells (36). Because we did not observe any
estrogen-mediated upregulation of LIN-28 and/or any expression of
LIN-28b, or any estrogen-mediated downregulation of DICER
and/or KSRP in our models, this indicates that these factors are not
responsible. Our data indicate that pri-mir-17–92 (not only let-7), is
regulated after induction. Additionally, many expression studies
note discordance in the levels of mature miRNAs derived from
polycistronic precursors. Although regulation of pri-mir-17–92-
derivedmicroRNAs could not be explained by the candidate factors
we tested, the apparent prevalence of regulatedmiRNAmaturation
strongly suggests involvement of additional RNA binding proteins
in this process.
The importance of miRNA activity in breast cancer biology is
also highlighted by the finding that a number of miRNAs show a
differential expression between ER positive and ER negative
breast cancers (37, 38). We demonstrated that pri-mir-17–92 ex-
pression is highly correlated with the level of ER in breast cancers,
and that pre-miR-18a derived fromDROSHA-pri-mir-17–92 cleav-
age is also significantly more expressed in ER-positive compared
to ER-negative tumors. This indicates that a specific increase of
this pri-miRNA also occurs in physiologic conditions. It is inter-
esting that miR-18a produced by pri-mir-17–92 is not expressed
Fig. 3. Pri-mir-17–92 is negatively regulated follow-
ing DROSHA cleavage prolonging miRNA matura-
tion over time. (A) Comparison of the levels of ex-
pression between pri-mir-17–92 (normalized to
GAPDH) and miRNAs encoded from this cluster (nor-
malized to U47). The mean of 3 experiments each
performed in triplicate are presented, error bars
represent SEM. (B) After starvation expression levels
of both pri-mir-17–92 and pre-miR-18a has been
analyzed by RT-qPCR using SYBR green and normal-
ized to U6 snRNA followed E2 treatment as indi-
cated. The mean of 3 experiments each performed in
triplicate are presented, error bars represent SEM.
The asterisk indicates P 0.05 in comparison to time
0 h, the double asterisk represents P  0.005 in
comparison to time 0 h. P values were obtained using
a 2-tailed Student’s t-test. (C) After starvation ex-
pression levels of miR-18a, miR-20a, and miR-342
were analyzed by RT-qPCR and normalized to U47
snRNA. The mean of 3 experiments each performed
in triplicate are presented, error bars represent SEM.
The asterisk indicates P  0.05 in comparison to
vehicle treatment, the double asterisk represents P
0.005 in comparison to vehicle treatment. P values
were obtained using a 2-tailed Student’s t-test. (D)
Representation of miR-18a, miR-20a, and miR-342
levels (normalization to U47 snoRNA) from 0 to 72 h of E2 treatment by RT-qPCR. The mean of 3 experiments each performed in triplicate are presented,
error bars represent SEM. (E) Representation of the miR-18a (normalization to U47), pre-miR-18a and pri-mir-17–92 levels (normalization to U6) from
0 to 72 h of E2 treatment. The mean of 3 experiments each performed in triplicate are presented, error bars represent SEM.
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preferentially in ER-positive tumors. This further suggests that
ER-positive tumors escape the inhibitory targeting of ER caused
by miRNAs by in turn downregulating DICER processing of those
miRNAs during tumor progression. Here we demonstrate that the
factors implicated in attenuation of miRNA processing are also
active in cancer tissues themselves.
The modulation of the pri-mir-17–92 by ER appears mediated
by the c-MYC oncogene by its direct interaction with themir-17–92
promoter. It has been reported that c-MYC directly downregulates
the expression of a set of miRNAs in B cells (39). Because we have
not observed any reduction of those after estrogenic stimulation, we
conclude that the upregulation of pri-mir-17–92 through ER-c-
MYC is specific to breast cells.
By forming a complex with several coactivators or corepres-
sors, ER transcriptionally modulates several genes implicated
in cell proliferation and apoptosis such as BCL2, c-MYC, and
cyclin D1. AIB1, SRC1, and TIF2 belong to the same family
of coactivators that interact and collaborate with ER in the
transcriptional regulation of target genes (40). MiR-17–5p and
miR-20a encoded by pri-mir-17–92, and the homologue miR-
106b, downregulate the translation of AIB1 (21, 22, 32).
Because following E2-mediated upregulation: (i) miR-18a,
miR-19b, and miR-20b downregulate ER and (ii) miR-20a,
miR-17–5p, miR-106a, and miR-20b downregulate AIB1, we
conclude that both primary transcripts are implicated in the
regulation of ER transcriptional activity upon estrogenic
stimulation. Several studies have indicated that after estro-
genic induction, both ER and AIB1 are rapidly downregu-
lated. This attenuation occurs at transcriptional, posttranscrip-
tional, and posttranslational levels (5–8). We propose here the
translational regulation by miRNAs as a further step of ER
transcriptional activity attenuation after estradiol-mediated
ER activation. Interestingly, this regulation occurs especially
at a later time and in a negative feedback loop because DICER
pri-mir-17–92 processing appeared inhibited after early ER
upregulation (Fig. S8).
Methods
MiRNA Microarray. Isolated RNA was labeled using the Agilent labeling kit
following the manufacturer’s instruction (Agilent Technologies). The Agilent
human (V1) miRNA microarray platform, containing probes for 470 human (and
64 viral miRNAs from the Sanger database v9.1), was used to perform miRNA
expression profiling.
RT-qPCR Assay. For RT-qPCR assays, cDNA was synthesized from 1 g of
purified Dnase-treated RNA by the SuperScript III First-Strand cDNA syn-
thesis system (Invitrogen); RT-qPCR was performed on a 7900HT Thermo-
cycler using the Power SYBR green PCR master mix (both from Applied
Biosystems). For detection of mature miRNAs, the TaqMan MicroRNA assay
kit (Applied Biosystems) was used. Sequences of primers used are provided
in Table S2.
ChIP. Cross-linked chromatin was prepared from MCF-7 cells as described
previously with minor modifications (43). Aliquots of 20 g were incubated
Fig. 4. ER modulates pri-mir-17–92 in breast cancer tissues. (A) Expression
levels of ER and pri-mir-17–92 (Pearson correlation 0.97) or (B) pre-miR-18a
(Pearson correlation 0.54) was measured by RT-qPCR in ER-positive breast
cancers. (C) RT-qPCR showed that expression levels of pre-miR-18a are signif-
icantly higher in ER-positive than in ER-negative tumors (unpaired, 2-tailed
Student’s t-test P 0.006). Error bars represent SEM. (D) RT-qPCR showed that
expression levels of miR-18a are not different between ER-positive and
ER-negative tumors (unpaired, 2-tailed Student’s t-test P  0.18). Error bars
represent SEM.
Fig. 5. MiR-18a, miR-19b, and miR-20b suppress ER-
mediated signaling. (A) Luciferase activity in MELN
cells untransfected or transiently transfected for 48 h
with pre-miR-18a, pre-miR-20b, and pre-miR-n.c. in the
absence or presence of 10 nM of E2 for 24 h. (B)
Luciferase activity in MELN cells transiently transfected
for 48 h with anti-miR-17–5p, anti-miR-18a, anti-miR-
19b, anti-miR-20b, anti-miR-n.c. or untransfected in
the absence or presence of 10 nM of E2 for 24 h. (C)
Western blot showing ER, AIB1, and -actin in MCF-7
cells untransfected or transiently transfected with pre-
miR-18a, pre-miR-19b, pre-miR-20b, and pre-miR-n.c.
(D) Densitometric analysis of ER Western blot shown
inCnormalized to-actin. (E) Densitometric analysis of
AIB1 Western blot (shown in C normalized to -actin.
The mean of 3 independent experiments are pre-
sented, error bars represent SEM. (F) Western blots
showing AIB1 and -actin in MCF-7 cells transfected
with anti-miR-n.c. and anti-miR-20b at 10, 30, and 100
nM concentrations. One representative experiment
from 3 independent experiments is shown.
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overnight with 2 g of c-Myc (sc-764) and ER (sc-543) antibodies (Santa
Cruz Biotechnology) or without (mock controls) in a total volume of 1 mL
and immunoprecipitated. Triplicate samples of 5 L of immunoprecipi-
tated genomic DNA were amplify by real time PCR. Values are expressed as
fold of enrichment with respect to input DNA. Primer sequences used in this
assay are listed in Table S2.
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Therapies targeting estrogen receptor  (ER, encoded by 
ESR1) have transformed the treatment of breast cancer. 
However, large numbers of women relapse, highlighting the 
need for the discovery of new regulatory targets modulating 
ER pathways1–5. An siRNA screen identified kinases 
whose silencing alters the estrogen response including those 
previously implicated in regulating ER activity (such as 
mitogen-activated protein kinase and AKT). Among the most 
potent regulators was lemur tyrosine kinase-3 (LMTK3), for 
which a role has not previously been assigned. In contrast to 
other modulators of ER activity, LMTK3 seems to have been 
subject to Darwinian positive selection, a noteworthy result 
given the unique susceptibility of humans to ER+ breast 
cancer. LMTK3 acts by decreasing the activity of protein kinase C  
(PKC) and the phosphorylation of AKT (Ser473), thereby 
increasing binding of forkhead box O3 (FOXO3) to the ESR1 
promoter. LMTK3 phosphorylated ER, protecting it from 
proteasomal degradation in vitro. Silencing of LMTK3 reduced 
tumor volume in an orthotopic mouse model and abrogated 
proliferation of ER+ but not ER− cells, indicative of its role 
in ER activity. In human cancers, LMTK3 abundance and 
intronic polymorphisms were significantly associated with 
disease-free and overall survival and predicted response to 
endocrine therapies. These findings yield insights into the 
natural history of breast cancer in humans and reveal LMTK3 
as a new therapeutic target.
More than two-thirds of breast tumors express ERα (ref. 2), and 
patients with ERα+ disease respond to antiestrogens (tamoxifen), 
estrogen withdrawal (aromatase inhibitors) and direct targeting of 
the receptor (fulvestrant)1. The introduction of these treatments has 
had a profound impact on patient survival6. However, resistance to 
these therapies is common, and in vitro evidence points to the role 
of ERα phosphorylation3 in the development of endocrine resist-
ance4,5. To identify kinases that regulate ERα activity, we performed 
a whole human kinome siRNA screen using expression of the 
 estrogen-responsive TFF1 gene, encoding trefoil factor-1, as a read-
out for altered ERα activity in the presence of estradiol (E2 (ref. 7)) 
(Supplementary Fig. 1). We identified five genes whose knockdown 
resulted in a >100% increase in TFF1 expression and 16 genes whose 
knockdown reduced TFF1 expression by <50% (Fig. 1a). Two further 
independent replicate screenings confirmed these findings (data not 
shown). The identification of the kinases mitogen-activated protein 
kinase-3 (MAPK3) and AKT, which phosphorylate ERα at Ser118 
and Ser167, respectively8–12, confirmed the screen could successfully 
identify regulators of estrogen-responsive gene expression.
We subsequently measured the expression of two other ERα reg-
ulated genes (PGR, encoding progesterone receptor, and GREB1, 
encoding growth regulation by estrogen in breast cancer-1)13 and two 
control genes (GAPDH, encoding glyceraldehyde 3-phosphate dehy-
drogenase, and MCL1, encoding myeloid cell leukemia sequence-1). 
Two of the five genes (LATS2 (encoding large tumor suppressor, 
homolog 2) and CCRK (encoding cell cycle–related kinase)) whose 
downregulation upregulated TFF1 also upregulated PGR or GREB1 
>100% (group A, upregulated), and three of the 13 kinases (TYRO3 
(encoding protein tyrosine protein kinase receptor 3), LMTK3 and 
KSR1 (encoding kinase suppressor of ras 1)) that downregulated TFF1 
expression were also able to downregulate the expression of both 
PGR and GREB1 >50% (group B, downregulated) (Supplementary 
Table 1), whereas the expression of GAPDH and MCL1 did not 
change, indicating that the effects were E2 treatment dependent.
To prioritize among the kinases whose silencing downregulated 
the activity of ERα, we asked whether any of the candidate proteins 
showed evidence of positive selection as measured by analyzing 
changes in synonymous versus nonsynonymous genomic altera-
tions. It is well established that humans and the great apes (especially 
chimpanzees) differ in their susceptibilities to epithelial neoplasms, 
including breast cancer14–18 possibly resulting from recent evolution-
ary events reflected in the adaptive profile of genes that have a regu-
latory role in estrogenic signaling. Of those genes that we found to 
Kinome screening for regulators of the estrogen receptor 
identifies LMTK3 as a new therapeutic target in breast cancer
Georgios Giamas1, Aleksandra Filipović1, Jimmy Jacob1, Walter Messier2, Hua Zhang1, Dongyun Yang3,  
Wu Zhang3, Belul Assefa Shifa1, Andrew Photiou1, Cathy Tralau-Stewart4, Leandro Castellano1, Andrew R Green5, 
R Charles Coombes1, Ian O Ellis5, Simak Ali1, Heinz-Josef Lenz3 & Justin Stebbing1
1Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital Campus, London, UK. 2Evolutionary Genomics, Inc., Lafayette, Colorado, USA. 
3Division of Medical Oncology, University of Southern California, Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California, USA. 4Drug 
Discovery Centre, Imperial College London, Biochemistry Building, South Kensington Campus, London, UK. 5Histopathology, School of Molecular Medical Sciences, 
University of Nottingham and Nottingham University NHS Hospital Trust, Nottingham, UK. Correspondence should be addressed to G.G. (g.giamas@imperial.ac.uk)  
or J.S. (j.stebbing@imperial.ac.uk).
Received 16 August 2010; accepted 10 March 2011; published online 22 May 2011; doi:10.1038/nm.2351
©
 2
01
1 
N
at
u
re
 A
m
er
ic
a,
 In
c.
  A
ll 
ri
g
h
ts
 r
es
er
ve
d
.
l e t t e r S
716  VOLUME 17 | NUMBER 6 | JUNE 2011 nature medicine
regulate ERα, only LMTK3 has been subject to recent Darwinian pos-
itive selection compared to its chimpanzee ortholog (Supplementary 
Table 2). Further, LMTK3 silencing consistently inhibited the expres-
sion of estrogen-regulated genes potently (Supplementary Fig. 2a 
and Supplementary Fig. 3), whereas transfection of LMTK3 in 
ERα-positive breast cancer cell lines (MCF-7 and ZR-75-1) resulted 
in opposite effects, as measured by quantitative RT-PCR analysis. 
(Supplementary Fig. 2b).
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Figure 2 Mechanisms of LMTK3 action on ERα  
transcription and translation. (a) Effects of LMTK3  
silencing on total ERα protein levels, in the presence or  
absence of the MG132 proteasome inhibitor. Mock  
treatment, Hiperfect transfection reagent alone; IB,  
immunoblot. (b) Protein half-life of ERα after silencing  
and overexpression of LMTK3. (c) ERα ubiquitination  
assay after LMTK3 silencing. WB, western blot; IP,  
immunoprecipitation. (d) In vitro phosphorylation of ERα by LMTK3. C, Coomassie; A, autoradiogram. (e) In vitro degradation assay of ERα. E1/E2/E3 are ubiquitin 
ligases; 26S is the proteasome fraction. (f) Coimmunoprecipitation and coimmunofluorescence of ERα and LMTK3. Scale bar, 50 µm. (g) Gene expression of ESR1, 
GATA3, FOXO3 and FOXM1 after LMTK3 silencing. (h) Effects of LMTK3 silencing on FOXO3, p-FOXO3 Ser318/Ser321, p-FOXO3 Thr32, p-AKT Ser473 and p-ERα 
Ser167 protein levels. In red is the fold change compared to the mock-treated samples relative to actin loading control. (i) Left, effects of FOXO3 overexpression on 
ERα protein levels. Right, effects of LMTK3 overexpression on FOXO3 binding to the ESR1 promoter. (j) Left, in vitro kinase assays examining the effect of LMTK3 
phosphorylation on the catalytic activity of PKC. Middle, effects of LMTK3 silencing on the ability of PKC to phosphorylate its substrates in vivo. Right, effects of 
LMTK3 silencing on ERα protein amounts in the presence of a PKC activator (PMA) or a PKC inhibitor (Go 6983). Error bars represent s.d. of two independent 
experiments in triplicate.
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LMTKs are a family of serine-threonine-tyrosine kinases19–21. 
A function has not been ascribed to LMTK3, although screens have 
suggested a putative role in the β-catenin pathway22 and leukemic cell 
survival23. We found that only LMTK3 isoform knockdown, and not 
LMTK1/2 isoform knockdown, inhibited the activity of an estrogen-
regulated luciferase reporter, whereas LMTK3 did not alter GAPDH or 
MCL1 expression (Supplementary Figs. 2c–e, 4 and 5). In addition, 
knockdown of LMTK3, but not LMTK1 or LMTK2, inhibited MCF-7 
human breast adenocarcinoma E2-dependent cell growth (Fig. 1b), 
accompanied by accumulation of cells in the sub-G1 phase (Fig. 1c,d). 
We obtained similar results in other ERα+ cell lines and saw no effects 
in ERα– cells (Supplementary Fig. 6). Taken together, these data 
indicate that LMTK3 is a regulator of ERα activity.
To establish the mechanisms of LMTK3 regulation of ERα in 
MCF-7 cells, we next examined ERα expression. ERα protein amounts 
were reduced 80% by LMTK3 knockdown (Fig. 2a). ERα amounts 
were higher in the presence versus absence of proteasome inhibitors 
(Fig. 2a), and the ERα half-life was reduced after LMTK3 knock-
down, whereas LMTK3 overexpression stabilized ERα (Fig. 2b). 
There was an increase in ERα ubiquitination after LMTK3 knock-
down (Fig. 2c). Moreover, phosphorylation of ERα by LMTK3 
(as suggested by data in Fig. 2d) protected ERα from in vitro proteasomal 
degradation (Fig. 2e), and LMTK3 and ERα were able to interact 
in vivo (Fig. 2f). Together, these data indicate that LMTK3 regulates 
ERα by phosphorylating and protecting it from proteasomal degrada-
tion. Next, we wished to understand the contribution of LMTK3 to 
ESR1 transcription. We observed that LMTK3 knockdown reduced 
expression of ESR1 mRNA (Fig. 2g). ERα expression is regulated 
by GATA binding protein 3 (encoded by GATA3 (ref. 24)), FOXO3 
(refs. 25–27) and forkhead box M1 (encoded by FOXM1 (ref. 28)), as 
well as by ERα regulating its own expression29. LMTK3-targeting siRNA 
(LMTK3 siRNA) did not affect mRNA levels of these genes (FOXO3, 
GATA3 and FOXM1) (Fig. 2g); however FOXO3 protein abundance 
was reduced 70%, and FOXO3 phosphorylation was reduced relative 
to total FOXO3 abundance (Fig. 2h). Overexpression of FOXO3 par-
tially rescued the LMTK3 siRNA–mediated decrease in ERα (Fig. 2i), 
whereas chromatin immunoprecipitation confirmed that overexpres-
sion of LMTK3 increased binding of FOXO3 to the ESR1 promoter 
(Fig. 2i). As it has already been described that AKT phosphorylates 
and inhibits FOXO3 by promoting its degradation30, we examined 
the effects of LMTK3 silencing on AKT. We found no changes in 
total AKT abundance, but we did see an increase in phospho-
rylated cytoplasmic AKT (on Ser473), suggesting that LMTK3 
siRNA–induced FOXO3 downregulation is regulated via AKT 
(Fig. 2h). Notably, we observed an increased phosphorylation of ERα 
at Ser167, despite decreased total ERα amounts, as a result of acti-
vated AKT, as previously described8 (Fig. 2h). As protein kinase C 
(PKC) activity has been implicated in ERα protein degradation31 and 
in decreased ESR1 transcription via activation of AKT and inhibi-
tion of FOXO3 (ref. 32), we examined the effects of LMTK3 on PKC. 
In vitro kinase assays indicated that LMTK3 inhibits the ability of 
PKC to phosphorylate histone (Fig. 2j), whereas the use of a specific 
 phospho-serine PKC substrate antibody showed that LMTK3 
 silencing increased the ability of PKC to phosphorylate a number of 
substrates (Fig. 2j). In addition, inhibition of PKC, using the Go 6983 
 inhibitor33, partly rescued the downregulation of ERα protein induced 
by LMTK3 silencing, whereas concurrent treatment with a PKC acti-
vator (PMA)34 and LMTK3 siRNA resulted in further degradation of 
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Figure 3 Association of LMTK3 expression and germline polymorphisms with clinical outcome.  
(a) Representative images of different immunohistochemistry staining intensities are shown. LMTK3  
staining: weak (H score = 0–25); moderate (H score = 26–134); strong (H score = 135–300). H score:  
histology score, a method of assessing the extent of nuclear immunoreactivity. Original magnification,  
200×; scale bars, 100 µm. (b–e) Kaplan-Meier plots showing the association between LMTK3 expression  
and disease-free survival (P = 0.012) (b), overall survival (P = 0.033) (c), response to endocrine therapy  
(P = 0.039) (d), response to chemotherapy (P = 0.184) (e). (f,g) Kaplan-Meier plots demonstrating the  
association between two LMTK3 polymorphisms and overall survival (P = 0.017) (f) and disease-free  
survival (P = 0.002) (g). 
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ERα (Fig. 2j). These data further imply that the effects of LMTK3 on 
ERα are both directly (ESR1) and indirectly (ERα protein) mediated 
via PKC signaling.
Our findings indicate that LMTK3 is key in regulating ERα 
 activity. To confirm these data in primary breast cancer, we used 
immunohistochemistry to determine LMTK3 abundance (Fig. 3a 
and Supplementary Fig. 7) in 613 breast cancer samples35. High 
nuclear LMTK3 expression was associated with a significantly 
shorter disease-free survival time (P = 0.01) and overall survival time 
(P = 0.03) (Fig. 3b,c). LMTK3 abundance was also predictive of response 
to endocrine therapy (P = 0.04) (Fig. 3d) but did not predict response to 
adjuvant chemotherapy (P = 0.18) (Fig. 3e). To further investigate the 
potential involvement of LMTK3 in the development of tamoxifen resist-
ance, we analyzed the effects of LMTK3 silencing in tamoxifen-resistant 
cell lines (BT-474, MLET5 and LCC9)36–38. Tamoxifen alone slightly 
affected baseline levels of cell growth, whereas addition of LMTK3 
siRNA increased the growth inhibitory effects of tamoxifen, and the 
expected elevated levels of phosphorylated ERα and its major oncogenic 
co-activator amplified in breast cancer 1 (AIB1) (ref. 39) were decreased, 
(Supplementary Fig. 8). In addition, LMTK3 was also essential for 
E2-induced growth, as silencing of LMTK3 impeded cell proliferation 
in the presence of E2 (Supplementary Fig. 9).
The significant associations of LMTK3 expression with clini-
cal outcome led us to test whether methylation might have a role in 
 transcription or translation of LMTK3. We found only five out of 
227 subjects12 (Supplementary Table 3) with a methylated LMTK3 gene, 
suggesting that methylation is not a prevalent mechanism in the control 
of LMTK3 expression in this context. In this cohort, we then examined 
polymorphisms that could underlie the differential levels of LMTK3 
in people with cancer. We found that two intronic polymorphisms 
(see Online Methods) were independently associated with disease-free 
survival and overall survival, suggesting functionally relevant poly-
morphisms. Individuals harboring the LMTK3 rs8108419 GG or AG 
and the LMTK3 rs9989661 TT alleles were at a lower risk of develop-
ing tumor recurrence, which is our reference with a relative risk = 1 
compared to patients carrying the LMTK3 rs8108419 AA and LMTK3 
rs9989661 CT or CC alleles who have an increased risk (relative risk = 
2.44; confidence interval: 1.40–4.25) (P = 0.002; Supplementary 
Table 4). Overall survival was associated with combined analyses of risk 
of these two polymorphisms (P = 0.017; Fig. 3f,g and Supplementary 
Table 4). In multivariate analyses, LMTK3 polymorphisms were an 
independent prognostic factor for both disease-free survival and overall 
survival (Supplementary Table 4). Next, to investigate the effects of 
LMTK3 knockdown on breast tumor xenograft growth, we injected 
naked LMTK3 siRNA, diluted in PBS, into pre-established human 
MCF-7 breast carcinoma tumors grown in nude mice. In vivo biolu-
minescence imaging of the xenografted tumors showed that loss of 
LMTK3 protein expression, observed by immunohistochemistry, leads 
to a significant decrease in tumor growth (Fig. 4 and Supplementary 
Table 5, P = 0.024).
The majority of human breast tumors express ERα, and individuals 
with ERα+ disease usually respond to endocrine therapies. Endocrine 
resistance is a major problem, highlighting a need for understanding 
the mechanisms of ERα action and the development of new therapeutic 
agents. By performing a kinome siRNA screen to identify new proteins 
modulating ERα transcriptional activity, combined with evolutionary 
and mechanistic analyses, we have established a role for LMTK3 in 
regulating ERα in breast cancer. We propose a model where LMTK3 
regulates the stability and activity of ERα at the mRNA level, via down-
regulation of PKC catalytic activity resulting in less phosphorylated 
AKT (Ser473) that stabilizes FOXO3, which in turn leads to increased 
ERα transcriptional activity, and at the protein level, directly by phos-
phorylating ERα and protecting it from proteasomal degradation 
(Supplementary Fig. 10). Notably, LMTK3 expression was down-
regulated by E2 and upregulated in response to tamoxifen, revealing a 
feedback loop between LMTK3 and ERα (Supplementary Fig. 11).
The demonstration that expression of and polymorphisms 
in LMTK3 are associated with clinical outcome and response to 
endocrine therapy in breast cancer, in combination with our in vivo 
studies, suggests clinical and translational relevance. Although pre-
sumably all proteins must have been positively selected for their bio-
chemical functions at some time in the past, very few show evidence 
of such adaptive evolution40. It is relevant that LMTK1 and LMTK2 
are not positively selected for between humans and chimpanzees; 
rather, they are well conserved. Positive selection has been opera-
tional on human LMTK3 (in a region containing no recognized 
conserved kinase domains (data not shown), which may have altered 
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the characteristics of human versus chimpanzee LMTK3. Although 
the selective pressure that drove this adaptive event is at present 
unclear, an evolutionary tradeoff may have led to increased human 
susceptibility to breast cancer. Most humans we examined had the 
‘protective’ TT allele, whereas the less-susceptible nonhuman pri-
mates lacked the protective TT allele as a result of selective pressure 
to counter possible deleterious effects of sequence changes to human 
LMTK3 (Supplementary Table 6). Further investigation of chim-
panzee LMTK3 may yield insights into the natural history of breast 
cancer in humans versus chimpanzees. Together, our data reveal 
LMTK3 as a potential biomarker of response to endocrine therapy 
in breast cancer and highlight its potential as a therapeutic target.
METHODS
Methods and any associated references are available in the online 
 version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
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ONLINE METHODS
High-throughput siRNA screening. The human kinase siRNA Set Version 
3.0 library (Qiagen) targeting 691 kinases and kinase-related genes was used. 
The library was supplied in a 96-well format and contained a pool of two indi-
vidual siRNAs per well, targeting two different sequences for each gene. MCF-7 
cells (American Type Culture Collection) were maintained in phenol red–free 
medium with 10% charcoal-stripped serum (DSS) 48 h before experimentation. 
Cells were plated in 24-well plates and transfected with siRNA (Qiagen) (final 
concentration 20 nM) using the Human Kinase siRNA Set Version 3.0 library 
and Hiperfect reagent according to the manufacturer’s instructions (Qiagen). At 
48 h after transfection, cells were treated with vehicle (ethanol) or E2 (10 nM) 
for 24 h, and cells were collected following RNA extraction and cDNA synthesis. 
Quantitative RT-PCR analysis to examine the expression of TFF1 and GAPDH 
(endogenous control) was performed for each well (kinase gene). Next, the TFF1 
gene expression after silencing each kinase individually was calculated in relation 
to GAPDH expression; screening was performed in duplicate.
Evolutionary analysis. Positive selection on the protein-coding regions of 
LMTK3 was detected by use of molecular evolution algorithms that character-
ize the relative proportion of nonsynonymous (replacement) nucleotide sub-
stitutions as compared to synonymous (silent) nucleotide substitutions in the 
kinase coding sequences. (The LMTK3 rs8108419 GG or AG and the LMTK3 
rs9989661 TT alleles were not examined in this manner, as these regions are 
exclusively intronic.) All kinases shown in our screen to modulate ERα, as well 
as the isoforms LMTK1 and LMTK2, were examined for evidence of sequence-
level positive selection between human and chimpanzee orthologs using Li93 
software (a kind gift from W. Hsiung-Li). Both whole coding sequence and 
subsection sliding windows were examined. Only LMTK3 showed evidence 
of positive selection (P < 0.005).
Candidate polymorphisms and genotyping. Candidate LMTK3 polymor-
phisms were chosen with the assistance of the Ensembl program (http://www.
ensembl.org/) using two main criteria. First, the polymorphism had to have 
some degree of likelihood of altering the function of the gene in a biologically 
relevant manner. The rs8108419 polymorphism is located in intron 2 of the 
LMTK3 gene, whereas the rs9989661 polymorphism is located in intron 15 of 
the LMTK3 gene. Intron polymorphisms can change gene transcription levels by 
alternative splicing or by affecting binding of a transcription factor. Second, the 
frequency of the polymorphism had to be sufficient that its impact in clinical out-
come would be meaningful on a population level (above 10% allele frequency). 
Genomic DNA was extracted from microdissected tissue specimens using 
the QIAamp kit (Qiagen). LMTK3 polymorphisms (rs8108419 and 
rs9989661) were tested by the PCR restriction fragment length polymorphism 
(PCR-RFLP) technique. Briefly, forward primer 5′-ATTCCACCACTCCC 
TCCAG-3′ and reverse primer 5′-GACCCTGCAGTGCCTCAC-3′ for 
rs8108419 and forward primer 5′-GGGCCTTCCCAAGTGGTT-3′ and 
reverse primer 5′-ATCCAAGCCTGGGGTGAG-3′ for rs9989661 were used 
for PCR amplification; PCR products were digested by the restriction enzyme 
BsrD1 (rs8108419) or Btsc1 (rs9989661), and alleles were separated on 4% 
NuSieve ethidium bromide–stained agarose gel (Lonza Rockland). Samples 
were obtained with approval from the Riverside Ethics Committee with appro-
priate informed consent from the subjects.
In vivo tumorigenicity assay in nude mice bearing orthotopic breast cancer 
xenografts. Bioluminescent MCF-7 breast cancer cell lines (PRECOS) were 
injected into the mammary fat pad of nude mice (PRECOS). When tumors 
reached an approximate volume of 100–200 mm3 (day 15), mice were randomly 
assigned to different groups (n = 8, each group) to receive intratumoral injec-
tions of 10 µg in vivo–modified LMTK3 siRNA or control siRNA (Qiagen). 
Three intratumoral injections were repeated every 3 d (50 µl volume per 
injection), and mice were killed 3 d after the last injection. Tumor growth 
was monitored with caliper measurements, and bioluminescent imaging was 
performed 24 h before dosing and 72 h after dosing. After the mice were killed, 
primary tumors were excised, weighed and formalin fixed. Samples were paraf-
fin embedded, cut at 3 µm and H&E stained for histological evaluation of target 
proteins expression. This study was conducted under the UK Home Office 
Licence number PPL 40/2962.
Additional methods. Detailed methodology is described in the Supplementary 
Methods.
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Introduction
MicroRNAs (miRNA) and RNA-binding proteins (RBPs)
are important post-transcriptional gene regulators.
RBPs influence the structure and interactions of the
RNAs and play critical roles in their biogenesis,
stability, function, transport and cellular localisation. It
is becoming apparent that miRNA activity is not
necessarily always determined by its expression in the
cell; miRNA activity can be affected by RBPs. Recent
studies have introduced a paradigm shift in our
understanding of the miRNA biogenesis pathway,
which was previously believed to be universal to all
miRNAs. It has now been proved that maturation
steps of individual miRNAs could be specific. RBPs like
KSRP, Lin-28 and many more have been proved
important for the biogenesis of miRNAs and this
regulation is crucial, as alteration of miRNA expression
has been linked to several cancers. Here we review the
recent progress in our understanding of the miRNA
biogenesis pathways regulated by RBPs which could
be potential therapeutic targets for different cancers.
MicroRNA biogenesis
miRNAs are endogenous non-coding RNAs of
approximately 22 nucleotides which, as
post-transcriptional modulators of gene expression,
mechanistically act by base-pair interaction with the
3′ UTR (prime untranslated region) of the messenger
RNA (mRNA), thereby inducing post-transcriptional
repression [1]. In other circumstances, when the
miRNAs interact partially with the 3′ UTR of their target
mRNAs, they induce their translational repression [2,3].
miRNAs are regulators of gene expression that control
many biological processes in development,
differentiation, growth and metabolism [4].
miRNAs were first discovered in nematodes in
1993 [5]. A single miRNA can bind to and regulate
many different mRNA targets and, conversely, several
different miRNAs can bind to and cooperatively
control a single mRNA target [6]. Analogous to
transcription factors, miRNAs regulate mRNAs in a
combinatorial fashion and single miRNAs can repress
the translation of many mRNAs [7]. Recently,
Eiring et al. [8] showed that miR-328 (miRNA-328) has
a second function, acting as a decoy by binding to
hnRNP E2 (heterogeneous nuclear ribonucleoprotein
E2) and lifting its translational repression of an mRNA
involved in myeloid cell differentiation.
miRNA genes are evolutionarily conserved and may
be located either within the introns or exons of
protein-coding genes (70%) or in intergenic areas
(30%) [9]. Transcription of miRNAs is typically
performed by RNA polymerase II, then the transcripts
are capped and polyadenylated [10]. A transcript may
encode clusters of distinct miRNAs, or it may encode
an miRNA and a protein. The resulting primary or
pri-miRNA transcript extends both 5′ and 3′ from the
miRNA sequence, and two sequential processing
reactions trim the transcript into the mature miRNA.
In the first processing step, which occurs in the
nucleus, the pri-miRNA is cleaved into pre-miRNA (an
approximately 70-nucleotide hairpin stem loop
intermediate) by a microprocessor complex that
consists of Drosha, an RNase III enzyme, and DGCR8, a
double-stranded RNA-binding domain (dsRBD)
protein [7]. The microprocessor complex also contains
a variety of cofactors including the DEAD box (amino
acid sequence D-E-A-D asp-glu-ala-asp) RNA helicases
p68 (DDX5) and p72 (DDX17), as well as
heterogeneous nuclear ribonucleoproteins
(hnRNPs) [11,12]. These auxiliary factors may function
to promote the fidelity, specificity or activity of Drosha
cleavage. Surprisingly, Drosha-mediated processing of
pri-miRNAs into pre-miRNAs is not obligatory. A few
intron-derived miRNAs called mirtrons are directly
released from their host transcripts after splicing as
pre-miRNA, so bypassing the Drosha cleavage [13,14].
After its formation, the pre-miRNA is actively
transported from the nucleus to the cytoplasm by the
Ran-GTP-dependent transporter Exportin 5
(Exp 5) [15,16]. Drosha cleavage occurs
co-transcriptionally, before splicing of the host
RNA [17], and generates a product with a two-
nucleotide 3′ overhang, characteristic of RNase III-
mediated cleavage. The overhang is recognised by
Exportin-5, which transports the pre-miRNA into the
cytoplasm via a Ran-GTP-dependent mechanism
[18,19]. In the cytoplasm, the pre-miRNA is further
‘diced’ into an approximately 22-nucleotide miRNA
duplex by Dicer, another RNase III enzyme, in
collaboration with the dsRBD proteins TRBP/PACT
[20–22]. The two miRNA strands are then separated
and one of the strands associates with an Argonaute
(AGO) protein within the RNA-induced silencing
complex (RISC or miRISC) where it acts as a guide to
repress target messages. The miRNA guides RISC to
complementary sites within the target mRNAs to
mediate repression of that target message.
Targets for breast cancer
RNA-binding proteins
RNA-binding proteins have a major role in every aspect
of RNA biology, from transcription, pre-mRNA splicing
and polyadenylation to RNA modification, transport,
localisation, translation and turnover [23]. RNAs in cells
are associated with RBPs to form ribonucleoprotein
(RNP) complexes. Post-translational modification of
RBPs generates additional layers of complexity, as it
can modify the RNA binding, function and localisation
of the RNP. Three types of modification have been
described for RBPs: phosphorylation, arginine
methylation and small ubiquitin-like modification
(SUMO). The complement of RBPs present at a
particular locale where the RNA is transcribed, or
changes in the post-translational modifications of
these proteins, would affect the resulting RNP
complex, modulating its downstream functional
activity [24]. Heterogeneous nuclear
ribonucleoproteins (hnRNPs) are complexes of RNA
and protein present in the nucleus during gene
transcription and subsequent post-transcriptional
modification of the newly synthesised RNA
(pre-mRNA). The discovery of the heterogeneous
nuclear ribonucleoproteins (hnRNP), and other
pre-mRNA/mRNA-binding proteins, led to the
identification of the first amino acid motifs and
functional domains that confer binding to RNA [25].
RBPs contain one or more often multiple RNA-binding
domains. Some well-characterised RNA-binding
domains (RBD, also known as RNP domain and RNA
recognition motif, RRM) include the following:
K-homology (KH) domain (type I and type II), RGG
(Arg-Gly-Gly) box, Sm domain, DEAD/DEAH box, zinc
finger (ZnF), double-stranded RNA-binding domain
(dsRBD), cold-shock domain, Pumilio/FBF (PUF or
Pum-HD) domain and the Piwi/Argonaute/Zwille (PAZ)
domain [24]. Many RBPs, like hnRNPs, have different
domains and they tend to shuttle between nucleus
and cytoplasm having roles in different cellular
processes. Many signalling pathways operate by
modifying the activity of specific RBPs, in which RNA
binding motifs are combined with other conserved
domains, such as protein–protein interaction domains
and consensus phosphorylation motifs [26].
MicroRNA regulation by RNA-binding
proteins
The regulation of microRNA expression is at three
different levels: pre-transcriptional, transcriptional and
post-transcriptional [27]. Most of the miRNA
regulation by RNA-binding proteins (RBPs) is at the
post-transcriptional level.
Many factors affect the biogenesis of the miRNAs
at the pre-transcriptional level. Besides the gain or loss
of miRNA gene copy number, by amplification,
translocation or deletion, research indicates that their
expression is epigenetically modulated, through
histone deacetylation and hypermethylation of miRNA
promoters [27]. Maturation of miRNAs requires
coordinated processing mechanisms by Drosha and
Dicer that post-transcriptionally generate mature
miRNAs from pri-miRNA transcripts. miR-18a is
processed from a polycistronic pri-miR-17-92
transcript, which harbours five additional miRNAs.
hnRNP A1, an mRNA splicing regulator, exclusively
stimulates maturation of miR-18a from the miR-17-92
cluster. Pri-miR-18a, but not other members of the
cluster, contains two regions of similarity to the
consensus hnRNP A1-binding site, UAGGGA/U, within
its terminal loop and stem [28,29]. Direct and specific
interaction of hnRNP A1 with the terminal loop and
stem of the pri-miR-18a hairpin induces a structural
rearrangement of the hairpin to generate a more
favourable Drosha/DGCR8 binding and cleavage site.
Thus, hnRNP A1 acts as a chaperone for recognition
and cropping of specific pri-miRNAs by
Drosha/DGCR8. Interestingly, approximately 14% of
human miRNAs contain highly conserved loop
sequences, suggesting that processing regulation by
hnRNPs and other nuclear RBPs might extend well
beyond miR-18a [29]. In addition to the general
miRNA machinery, different studies have linked
specific miRNAs to cancer. Oncogenic miRNA gene
miR-17-92 is the most highly expressed cluster in
cancers. This is a cluster of six miRNAs located on
13q31.3, a locus that is frequently amplified in
lymphomas [30]. The miR-17-92 cluster is highly
expressed in a variety of solid malignancies, including
cancers of the colon, lung, pancreas, prostate and
stomach, as well as lymphomas. The polycistronic
miRNA cluster produces a single primary transcript
yielding the six mature miRNAs: miR-17, miR-18a,
miR-19a, miR-20a, miR-19b and miR-92a. The
sequences of the mature miRNAs are highly conserved
in all vertebrates. The human miR-17-92 cluster is
located in the third intron of the primary transcript
C13orf25. Despite the high conservation of miRNA
sequences, the exonic sequences of C13orf25 are not
conserved across species, indicating that it is most
likely that the only function of the transcript is the
production of miRNAs [31]. It has been shown that
c-MYC directly induces the transcription of the
miR-17-92 cluster during both B cell proliferation and
oestrogen receptor (ESR1) induction in breast
cells [32,33]. Recent studies dissected the miR-17-92
cluster to its individual miRNA components and
identified their relative contributions to oncogenic
transformation in mouse model systems [34,35]. They
identified miR-19 as the potent oncogene of the
miR-17-92 cluster by inhibiting the expression of the
tumour suppressor PTEN; miR-19 promotes cellular
growth and cancer.
Many miRNAs are regulated at the Dicer
processing step. Pre-miR-138 is expressed ubiquitously
but its mature form is restricted just to certain cell
types, indicating tissue-specific Dicer processing of this
miRNA [36]. Recently, it has been demonstrated that
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Lin-28 is a stem-cell-specific regulator of let-7
post-transcriptional maturation that controls both
Drosha and Dicer processing. In the nucleus, Lin-28
inhibits microprocessor-mediated cleavage of
pri-let-7 [37], by competing with Drosha [38,39]. In
the cytoplasm, Lin-28 is able to inhibit Dicer-mediated
cleavage of the pre-let-7 family member [40] by
recruiting a terminal uridylyl transferase (TUTase) to
the precursor. The uridylated pre-let-7 (up-let-7)
cannot be processed by Dicer and is degraded by an
unidentified nuclease [41]. The KH-type splicing
regulator protein (KSRP, also known as KHSRP)
recognises G-rich regions, including a GGG triplet,
present within the terminal loops of a subset of
pri-miRNAs, to promote Drosha/DGCR8-mediated
processing [42]. Upon binding, KSRP can optimise the
positioning and recruitment of the miRNA
precursor-processing complexes through
protein–protein interactions. KSRP is associated with
the terminal loop of the target miRNA precursors
during nucleocytoplasmic transit and also promotes
the processing of the target pre-miRNAs by Dicer in
the cytoplasm. This further suggests that specific
recognition of the terminal loop by RBPs is an
important means to extend regulation of miRNA
processing down to the level of individual miRNAs.
Binding of RBPs to specific sequences present in the
terminal loop regions of miRNA precursors potentially
either competes for binding or promotes recruitment
of processing factors. Changes of expression, RNA-
binding activity, interacting protein partners and
subcellular localisation of RBPs in response to
extracellular signals might serve to regulate biogenesis
of individual miRNAs.
It is well established that RBPs can modulate the
function of miRNAs in different ways either through
the biogenesis of miRNAs or by directly interacting
with the miRNA binding sites; for example proteins
like Deadend 1 or HuR (Hu antigen R, also known as
ELAV1) can compete with miRNA binding sites on
mRNAs and modulate miRNA function [43]. Recently,
it was discovered that miR-328 has a second function,
acting as a decoy by binding to hnRNP E2 and lifting
its translational repression of an mRNA involved in
myeloid cell differentiation [8]. These findings are
intriguing because an miRNA-mediated regulatory
function associated with RBPs has not been reported
before. Moreover, the general view of miRNA
functions entails a model in which miRNAs serve as
guides for Ago protein complexes, the actual
mediators of post-transcriptional gene silencing.
Eiring et al. demonstrated that miR-328 can act
independently of Ago proteins by interacting directly
with hnRNP E2 and the discovery of this new function
for miRNAs raises a number of fascinating questions.
These findings not only offer new insights into the
dual role of miR-328 but also suggest a novel
function for miRNAs as direct inhibitors of protein
activity, thereby offering a paradigm shift for miRNA-
mediated gene regulation. It is likely that the dual role
(decay/decoy) activity of miRNAs is not limited to
miR-328 but can be extended to other miRNAs
containing nucleotide sequences resembling the
consensus RNA-binding sites for RBPs that are involved
in cancer as well as non-cancer-related diseases. It is
clear that interplay between miRNAs and RBPs exists,
which is important for proper function of processes
involved in differentiation, cell cycle, stress and cell
survival. As miRNAs play a very prominent role in
cancer and RBPs regulate miRNA biogenesis and
activity, it shows miRNA–RBP interplay is important for
the regulation of cancerous pathways.
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Summary of methods & results
Methods
Clinical samples
A cohort of patients with early primary breast 
cancer (BC) who received surgery in Oxford, 
UK (1989–1993) was considered (n = 219, of 
which 207 were suitable for RNA analysis) [1]. 
Complete 10-year folow-up was available for 
al patients. Tumor subtypes included estrogen 
receptor negative (ER-; n = 82), positive (ER+; 
n = 90) and triple-negative (n = 37). Total RNA 
was extracted from whole fresh frozen tumor 
samples after visual assessment. No micro-
dissection of tumor cels was performed, as 
there is evidence that signaling from the stroma 
has an important role in cancer progression [2].
RNA-expression proﬁling
Matched miRNA and mRNA profiling was 
performed by using Ilumina human ref seq-8 
and miRNA v1 arrays. Primary miRNA tran-
script (pri-miRNA) expresion was therefore also 
available.
Association of miRNA expression with survival 
independent of clinicopathological factors 
& validation using other datasets
Penalized Cox regression was used to iden-
tify miRNAs that were prognostic for distant 
relapse-free survival (DRFS) after surgery, 
independent of known clinicopathological 
factors (i.e., age, tumor size and grade, lymph 
node status, ER status, chemotherapy treatment, 
and gene signatures of biological processes). 
Previously published BC cohorts with available 
Afymetrix U133A-B/plus2 array data were then 
investigated to validate the miRNAs identiﬁed 
in the Oxford cohort. Four additional datasets 
were analyzed for DRFS (n = 592) and six data-
sets for recurrence-free survival (n = 1050) with 
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miRNAs play a role in post-transcriptional gene regulation by translational repression and/or 
mRNA degradation in a very tissue-speciﬁc manner. In order to understand the function of a 
miRNA, it is best to identify the genes that it regulates. Putative mRNA targets of miRNAs 
identiﬁed from seed sequence matches are available using computational algorithms in various 
web-based databases. However, these tend to have high false-positive rates and, owing to a 
whole-genome approach, cannot identify tissue/tumor speciﬁcity of regulation. The evaluated 
article presents a large amount of data analyzing global RNA expression in breast cancer and 
examines whether miRNAs are prognostic due to their effects on mRNA targets. This valuable 
and important resource of combined miRNA and mRNA expression in breast cancer and its 
subtypes has been summarized. Many studies have now investigated the integrated analysis of 
miRNA:mRNA proﬁles in human malignancies, the goal as always being to identify novel 
biomarkers and therapeutic targets for each tumor.
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regard to pri-miRNA and target mRNA expression of the mature 
miRNAs identified. Eight published gene expression signatures 
were implemented as surrogate markers of biological processes 
in cancer (i.e., proliferation, estrogen receptor 1 and human 
EGF receptor 2 signaling, stem cell, invasion, immune response, 
 apoptosis and hypoxia).
miRNA:mRNA target relationships
To identify functional miRNAs, several statistical meth-
ods were used to confirm strong anticorrelation of predicted 
mRNA targets (i.e., cumulative relative risk, predicted target 
signature score and regulatory effect score). These constraints 
were imposed to remove spurious matches and identify a subset 
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Figure 1. Pri-miRNAs, mature miRNAs and miRNA-processing genes associated with clinical outcome in breast cancer. 
(A) Part of the miRNA:mRNA interaction network for prognostic miRNAs in breast cancer (green, key biological processes associated 
with miRNA expression; †NFE2L2 protein expression was assessed in 137 cases by immunohistochemistry and confirmed to be weak in 
those tumors with high miR-144; ‡downregulation of cognate targets for these miRNAs was validated in independent breast cancer 
datasets. (B) Independently prognostic miRNAs for DRFS in estrogen receptor-positive tamoxifen-treated (ER+, n = 90) and ER- (n = 82)
breast cancer (red, upregulated; blue, downregulated; §miRNAs also prognostic in triple-negative receptor [TNR], n = 37). (C) Primary 
(pri-)miRNA expression of the mature miRNA was correlated in other published cohorts for DRFS by meta-analysis. Summary hazard 
ratios and 95% CI for pri-miR-128a, pri-miR-210, pri-miR-548d and pri-miR-342 were 2.49 (1.44–4.32), 3.1 (1.43–6.74), 3.54 (2.06–
6.09) and 0.44 (0.26–0.76), respectively (i.e., patients with high pri-miR-210 develop distant disease 2.5-times more frequently per unit 
time compared with patients with low expression; patients with high pri-miR-342 develop distant disease slower than those with low 
levels). Some of these pri-miRNAs were also prognostic for recurrence-free survival. (D) Expression levels of miRNA-processing genes 
were found to be prognostic for DRFS at Cox univariate analysis (e.g., patients with high Argonaute 2 had a hazard ratio of 2.63 for distal 
breast cancer relapse). 
DRFS: Distant relapse-free survival; ER: Estrogen receptor; RFS: Relapse-free survival.
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of tissue-specific, functional mRNA targets of a dysregulated 
miRNA [3], as there is a ‘many-to-many relationship’ between 
miRNAs and mRNAs, since a single miRNA targets mul-
tiple mRNAs and a single mRNA is regulated by multiple 
miRNAs [4]. 
Results
Identification of independently prognostic miRNAs in breast 
cancer 
By including clinical, pathological and molecular factors, the two-
step Cox analysis approach allowed the identification of miRNAs 
associated with clinical outcome or a specific covariate, indepen-
dently from other miRNAs and covariates. miRNA signatures 
were able to effectively dichotomize patients into good and poor 
prognosis groups. 
The miRNAs independently prognostic of DRFS in ER+, ER- 
and triple-negative receptor subtypes are shown in Figure 1A & B. 
Two previously studied prognostic miRNAs were upregulated: 
miR-128 in ER+ and miR-210 in ER- [5]. Three additional miR-
NAs were independently prognostic when all samples were 
included (high miR-29c and -642, good prognosis; high miR-
548d, poor prognosis). Of note, other independent prognostic 
factors included: lymph-node disease, tumor grade; proliferation 
and hypoxia gene signatures in ER+ patients; and hypoxia, inva-
sion and immune response signatures in ER- patients. However, 
compared with these factors, miRNAs have the benefit of being 
very stable and can easily be measured in blood, biopsy or 
 formalin-fixed paraffin-embedded samples.
Prognostic miRNA clusters in ER+ & ER- breast cancer
miR-451 functions in a cluster with miR-144, and both were 
associated with good prognosis in ER+ patients at univariate 
analysis, although high miR-144 also predicted poor prognosis 
in ER- cases. Thus the cluster has different roles in the two sub-
types. The miR-24/27/23 cluster seems to have a specific role in 
only ER- patients and was associated with a poor prognosis in this 
group, but not in ER+ patients (i.e., high miR-23b and -24 both 
present a hazard ratio >2 of distant relapse in all 207 BC patients; 
while miR-27b, 24 and 24-1* present a hazard ratio of 2.08, 3.63 
and 5.23, respectively, in ER- patients).
Meta-analysis of coordinated pri-miRNA expression
The pri-miRNAs for six of the mature miRNAs identified (pri-
miR-128a, -210, -29c, -342, -27b and -548d) were found to have 
coordinated expression in independent cohorts and many were 
concordantly prognostic (Figure 1C). This indicates transcriptional 
regulation of these miRNAs in BC, as opposed to modulation 
due to abnormal processing. 
Prognostic miRNAs associated with pathways & biological 
processes in breast cancer
Significantly downregulated mRNA targets were identified as 
members of pathways dysregulated in BC, especially tumor 
growth and metastasis (Figure 1A). Major biological processes were 
associated with miRNA expression, including: 
• High miR-210 with increased hypoxia, proliferation (independ-
ent of grade and ER status) and invasion. miR-210 was also 
associated with ESR1 gene signature, even though raised 
miR-210 was prognostic in ER- patients; 
• Low miR-150 with high immune response; 
• High miR-27b with promotion of invasion; 
• High miR-769-3p and high miR-144 with high proliferation;
• Low miR-135a/high miR-128a with ER positivity (the latter 
confirmed by both ESR1 gene signature and immuno-
histochemistry).
However miRNA expression was still prognostic independent 
of these gene signatures. 
The miR-210, -128 and -27b targets were then validated in 
independent BC datasets and found to be consistently downregu-
lated and associated with worse prognosis (Figure 1A). In addition, 
downregulated mRNA targets (ISCU, CBX7 and IGF1R) were 
correlated in vitro with high miR-210 expression and downregula-
tion of NFE2L2 protein was measured by immunohistochemistry 
(target of miR-144).
miRNA-processing genes are dysregulated in breast cancer
As not all of the pri-miRNA levels matched with the mature 
expression, miRNA-processing genes were measured and 
found to also have prognostic significance (Figure 1D). Again, 
the mature prognostic miRNAs identified (Figure 1B) were still 
independently significant despite processing gene expression, 
reinforcing that the altered expression of these miRNAs is 
caused by transcriptional regulation as opposed to differential 
miRNA processing. 
Interestingly, the disruption of miRNA production by deple-
tion of Drosha, DCGR8 or Dicer has been shown to promote 
tumorigenesis [6–8] (e.g., Dicer is targeted by miR-103/107 leading 
to a reduction in mature miRNAs, including the miR-200 fam-
ily, enhancing epithelial-to-mesenchymal transition and migra-
tion in vitro, as well as increased metastatic colonization in vivo 
[9]). In agreement with the current study, others have shown 
that upregulation of Argonaute 2 (AGO2), a component of the 
miRNA-induced silencing complex (miRISC) which is essential 
for miRNA-mediated repression, is associated with advanced 
tumors and distant metastases [10]. 
Expert commentary
miRNAs are consistently dysregulated in human cancers and 
have major roles as either oncogenes or tumor-suppressor genes. 
Bioinformatic analysis has greatly improved the ability to pre-
dict bona fide miRNA targets and is based on the evolutionarily 
conserved seed matches in the mRNA 3´ untranslated region. 
However, due to the sophistication of miRNA:mRNA interac-
tions and the small effect exerted by an individual miRNA, few 
miRNA targets have been functionally validated [11]. The com-
putational prediction programs developed can identify putative 
miRNA targets, but these suffer from high false-positive/-negative 
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Key issues
• The study under evaluation is the largest combined miRNA:mRNA profiling in breast cancer, revealing some important functional roles.
• Ten prognostic miRNAs for distant relapse in breast cancer patients were identified in this study, including: miR-767-3p, -769-3p, -128a
and -135a (all estrogen receptor-positive); and miR-27b, -144, -210, -342, -30c and -150 (all estrogen receptor-negative).
• Many of these miRNAs have been validated in a multicentric fashion (n >1000) by examining expression of their primary transcript and 
cognate mRNA targets.
• Clearly important candidates that should be considered for further investigation/therapeutic potential are miR-150, -210, 
-128a and -27b.
• Many important cancers, such as those of the lung, pancreas and prostate, are yet to be sequenced using this approach. 
readings due to the low-throughput nature of the query design 
(gene by gene or miRNA by miRNA) [12]. 
This large study has elegantly used microarray and next-
generation sequencing technologies to determine the interactions 
between miRNA:mRNA as a whole network, rather than individ-
ual targets in BC. Crucially, clinicopathological factors, includ-
ing survival outcomes, were also assessed. The data provided on 
specific miRNAs in ER+ and ER- breast cancer specimens could 
be the key to finding a specific target for ER-based therapies, and 
the prognostic nature of the miRNA signatures may outperform 
current validated tools [13,14]. 
Recently, several groups have investigated the combined analy-
sis of miRNA–mRNA expressions in breast and other human 
cancers (TABle 1). Enerly et al. have similarly identified biological 
processes in BC in which a ‘pivot’ miRNA plays a role, pointing to 
potential direct regulation by the miRNA [15]. Notably, miR-150 
was again found to be upregulated and have strong enrichment of 
the immune response term among its positive correlated mRNAs 
and low levels were associated with poor prognosis, validating the 
current study [15]. Patients with colorectal cancer and low miR-150 
also have poor survival and a worse response to adjuvant chemo-
therapy [16]. Interestingly, miR-150 has recently been shown to 
modulate the development of natural killer and invariant natural 
killer T-cell development in the innate immune system [17]. 
Although previously recognized, the role of hypoxia-inducible 
miR-210 (by HIFa) in BC is of great interest [18,19]. HIFa regu-
lates genes involved in adaptation and protection against hypoxia; 
however, miR-210 regulates many genes that are not induced 
under hypoxia (e.g., oncogene HOXA1) [19]. Thus, HIFa is able 
to inhibit tumor growth through miR-210 regulation. Conversely, 
miR-210 expression is elevated in several cancers, and correlated 
with breast and melanoma metastasis [18].
Finally, in this analysis miR-27b was associated with the 
invasion gene signature and has been shown to stimulate cell 
migration/invasion in BC cells, although not solely by repression 
of tumor suppressor target ST14 [20].
Five-year view 
These data are a useful resource for future validation studies. 
From this study, the prognostic miR-128a, -27b and -210 showed 
evidence of cognate target downregulation, and expression of 
their targets was prognostic in a meta-analysis of several cohorts. 
Further insights into these miRNAs could be gained by perform-
ing advanced techniques such as high-throughout sequencing 
of RNAs isolated by crosslinking immunoprecipitation, which 
identifies functional protein–RNA interaction sites [21]. The miR-
NAs are coimmunoprecipitated with AGO proteins and bound 
RNA fragments sequenced by high-throughout methods, yield-
ing genome-wide maps and functional insights, which could also 
be used to decode a precise map linking miRNA-binding sites 
to mRNA transcripts. This should provide a new approach to 
understanding the role of miRNAs in cancer biology. In addition, 
the maps allow target site determination for RNA interference 
therapy on clinically relevant mRNAs. 
The main focus for the next few years will be delivering poten-
tial miRNAs to cancer patients, a task that has caused problems 
in the progress of siRNA treatments. The recent clinical success 
of a nanoparticle delivery system [22] and the continuing emer-
gence of new technologies suggest that miRNA therapeutics is 
achievable.
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Mutations  of the retinoblastoma gene (RB1) 
resulting in los of function have been identiﬁed 
in several human cancers, including those of the 
breast, lung and bladder, as wel as in the rare 
inherited malignant tumor of the eye. Similarly, 
los or reduction of CDH1 (the gene encoding 
E-cadherin) is asociated with increased invasion, 
metastasis and poor prognosis in several malig-
nancies. Both retinoblastoma protein (RB) and 
E-cadherin are  downregulated in the invasive 
and aggresive subtypes of breast carcinoma, but 
the relationship between these two proteins has 
remained uncertain.
Summary of methods & results
Retinoblastoma protein controls 
epithelial-to-mesenchymal transition in 
breast cancer cels
Depletion  of  RB tumor suppressor  protein  by 
siRNAs leads to downregulation of E-cadherin, 
disruption of cel–cel adhesion and induction 
of the mesenchymal marker vimentin in breast 
cancer cels,  which are the  halmarks  of the 
epithelial-to-mesenchymal transition (EMT) [1]. 
EMT contributes to the invasive and metastatic 
ability  of cels, and infection  of  RB-negative 
breast cancer cels (e.g., BT549) with an adeno-
virus encoding human RB (Ad-RB) was found 
to cause  mesenchymal-to-epithelial transition 
(MET) at the mRNA level, accompanied by a 
marked reduction in invasiveness. This reduc-
tion  of invasiveness  was also seen after infec-
tion  of  MDA-MB-231 (RB-inactivated) and 
MDA-MB-157 (poorly expresing RB) breast can-
cer cels with Ad-RB Am (an adenovirus encod-
ing an active mutant of RB that is refractory to 
CDK-mediated phosphorylation). 
RB is suppressed in mesenchymal breast 
cancer cels & patient samples
Mesenchymal  breast cancer cels (e.g., 
MDA-MB-436,  BT549,  MDA-MB-157 and 
MDA-MB-231) were shown to expres vimentin, 
ﬁbronectin  or  N-cadherin and  were  devoid  of 
E-cadherin (see FIGURE 1). In addition, cels with 
reduced RB expresion were subsequently demon-
strated to have high levels of p16 (an endogenous 
CDK inhibitor) through negative feedback. RB 
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expression was next examined by immunohistochemical analysis 
in 18 TNBC patient specimens: RB was positive in 22% (four out 
of 18) of patients; inactivated in 28% (five out of 18) of patients 
and negative in 50% (nine out of 18) of patients.
RB/ZEB/miR-200 pathway controls EMT
RB depletion in epithelial breast cancer cells (e.g., MCF7, T47D 
and HCC1428) resulted in increased expression of ZEB1 and 
ZEB2 (transcriptional repressors of E-cadherin) and consequently 
EMT. This effect was completely inhibited by simultaneous 
knockdown of ZEB1 and ZEB2, indicating that these proteins 
are vital to RB-mediated EMT. In addition, as the miR-200 fam-
ily members are known to target the ZEBs via a reciprocal feed-
back loop [2], forced expression of miR-200a/b was able to effi-
ciently inhibit EMT in RB-depleted cells by targeting ZEBs. In 
RB-inactive/negative patient specimens, immuno histochemical 
analysis revealed that 43% (six out of 14) of patients expressed 
ZEB1, indicating that RB depletion may be required for 
ZEB1-induced EMT in triple-negative breast cancer (TNBC).
ZEB1 depletion induces MET
As seen in other tumor types, such as pancreas [3] and prostate [4], 
suppression of ZEB1 was able to reverse EMT (i.e., MET) with 
increased cell–cell adhesion and induction of epithelial markers 
in MDA-MB-231 breast cancer cells. This effect was stronger 
than for ZEB2 alone, but maximal with combined silencing of 
ZEB1 and ZEB2. 
CDK inhibition leads to a reduction in 
ZEB1
CDK inhibitors have potential as antican-
cer drugs. Using a Screening Committee 
of Anticancer Drugs inhibitor kit, a CDK4 
inhibitor was demonstrated to induce cell 
cycle arrest and MET (by downregulation 
of ZEB1 and SLUG, another EMT-related 
transcriptional repressor) in MDA-MB-231 
cells. The reduction of ZEB1 was found to be 
caused by increased levels of miR-200a and 
miR-200b, as well as by direct degradation 
by the proteasome.
The CDK4/6 inhibitor, PD0332991 
(Pfizer), was shown to have even more 
profound effects on ZEB1 in vivo. Using 
an MDA-MB-231 orthotopic xenograft 
model in nude mice, oral administration of 
PD0332991 (n = 4) over a 2-week period 
resulted in a significant reduction in tumor 
growth compared with a vehicle control 
(n = 6). Given that this CDK inhibitor was 
able to reduce the expression of ZEB1 in vitro 
(as well as cell proliferation and invasiveness), 
this is the likely mechanism in vivo, provid-
ing further evidence for the potential use of 
such compounds in cancer therapy. 
Discussion
TNBC refers to a subgroup of breast carcinomas that do not 
express estrogen receptors, progesterone receptors or HER2 and 
accounts for 15–20% of all breast cancer cases. Earlier studies 
showed that RB acts as a regulator of E-cadherin by binding to 
its promoter sequence in conjunction with the transcription factor 
activator protein-2A, but the inactivation of RB induces down-
regulation of the adhesion molecule E-cadherin, thereby inducing 
EMT and tumor progression [1]. Further studies revealed that RB 
inactivation leads to a sequence of molecular events culminating 
in EMT, including an increase in the expression of ZEB1 and 
ZEB2, which act as transcriptional repressors of E-cadherin. This 
study demonstrated that a similar effect was induced by down-
regulation of the miR-200 family, although the precise molecu-
lar association between RB and these miRNAs requires further 
evaluation [5]. A number of recent studies have described the role 
played by miRNAs in regulating EMT, and the miR-200 family 
has been shown to be vital to this process, in part owing to the 
ZEB/miR-200 double-negative feedback loop [6,7].
A recent study showed that expression of the miR-200a/141 clus-
ter resulted in G1 arrest, due to increased p27/KIP1 and decreased 
CDK6 expression, but expression of the 200bc/429 cluster resulted 
in G2 arrest with a reduction of p27/KIP1 and upregulation of 
the inhibitory phosphorylation of CDC25C [5]. This suggests that 
downregulation of ZEB1 expression by CDK inhibitors in breast 
cancer cells demonstrated in the current study may be due to the 
reciprocal suppression of ZEB and the miR-200 family [5]. 
Figure 1. Retinoblastoma protein inactivation is associated with the 
mesenchymal phenotype in breast cancer. Cells and tissue samples (triple-negative
breast cancer) with inactive RB have an EMT phenotype, which is more aggressive, 
invasive and metastatic. The CDK4/6 inhibitor PD0332991 is able to attenuate
phosphorylation of RB and, via the induction of miR-200a/b, leads to downregulation of
ZEB1 and increased transcription of the CDH1 gene, which encodes the cell–cell 
adhesion molecule E-cadherin. 
EMT: Epithelial-to-mesenchymal transition; RB: Retinoblastoma protein;  
TNBC: Triple-negative breast cancer.
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Adenovirus-mediated overexpression of RB in MDA-MB-231 and 
BT549 cells (both RB-inactive cells) resulted in a reduction of ZEB1 
and ZEB2 mRNA, respectively, suggesting that RB transcriptionally 
suppresses the expression of ZEBs. Furthermore, it was observed that 
the reduction in ZEB1 expression induced by CDK inhibition was 
mediated by the ubiquitin–proteasome pathway. Interestingly, ZEB1 
possesses an LXCXE RB-binding motif, which suggests that an E3 
ubiquitin ligase may target the RB–ZEB1 complex. 
In-depth studies involving the screening of CDK inhibitors 
that suppress ZEB1 expression revealed a CDK4/6 inhibi-
tor (PD0332991) that decreased phosphorylation of RB on 
Ser807/811, induced cell cycle arrest and inhibited tumor growth. 
It was also shown that this effect was not due to cell cycle-depend-
ent expression of ZEB1 or E2F1-mediated signaling. Furthermore, 
shRNA-mediated depletion of ZEB1 resulted in significant inhi-
bition of cell proliferation, and treatment with PD0332991 sup-
pressed cell invasiveness, which may be due to the inhibition of 
ZEB-mediated mesenchymal phenotypes. This study provides 
further evidence that ZEB1 expression is a potential marker of 
poor prognosis in breast cancer, as in several other tumors [8], 
and may serve as a predictive marker for the treatment of TNBC. 
However, further studies are necessary to determine whether the 
expression of ZEB1 influences the prognosis of TNBC patients.
Five-year view
TNBC is characterized by distinct molecular and histological 
features [9]. TNBC is generally associated with an unfavorable 
prognosis, but a subgroup of patients demonstrate an increased 
sensitivity to conventional chemotherapeutic agents [9]. Current 
attempts to improve prognosis for patients with TNBC entail 
the development and use of novel targeted agents in conjunc-
tion with optimizing the type and scheduling of currently avail-
able cytotoxic agents. An interesting clinical target in TNBC 
is the enzyme poly-ADP ribose polymerase (PARP), and treat-
ment with the PARP inhibitor iniparib was associated with sig-
nificant improvements in the rate of tumor regression, median 
progression-free survival and median overall survival in patients 
with TNBC when used in conjunction with gemcitabine and 
carboplatin [10]. Other potential targets in TNBC include the 
EGF receptor and VEGF [11]. However, new therapeutic targets 
are required to improve prognosis in these patients.
RB is one of the most studied proteins in cancer biology and has 
been shown to interact with over 100 other proteins, and its asso-
ciation with the E2F transcription factors has been particularly 
well described. The biological functions of RB include tumor 
suppression, regulation of the cell cycle, differentiation and 
apoptosis [12,13]. TNBC has distinct clinico–pathological fea-
tures and falls within the basal-like histological subset of breast 
cancers, which frequently exhibit inactivation of RB [14]. EMT 
plays an important role in breast cancer metastasis, especially in 
TNBC. This particular study revealed that RB inactivation is 
one of the key events underlying the mesenchymal and aggres-
sive phenotype of TNBC, and exploration of the molecular links 
between RB inactivation and EMT may thus reveal new targets 
for TNBC treatment. ZEB1 and ZEB2 are crucial EMT activa-
tors, whereas members of the miR-200 family induce epithelial 
differentiation. They are reciprocally linked in a feedback loop 
and strictly control the expression of one another. Proteins that 
could possibly regulate the miR-200 family in RB-inactive cells 
would be important in maintaining cellular plasticity and may 
represent future potential therapeutic targets [4]. This study shows 
that the CDK inhibitor PD0332991 suppressed ZEB1 expression 
and may be effective for the treatment of patients with TNBC. 
Recent clinical trials have proved the importance of PD0332991 
in treating different cancers [15,16], which suggests that it could 
be a potential candidate for TNBC treatment and could provide 
the key to treating this lethal disease. Maintaining the status of 
RB in cancer treatment, or developing drugs that can mimic the 
function of RB, are important strategies that could be used to 
develop new cancer therapeutic targets with potentially fewer side 
effects [12]. Current and future studies will focus on the discovery 
of novel targets such as RB in TNBC and the design of agents to 
inhibit or promote their activity. Interestingly, in a recent deep 
sequencing of breast cancer, miR-210 was found to be upregu-
lated in the transition from in situ to invasive ductal carcinoma, 
and several crucial breast cancer genes were found to be inversely 
related to its expression including BRCA1, FANCD, FANCF, 
PARP1, CDH1 and RB1 [17]. Furthermore, TNBC was character-
ized by activation of miR-200c, miR-128 and the polycistronic 
miR-17-92 cluster compared with other breast cancer subtypes.
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Key issues
• Inactivation of retinoblastoma protein (RB) contributes to mesenchymal-like morphology with an invasive phenotype in breast 
cancer cells.
• RB is inactivated in clinical specimens of triple-negative breast cancer, suggesting that restoration of the function of RB could be a 
therapeutic solution.
• Identification of CDK inhibitors that induce downregulation of ZEB1 expression may show potential for triple-negative breast cancer
treatment.
• The evaluated study provides links between RB, the miR-200 family and ZEB1/2; however, further investigation is required to
understand the mechanisms involved.
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Summary of methods & results
Methods
The primary objective was to investigate whether 
circulating tumor cel (CTC) counts between 
baseline and the second treatment cycle were 
associated  with  progression-free survival and 
overal survival. Secondary objectives were to 
analyze CTC counts between baseline and cycle 
3/4 (C3/4), and to compare  CTC counts to 
known serum tumor markers (carcinoembryonic 
antigen [CEA], carcinoma antigen [CA] 15-3 
and lactate  dehydrogenase).  Additional  data 
showing correlations between CTC counts and 
the serum marker CYFRA 21-1 were presented 
at the IMPAKT  Breast  Cancer  Conference 
(May 2011) [1,2]. 
Inclusion criteria were: metastatic breast can-
cer (MBC) patients prior to ﬁrst-line chemo-
therapy; subsequently treated with or without 
targeted therapy (e.g.,  depending  on  HER2 
status); and with a life expectancy of at least 
3 months.  Prior  hormone therapy for  MBC 
was  permitted.  Blood tests and  CTC counts 
were performed at baseline (C1), before each 
treatment cycle and at  disease  progression 
(data not shown). Radiological assessment of 
tumor response was carried out at baseline and 
before C3 or 4. A CTC prognostic threshold of 
≥5 CTCs/7.5 ml was used [3–6]. 
The landmark study  by  Cristofanili et al. 
identiﬁed that a ≥5 CTCs count before treat-
ment was an independent predictor of progres-
sion-free survival (PFS) and in MBC [7]. The 
IC 2006-04 (2005) was speciﬁcaly designed 
to confirm this. In the  Cristofanili study 
(n = 177), 175 patients were required to achieve 
80% power (two-sided; a = 0.05). Hence it was 
calculated for the IC 2006-04 that 216 patients 
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The metastatic transformation of epithelial tumors progresses through various steps leading to 
the generation of circulating tumor cels (CTCs). Measurement of CTCs in the peripheral blood 
is being increasingly recognized as a promising tool in breast oncology. Several studies have 
evaluated the prognostic signiﬁcance of CTCs in newly diagnosed metastatic breast cancer 
(MBC) patients. The IC 2006-04 was a high-powered, prospective, multicenter, observational 
study conceived to assess CTC changes in women with MBC treated with ﬁrst-line chemotherapy. 
Levels ≥5  CTCs/7.5 ml  blood  at  baseline  and  before the second cycle  of treatment  were 
independent prognostic factors associated with shorter progression-free and overal survival. 
This study provides further level I evidence for the clinical and prognostic value of CTCs in MBC, 
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with ≥5 CTCs at baseline were needed to see a 35% difference 
in 6-month PFS rates between those women with <5 CTC and 
≥5 CTCs before C2. The accrual was extended to 267 patients 
as there were fewer patients with ≥5 CTCs at baseline, consistent 
with the Cristofanilli study.
Results
Results at baseline
Circulating tumor cells effectively predicted worse outcomes 
in MBC (Table 1). A baseline, CTC count ≥5 was an indepen-
dent prognostic factor for PFS and in multivariate ana lysis with 
a relative risk of disease progression of 1.9 (95% CI: 1.2–2.8; 
p = 0.003) and mortality of 2.4 (95% CI: 1.1–5.4; p = 0.03). 
The presence of a single CTC at baseline was an independent 
predictor of PFS but not (relative risk [RR]: 1.9; 95% CI: 1.1–3.0; 
p = 0.006). PFS was double in women with no CTC at baseline 
(19.9 months) compared with those with CTC positivity. 
Results prior to second cycle of treatment
A CTC count of ≥5 after C1 was associated with reduced 6-month 
PFS rates (C1 >5/C2 >5 64% vs C1 >5/C2<5 75%; p = 0.0001). 
Median PFS was 6.9 and 12 months, respectively and was sig-
nificantly different between the two groups (C1 >5/C2 >5 95% 
vs C1 >5/C2 <5 78%; p = 0.0001). At 2 years, all patients with 
C2 >5 had disease progression compared with 71% of those with 
<5 CTC. A total of 89% with <5 CTC at baseline and C2 were 
still alive at 2 years compared with 60 and 31% with C1 >5/C2 
<5 and C1 >5/C2 >5, respectively. 
Serum markers including CYFRA 21-1
Circulating tumor cells had prognostic value independent of other 
serum markers. A total of 26% of patients had false-negative 
results with both CEA and CA 15-3 at baseline. A raised baseline 
CEA predicted PFS (RR: 2.0: 1.2–3.1; p = 0.002). For patients 
with one raised serum marker and ≥5 CTCs at baseline, there was 
no significant difference in the 6-month PFS predictive value of 
any of these biomarkers. 
Breast carcinoma expresses cytokeratin (CK) 19 fragments in 
primary and metastatic lesions. CYFRA 21-1 is a marker that 
consists of two monoclonal antibodies reacting specifically against 
fragments of CK 19 in the serum. CYFRA 21-1 has been shown to 
have high sensitivity for recurrent primary disease and MBC with 
strong prognostic value [8]. CTC and CYFRA 21-1 were correlated 
with other serum markers, tumor burden, performance status 
and number of metastatic sites, but were independent of tumor 
subtype. CYFRA 21-1 was also associated with PFS (p = 0.05) at 
multivariate ana lysis [2]. 
Response to treatments
Circulating tumor cells must be used cautiously to monitor treat-
ment response. First-line treatment was less heterogeneous than 
previously reported [7]. Notably, 47% of patients received bevaci-
zumab plus chemotherapy in this study. After one treatment cycle, 
90% of patients had stable or lower CTC counts. Chemotherapy 
plus anti-HER2 therapy or bevacizumab was associated with a 
statistically nonsignificant (p = 0.14) increase in the rate of reduc-
tion in CTC counts below 5, compared with chemotherapy alone 
(83, 64 and 53%, respectively). 
Circulating tumor cell count could not predict radiological 
complete/partial response (CR/PR) to treatment at baseline or 
C2, but the ≥5 CTCs threshold could differentiate between 
CR/PR and stable or progressive disease at the time of radiologi-
cal evaluation (i.e., C3/4; p = 0.02). Patients with ≥1 CTC at C2 
were predicted to have progressive disease at C3/4. This was not 
the case at baseline or C3/C4. CTCs were not shown to be pre-
dictors of tumor response to therapy, but may predict  progression 
earlier than radiological evaluation.
Discussion
Circulating tumor cells are a rare peripheral cell population; 
however, their isolation and enumeration is achievable using 
the CellSearch™ system (Veridex, NJ, USA). This allows auto-
mated enrichment and immunocytochemical detection for CTCs. 
Several studies have found CTCs both in patients with declared 
metastatic disease, and also in patients with nonmeasurable 
MBC [9]. Early detection of CTCs can serve as a predictor of 
metastases [3–5,7,10] and provide significant prognostic information 
about patients with MBC, but it is still up to the clinician to inter-
pret this information. The relevance of a single CTC at follow-up 
remains uncertain. Initial results from the Simultaneous Study 
of Docetaxel-Gemcitabine Combination adjuvant treatment, as 
well as Extended Bisphosphonate and Surveillance (SUCCESS) 
trial (n = 2026) demonstrated that the presence of a single CTC 
in early breast cancer predicted poor disease-free, distant disease-
free, and overall survival at more than 3 years follow-up, confirm-
ing the independent prognostic relevance of CTC counts [11]. The 
ideal CTC data should contribute to a decision in real practice 
that results in a more favourable clinical outcome for the patient, 
including increased overall survival, improved disease-free/
progression-free survival, enhanced quality of life or a medico-
economic benefit [12]. Ongoing randomized interventional trials 
have been designed to demonstrate the usefulness of CTC count 
in MBC (Table 1). CTC levels might enable personalization of 
therapies at all stages of breast cancer by better identifying high-
risk patients and allowing clinicians to implement additional 
treatments when necessary. 
Five-year view
Circulating tumor cells are rapidly becoming one of the key bio-
markers for understanding metastasis and have the potential to 
provide better insights into tumor biology by allowing a ‘blood 
biopsy’ for various epithelial cancers. Characterization of CTCs 
in metastatic cancer patients could provide additional informa-
tion to enhance their management. Whilst the CellSearch sys-
tem is the most widely used detection method, newer technolo-
gies are becoming available. A high-throughput microfluidic 
mixing device, the herringbone-chip (HB-chip), has been dem-
onstrated to provide an enhanced platform for CTC isolation. 
The HB-chip uses calibrated microfluidic flow patterns to drive 
cells into contact with the antibody-coated walls of the device; 
Jacob, Krell, Castellano, Jiao, Stebbing & Frampton
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this CTC-chip provides improved yield and purity of captured 
CTCs, preserving viability and allowing for detailed molecular 
and functional characterization [13]. Eventual gene expression 
profiling of CTCs may allow new potential therapeutic targets 
to be realized [14]. One study has isolated >100 CTCs from three 
metastatic patients (colorectal, prostate and breast) and, using 
the RNA extracted from CTC-enriched and CTC-depleted 
portions, have performed global gene-expression profiles, gener-
ating a list of cancer-specific, CTC-specific genes [15]. Recently, 
Flores et al. demonstrated the feasibility of molecular profiling 
of CTCs from patients with MBC using FISH [16]. That study 
assessed the HER2 gene amplification status of CTCs and com-
pared it with the primary and metastatic tissue. Interestingly, in 
patients with HER2-negative primary cancers, 33% had CTCs 
with clear amplification of the HER2 locus. Finally, while the 
transcriptomic ana lysis of nonmetastatic breast cancers accord-
ing to CTC detection has been unsuccessful [17], the processing 
of low numbers of CTCs in a high background of leukocytes 
is now possible and has allowed mRNA and miRNA profiling 
in MBC patients [18]. 
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Key issues
• First study to be prospectively designed and statistically powered for reporting circulating tumor cell (CTC)-related outcome as the 
primary measure in metastatic breast cancer (MBC) patients treated with first-line chemotherapy.
• CTCs are clinically valuable and an independent prognostic marker in newly diagnosed MBC (level II evidence).
• Persistently high CTC count (≥5 CTCs/7.5 ml) after initial treatment is an early predictive marker of poor PFS and OS (doubles hazard for 
both), even before radiological evaluation.
• There is some evidence that ≥1 CTCs/7.5 ml threshold can be used to define patients at high risk: patients with ≥1 CTC at baseline have 
shorter PFS and patients with ≥1 CTC after initial treatment are predicted to have progression at time of radiological evaluation; this 
differs from metastatic colorectal cancer where <3 CTCs/7.5 ml has been correlated with an unfavorable prognosis.
• Presence of CTCs seem to predict prognosis at any time during the treatment of MBC, raising the possibility that this measurement will 
allow proper staging of the disease.
• CTC results had prognostic value independent of other serum tumor markers (carcinoembryonic antigen, carcinoma antigen 15-3 and 
LDH); CYFRA 21-1 associated with PFS.
• Unable to demonstrate that CTCs can evaluate tumor response to therapy in MBC (awaiting results of ongoing interventional trials).
• Efforts are being made to perform molecular and functional characterization of CTCs; this might contribute to a greater understanding 
of cancer metastasis, the role of cancer stem cells and epithelial-to-mesenchymal transition
• Provides evidence that CTCs can be further investigated to develop personalized treatment regimens aiming for improved outcomes in 
MBC patients.
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